
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934**

Date: July 23, 2021

UBS AG
Commission File Number: 1-15060

(Registrant's Name)


Bahnhofstrasse 45, Zurich, Switzerland
Aeschenvorstadt 1, Basel, Switzerland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.

Form 20-F

Form 40-F

This Form 6-K consists of the Second Quarter 2021 Report of UBS AG, which appears immediately following this page.



UBS AG

Second quarter 2021 report

Corporate calendar UBS AG

Publication of the third quarter 2021 report: Friday, 29 October 2021

Publication dates of quarterly and annual reports and results are made available as part of the corporate calendar of UBS AG at ubs.com/investors

Contacts

Switchboards

For all general inquiries
ubs.com/contact

Zurich +41-44-234 1111
London +44-207-567 8000
New York +1-212-821 3000
Hong Kong +852-2971 8888
Singapore +65-6495 8000

Investor Relations

Institutional, professional and retail investors are supported by UBS's Investor Relations team.

UBS AG, Investor Relations
P.O. Box, CH-8098 Zurich, Switzerland

ubs.com/investors

Zurich +41-44-234 4100
New York +1-212-882 5734

Media Relations

Global media and journalists are supported by UBS's Media Relations team.

ubs.com/media

Zurich +41-44-234 8500
mediarelations@ubs.com

London +44-20-7567 4714
ubs-media-relations@ubs.com

New York +1-212-882 5858
mediarelations@ubs.com

Hong Kong +852-2971 8200
sh-mediarelations-ap@ubs.com

Imprint

Publisher: UBS AG, Zurich, Switzerland | ubs.com/media
Language: English

© UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

3 Introduction

1. Risk and capital management

- 8 Risk management and control
- 9 Capital management

2. Consolidated financial statements

- 17 UBS AG interim consolidated financial statements (unaudited)

3. UBS AG standalone financial information

- 71 UBS AG interim standalone financial information (unaudited)

Appendix

- 74 Alternative performance measures
- 77 Abbreviations frequently used in our financial reports
- 79 Information sources
- 80 Cautionary statement

UBS AG consolidated key figures

UBS AG consolidated key figures

USD million, except where indicated	As of or for the quarter ended				As of or year-to-date	
	30.6.21	31.3.21	31.12.20	30.6.20	30.6.21	30.6.20
Results						
Operating income	9,071	8,836	8,220	7,512	17,906	15,521
Operating expenses	6,589	6,684	6,324	5,987	13,274	12,197
Operating profit / (loss) before tax	2,481	2,151	1,896	1,525	4,632	3,324
Net profit / (loss) attributable to shareholders	1,913	1,710	1,563	1,194	3,623	2,615
Profitability and growth						
Return on equity (%)	13.6	11.9	10.9	8.4	12.7	9.3
Return on tangible equity (%)	15.3	13.4	12.2	9.5	14.3	10.5
Return on common equity tier 1 capital (%)	19.4	17.8	16.3	13.0	18.6	14.4
Return on risk-weighted assets, gross (%)	12.5	12.3	11.7	10.9	12.4	11.6
Return on leverage ratio denominator, gross (%) ¹	3.5	3.4	3.3	3.2	3.4	3.4
Cost / income ratio (%)	73.3	75.9	76.3	76.9	74.6	75.9
Net profit growth (%)	60.3	20.3	151.3	(8.7)	38.5	10.1
Resources						
Total assets	1,085,861	1,109,234	1,125,327	1,063,446	1,085,861	1,063,446
Equity attributable to shareholders	55,361	57,446	57,754	55,384	55,361	55,384
Common equity tier 1 capital ²	40,190	38,826	38,181	37,403	40,190	37,403
Risk-weighted assets ²	290,470	285,119	286,743	284,798	290,470	284,798
Common equity tier 1 capital ratio (%) ²	13.8	13.6	13.3	13.1	13.8	13.1
Going concern capital ratio (%) ²	19.1	18.7	18.3	17.9	19.1	17.9
Total loss-absorbing capacity ratio (%) ²	34.6	34.2	34.2	31.9	34.6	31.9
Leverage ratio denominator ^{1,2}	1,039,375	1,039,736	1,036,771	974,135	1,039,375	974,135
Common equity tier 1 leverage ratio (%) ^{1,2}	3.87	3.73	3.68	3.84	3.87	3.84
Going concern leverage ratio (%) ^{1,2}	5.3	5.1	5.1	5.2	5.3	5.2
Total loss-absorbing capacity leverage ratio (%) ²	9.7	9.4	9.5	9.3	9.7	9.3
Other						
Invested assets (USD billion) ³	4,485	4,306	4,187	3,588	4,485	3,588
Personnel (full-time equivalents)	47,227	47,592	47,546	47,120	47,227	47,120

¹ Leverage ratio denominators and leverage ratios for the respective periods in 2020 do not reflect the effects of the temporary exemption that applied from 25 March 2020 until 1 January 2021 and was granted by FINMA in connection with COVID-19. Refer to the "Regulatory and legal developments" section of our Annual Report 2020 for more information. ² Based on the Swiss systemically relevant bank framework as of 1 January 2020. Refer to the "Capital management" section of this report for more information. ³ Consists of invested assets for Global Wealth Management, Asset Management and Personal & Corporate Banking. Refer to "Note 32 Invested assets and net new money" in the "Consolidated financial statements" section of our Annual Report 2020 for more information.

Alternative performance measures

An alternative performance measure (an APM) is a financial measure of historical or future financial performance, financial position or cash flows other than a financial measure defined or specified in the applicable recognized accounting standards or in other applicable regulations. We report a number of APMs in our external reports (annual, quarterly and other reports). We use APMs to provide a more complete picture of our operating performance and to reflect management's view of the fundamental drivers of our business results. A definition of each APM, the method used to calculate it and the information content are presented under "Alternative performance measures" in the appendix to this report. Our APMs may qualify as non-GAAP measures as defined by US Securities and Exchange Commission (SEC) regulations.

Introduction

Overview

UBS Group AG is the holding company for the UBS Group and the parent company of UBS AG. UBS Group AG holds 100% of the issued shares in UBS AG. Financial information for UBS AG consolidated does not differ materially from that for UBS Group AG consolidated.

This report includes risk and capital management information for UBS AG consolidated and the interim consolidated financial statements, as well as UBS AG standalone financial information for the quarter ended 30 June 2021. Regulatory information for UBS AG standalone is provided in the 30 June 2021 Pillar 3 report, available under "Pillar 3 disclosures" at ubs.com/investors.

- › Refer to the **UBS Group second quarter 2021 report, available under "Quarterly reporting" at ubs.com/investors, for more information**

Comparison between UBS Group AG consolidated and UBS AG consolidated

The table on the following page contains a comparison of selected financial and capital information between UBS Group AG consolidated and UBS AG consolidated.

The accounting policies applied under International Financial Reporting Standards (IFRS) to both the UBS Group AG and the UBS AG consolidated financial statements are identical. However, there are certain scope and presentation differences as noted below.

- Assets, liabilities, operating income, operating expenses and operating profit before tax relating to UBS Group AG and its directly held subsidiaries, including UBS Business Solutions AG, are reflected in the consolidated financial statements of UBS Group AG but not in those of UBS AG. UBS AG's assets, liabilities, operating income and operating expenses related to transactions with UBS Group AG and its directly held subsidiaries, including UBS Business Solutions AG and other shared services subsidiaries, are not subject to elimination in the consolidated financial statements of UBS AG, but are eliminated in the consolidated financial statements of UBS Group AG. UBS Business Solutions AG and other shared services subsidiaries of UBS Group AG charge other legal entities within the UBS AG consolidation scope for services provided, including a markup on costs incurred.
- The equity of UBS Group AG consolidated was USD 3.4 billion higher than the equity of UBS AG consolidated as of 30 June 2021. This difference was mainly driven by higher dividends paid by UBS AG to UBS Group AG compared with

the dividend distributions of UBS Group AG, as well as higher retained earnings in the consolidated financial statements of UBS Group AG, largely related to the aforementioned markup charged by shared services subsidiaries of UBS Group AG to other legal entities in the UBS AG scope of consolidation. In addition, UBS Group AG is the grantor of the majority of the compensation plans of the Group and recognizes share premium for equity-settled awards granted. These effects were partly offset by treasury shares acquired and canceled as part of our share repurchase programs and those held to hedge share delivery obligations associated with Group compensation plans, as well as additional share premium recognized at the UBS AG consolidated level related to the establishment of UBS Group AG and UBS Business Solutions AG, a wholly owned subsidiary of UBS Group AG.

- The going concern capital of UBS Group AG consolidated was USD 3.8 billion higher than the going concern capital of UBS AG consolidated as of 30 June 2021, reflecting higher common equity tier 1 (CET1) capital of USD 2.4 billion and going concern loss-absorbing additional tier 1 (AT1) capital of USD 1.4 billion.
- The CET1 capital of UBS Group AG consolidated was USD 2.4 billion higher than that of UBS AG consolidated as of 30 June 2021. The higher CET1 capital of UBS Group AG consolidated was primarily due to higher UBS Group AG consolidated IFRS equity of USD 3.4 billion, as described above, and lower UBS Group AG accruals for future capital returns to shareholders, partly offset by compensation-related regulatory capital accruals and a capital reserve for potential share repurchases at the UBS Group AG level.
- The going concern loss-absorbing AT1 capital of UBS Group AG consolidated was USD 1.4 billion higher than that of UBS AG consolidated as of 30 June 2021, mainly reflecting deferred contingent capital plan awards granted at the Group level to eligible employees for the performance years 2016 to 2020, partly offset by two loss-absorbing AT1 capital instruments on-lent by UBS Group AG to UBS AG.

- › Refer to "**Holding company and significant regulated subsidiaries and sub-groups**" under "**Complementary financial information**" at ubs.com/investors for an illustration of the consolidation scope differences between UBS AG and UBS Group AG

- › Refer to the "**Capital management**" section of this report for more information about differences in the loss-absorbing capacity between UBS Group AG consolidated and UBS AG consolidated

Comparison between UBS Group AG consolidated and UBS AG consolidated

	As of or for the quarter ended 30.6.21		
	UBS Group AG consolidated	UBS AG consolidated	Difference (absolute)
<i>USD million, except where indicated</i>			
Income statement			
Operating income	8,976	9,071	(94)
Operating expenses	6,384	6,589	(206)
Operating profit / (loss) before tax	2,593	2,481	111
<i>of which: Global Wealth Management</i>	<i>1,294</i>	<i>1,273</i>	<i>21</i>
<i>of which: Personal & Corporate Banking</i>	<i>498</i>	<i>496</i>	<i>2</i>
<i>of which: Asset Management</i>	<i>255</i>	<i>254</i>	<i>1</i>
<i>of which: Investment Bank</i>	<i>668</i>	<i>655</i>	<i>14</i>
<i>of which: Group Functions</i>	<i>(124)</i>	<i>(197)</i>	<i>73</i>
Net profit / (loss)	2,012	1,919	93
<i>of which: net profit / (loss) attributable to shareholders</i>	<i>2,006</i>	<i>1,913</i>	<i>93</i>
<i>of which: net profit / (loss) attributable to non-controlling interests</i>	<i>6</i>	<i>6</i>	<i>0</i>
Statement of comprehensive income			
Other comprehensive income	591	592	(1)
<i>of which: attributable to shareholders</i>	<i>576</i>	<i>578</i>	<i>(1)</i>
<i>of which: attributable to non-controlling interests</i>	<i>14</i>	<i>14</i>	<i>0</i>
Total comprehensive income	2,602	2,510	92
<i>of which: attributable to shareholders</i>	<i>2,582</i>	<i>2,491</i>	<i>92</i>
<i>of which: attributable to non-controlling interests</i>	<i>20</i>	<i>20</i>	<i>0</i>
Balance sheet			
Total assets	1,086,519	1,085,861	658
Total liabilities	1,027,469	1,030,216	(2,746)
Total equity	59,050	55,645	3,405
<i>of which: equity attributable to shareholders</i>	<i>58,765</i>	<i>55,361</i>	<i>3,405</i>
<i>of which: equity attributable to non-controlling interests</i>	<i>284</i>	<i>284</i>	<i>0</i>
Capital information			
Common equity tier 1 capital	42,583	40,190	2,393
Going concern capital	59,188	55,398	3,790
Risk-weighted assets	293,277	290,470	2,807
Common equity tier 1 capital ratio (%)	14.5	13.8	0.7
Going concern capital ratio (%)	20.2	19.1	1.1
Total loss-absorbing capacity ratio (%)	35.6	34.6	1.0
Leverage ratio denominator ¹	1,039,939	1,039,375	564
Common equity tier 1 leverage ratio (%) ¹	4.09	3.87	0.23
Going concern leverage ratio (%) ¹	5.7	5.3	0.4
Total loss-absorbing capacity leverage ratio (%)	10.0	9.7	0.4

¹ Leverage ratio denominators and leverage ratios for 31 December 2020 do not reflect the effects of the temporary exemption that applied from 25 March 2020 until 1 January 2021 and was granted by FINMA in connection with COVID-19. Refer to the "Regulatory and legal developments" section of our Annual Report 2020 for more information.

As of or for the quarter ended 31.3.21			As of or for the quarter ended 31.12.20		
UBS Group AG consolidated	UBS AG consolidated	Difference (absolute)	UBS Group AG consolidated	UBS AG consolidated	Difference (absolute)
8,705	8,836	(130)	8,117	8,220	(103)
6,407	6,684	(277)	6,132	6,324	(192)
2,298	2,151	147	1,985	1,896	89
1,409	1,391	18	864	855	9
389	390	0	353	353	(1)
227	227	0	401	401	0
412	394	17	529	528	1
(139)	(251)	112	(161)	(241)	79
1,827	1,713	114	1,645	1,572	73
1,824	1,710	114	1,636	1,563	73
3	3	0	9	9	0
(2,166)	(2,032)	(135)	83	54	29
(2,154)	(2,019)	(135)	65	36	29
(12)	(12)	0	18	18	0
(339)	(319)	(21)	1,728	1,626	102
(330)	(309)	(21)	1,701	1,599	102
(9)	(9)	0	27	27	0
1,107,712	1,109,234	(1,522)	1,125,765	1,125,327	438
1,049,379	1,051,481	(2,102)	1,066,000	1,067,254	(1,254)
58,333	57,753	580	59,765	58,073	1,691
58,026	57,446	580	59,445	57,754	1,691
307	307	0	319	319	0
40,426	38,826	1,600	39,890	38,181	1,709
56,288	53,255	3,033	56,178	52,610	3,567
287,828	285,119	2,710	289,101	286,743	2,358
14.0	13.6	0.4	13.8	13.3	0.5
19.6	18.7	0.9	19.4	18.3	1.1
35.0	34.2	0.7	35.2	34.2	1.0
1,038,225	1,039,736	(1,511)	1,037,150	1,036,771	379
3.89	3.73	0.16	3.85	3.68	0.16
5.4	5.1	0.3	5.4	5.1	0.3
9.7	9.4	0.3	9.8	9.5	0.3

Risk and capital management

Management report

Risk management and control

UBS AG consolidated risk profile

The risk profile of UBS AG consolidated does not differ materially from that of UBS Group AG consolidated and the risk information provided in the UBS Group second quarter 2021 report is equally applicable to UBS AG consolidated.

The credit risk profile of UBS AG consolidated differs from that of UBS Group AG consolidated primarily in relation to

receivables of UBS AG and UBS Switzerland AG from UBS Group AG. The total banking products exposure of UBS AG consolidated as of 30 June 2021 was USD 1.2 billion, or 0.2%, higher than the exposure of UBS Group, compared with USD 3.3 billion, or 0.5%, as of 31 March 2021.

› **Refer to the “Risk management and control” section of the UBS Group second quarter 2021 report for more information**

Capital management

Going and gone concern requirements and information

UBS is considered a systemically relevant bank (an SRB) under Swiss banking law and, on a consolidated basis, both UBS Group AG and UBS AG are required to comply with regulations based on the Basel III framework as applicable for Swiss SRBs.

The Swiss SRB framework and requirements applicable to UBS AG consolidated are consistent with those applicable to UBS Group AG consolidated and are described in the “Capital, liquidity and funding, and balance sheet” section of our Annual Report 2020.

UBS AG is subject to going and gone concern requirements on a standalone basis. Capital and other regulatory information for UBS AG standalone is provided under “Holding company and significant regulated subsidiaries and sub-groups” at ubs.com/investors and in the 30 June 2021 Pillar 3 report, which will be available as of 20 August 2021 under “Pillar 3 disclosures” at ubs.com/investors.

The table on the next page provides the risk-weighted assets (RWA)- and leverage ratio denominator (LRD)-based requirements and information as of 30 June 2021 for UBS AG consolidated.

Swiss SRB going and gone concern requirements and information

As of 30.6.21	RWA		LRD	
<i>USD million, except where indicated</i>	in %		in %	
Required going concern capital				
Total going concern capital	13.96¹	40,552	4.88¹	50,670
Common equity tier 1 capital	9.66	28,062	3.38²	35,079
<i>of which: minimum capital</i>	<i>4.50</i>	<i>13,071</i>	<i>1.50</i>	<i>15,591</i>
<i>of which: buffer capital</i>	<i>5.14</i>	<i>14,930</i>	<i>1.88</i>	<i>19,488</i>
<i>of which: countercyclical buffer</i>	<i>0.02</i>	<i>61</i>		
Maximum additional tier 1 capital	4.30	12,490	1.50	15,591
<i>of which: additional tier 1 capital</i>	<i>3.50</i>	<i>10,166</i>	<i>1.50</i>	<i>15,591</i>
<i>of which: additional tier 1 buffer capital</i>	<i>0.80</i>	<i>2,324</i>		
Eligible going concern capital				
Total going concern capital	19.07	55,398	5.33	55,398
Common equity tier 1 capital	13.84	40,190	3.87	40,190
Total loss-absorbing additional tier 1 capital	5.24	15,208	1.46	15,208
<i>of which: high-trigger loss-absorbing additional tier 1 capital</i>	<i>4.37</i>	<i>12,702</i>	<i>1.22</i>	<i>12,702</i>
<i>of which: low-trigger loss-absorbing additional tier 1 capital³</i>	<i>0.86</i>	<i>2,506</i>	<i>0.24</i>	<i>2,506</i>
Required gone concern capital⁴				
Total gone concern loss-absorbing capacity⁵	10.60	30,803	3.76	39,071
<i>of which: base requirement</i>	<i>12.86</i>	<i>37,354</i>	<i>4.50</i>	<i>46,772</i>
<i>of which: additional requirement for market share and LRD</i>	<i>1.08</i>	<i>3,137</i>	<i>0.38</i>	<i>3,898</i>
<i>of which: applicable reduction on requirements</i>	<i>(3.34)</i>	<i>(9,688)</i>	<i>(1.12)</i>	<i>(11,598)</i>
<i>of which: rebate granted (equivalent to 47.5% of maximum rebate)⁶</i>	<i>(2.54)</i>	<i>(7,368)</i>	<i>(0.89)</i>	<i>(9,257)</i>
<i>of which: reduction for usage of low-trigger tier 2 capital instruments</i>	<i>(0.80)</i>	<i>(2,320)</i>	<i>(0.23)</i>	<i>(2,342)</i>
Eligible gone concern capital				
Total gone concern loss-absorbing capacity	15.53	45,110	4.34	45,110
Total tier 2 capital	1.80	5,232	0.50	5,232
<i>of which: low-trigger loss-absorbing tier 2 capital</i>	<i>1.61</i>	<i>4,686</i>	<i>0.45</i>	<i>4,686</i>
<i>of which: non-Basel III-compliant tier 2 capital</i>	<i>0.19</i>	<i>547</i>	<i>0.05</i>	<i>547</i>
TLAC-eligible senior unsecured debt	13.73	39,878	3.84	39,878
Total loss-absorbing capacity				
Required total loss-absorbing capacity	24.57	71,356	8.63	89,741
Eligible total loss-absorbing capacity	34.60	100,508	9.67	100,508
Risk-weighted assets / leverage ratio denominator				
Risk-weighted assets		290,470		
Leverage ratio denominator				1,039,375

1 Includes applicable add-ons of 1.08% for RWA and 0.375% for LRD. 2 Our minimum CET1 leverage ratio requirement of 3.375% consists of a 1.5% base requirement, a 1.5% base buffer capital requirement, a 0.25% LRD add-on requirement and a 0.125% market share add-on requirement based on our Swiss credit business. 3 The relevant capital instruments were issued after the new Swiss SRB framework had been implemented and qualify as going concern capital at the UBS AG consolidated level, as agreed with FINMA. 4 A maximum of 25% of the gone concern requirements can be met with instruments that have a remaining maturity of between one and two years. Once at least 75% of the minimum gone concern requirement has been met with instruments that have a remaining maturity of greater than two years, all instruments that have a remaining maturity of between one and two years remain eligible to be included in the total gone concern capital. 5 The gone concern requirement after the application of the rebate for resolvability measures and the reduction for the use of higher quality capital instruments is floored at 8.6% and 3% for the RWA- and LRD-based requirements, respectively. This means that the combined reduction may not exceed 5.34 percentage points for the RWA-based requirement of 13.94% and 1.875 percentage points for the LRD-based requirement of 4.875%. 6 Based on the actions we completed up to December 2020 to improve resolvability, FINMA granted an increase of rebate on the gone concern requirement from 47.5% to 55.0% of the maximum rebate, effective from 1 July 2021.

Swiss SRB going and gone concern information

<i>USD million, except where indicated</i>	30.6.21	31.3.21	31.12.20
Eligible going concern capital			
Total going concern capital	55,398	53,255	52,610
Total tier 1 capital	55,398	53,255	52,610
Common equity tier 1 capital	40,190	38,826	38,181
Total loss-absorbing additional tier 1 capital	15,208	14,429	14,430
<i>of which: high-trigger loss-absorbing additional tier 1 capital</i>	<i>12,702</i>	<i>11,930</i>	<i>11,854</i>
<i>of which: low-trigger loss-absorbing additional tier 1 capital¹</i>	<i>2,506</i>	<i>2,499</i>	<i>2,575</i>
Eligible gone concern capital			
Total gone concern loss-absorbing capacity	45,110	44,381	45,545
Total tier 2 capital	5,232	5,253	7,744
<i>of which: low-trigger loss-absorbing tier 2 capital</i>	<i>4,686</i>	<i>4,709</i>	<i>7,201</i>
<i>of which: non-Basel III-compliant tier 2 capital</i>	<i>547</i>	<i>544</i>	<i>543</i>
TLAC-eligible senior unsecured debt	39,878	39,129	37,801
Total loss-absorbing capacity			
Total loss-absorbing capacity	100,508	97,636	98,155
Risk-weighted assets / leverage ratio denominator			
Risk-weighted assets	290,470	285,119	286,743
Leverage ratio denominator ²	1,039,375	1,039,736	1,036,771
Capital and loss-absorbing capacity ratios (%)			
Going concern capital ratio	19.1	18.7	18.3
<i>of which: common equity tier 1 capital ratio</i>	<i>13.8</i>	<i>13.6</i>	<i>13.3</i>
Gone concern loss-absorbing capacity ratio	15.5	15.6	15.9
Total loss-absorbing capacity ratio	34.6	34.2	34.2
Leverage ratios (%)²			
Going concern leverage ratio	5.3	5.1	5.1
<i>of which: common equity tier 1 leverage ratio</i>	<i>3.87</i>	<i>3.73</i>	<i>3.68</i>
Gone concern leverage ratio	4.3	4.3	4.4
Total loss-absorbing capacity leverage ratio	9.7	9.4	9.5

¹ The relevant capital instruments were issued after the new Swiss SRB framework had been implemented and qualify as going concern capital of UBS AG, as agreed with FINMA. ² The leverage ratio denominator (LRD) and leverage ratios for 31 December 2020 do not reflect the effects of the temporary exemption that applied from 25 March 2020 until 1 January 2021 and was granted by FINMA in connection with COVID-19. Refer to "UBS AG consolidated total loss-absorbing capacity and leverage ratio information" in the "Capital, liquidity and funding, and balance sheet" section of the combined UBS Group AG and UBS AG Annual Report 2020, available under "Annual reporting" at ubs.com/investors, for more information.

UBS Group AG vs UBS AG consolidated loss-absorbing capacity and leverage ratio information

Swiss SRB going and gone concern information

As of 30.6.21

<i>USD million, except where indicated</i>	UBS Group AG (consolidated)	UBS AG (consolidated)	Difference
Eligible going concern capital			
Total going concern capital	59,188	55,398	3,790
Total tier 1 capital	59,188	55,398	3,790
Common equity tier 1 capital	42,583	40,190	2,393
Total loss-absorbing additional tier 1 capital	16,605	15,208	1,397
<i>of which: high-trigger loss-absorbing additional tier 1 capital</i>	14,096	12,702	1,395
<i>of which: low-trigger loss-absorbing additional tier 1 capital</i>	2,509	2,506	3
Eligible gone concern capital			
Total gone concern loss-absorbing capacity	45,110	45,110	
Total tier 2 capital	5,232	5,232	
<i>of which: low-trigger loss-absorbing tier 2 capital</i>	4,686	4,686	
<i>of which: non-Basel III-compliant tier 2 capital</i>	547	547	
TLAC-eligible senior unsecured debt	39,878	39,878	
Total loss-absorbing capacity			
Total loss-absorbing capacity	104,298	100,508	3,790
Risk-weighted assets / leverage ratio denominator			
Risk-weighted assets	293,277	290,470	2,807
Leverage ratio denominator	1,039,939	1,039,375	564
Capital and loss-absorbing capacity ratios (%)			
Going concern capital ratio	20.2	19.1	1.1
<i>of which: common equity tier 1 capital ratio</i>	14.5	13.8	0.7
Gone concern loss-absorbing capacity ratio	15.4	15.5	(0.1)
Total loss-absorbing capacity ratio	35.6	34.6	1.0
Leverage ratios (%)			
Going concern leverage ratio	5.7	5.3	0.4
<i>of which: common equity tier 1 leverage ratio</i>	4.09	3.87	0.23
Gone concern leverage ratio	4.3	4.3	0.0
Total loss-absorbing capacity leverage ratio	10.0	9.7	0.4

Reconciliation of IFRS equity to Swiss SRB common equity tier 1 capital (UBS Group AG vs UBS AG consolidated)

As of 30.6.21

<i>USD million</i>	UBS Group AG (consolidated)	UBS AG (consolidated)	Difference
Total IFRS equity	59,050	55,645	3,405
Equity attributable to non-controlling interests	(284)	(284)	0
Defined benefit plans, net of tax	(144)	(144)	
Deferred tax assets recognized for tax loss carry-forwards	(5,183)	(5,183)	
Deferred tax assets on temporary differences, excess over threshold		(92)	92
Goodwill, net of tax	(5,883)	(5,883)	
Intangible assets, net of tax	(200)	(200)	
Compensation-related components (not recognized in net profit)	(1,680)		(1,680)
Expected losses on advanced internal ratings-based portfolio less provisions	(463)	(463)	
Unrealized (gains) / losses from cash flow hedges, net of tax	(1,365)	(1,365)	0
Own credit related to gains / losses on financial liabilities measured at fair value that existed at the balance sheet date	279	279	
Own credit related to gains / losses on derivative financial instruments that existed at the balance sheet date	(50)	(50)	
Unrealized gains related to debt instruments at fair value through OCI, net of tax	(89)	(89)	
Prudential valuation adjustments	(146)	(146)	
Capital reserve for potential share repurchases	(587)		(587)
Other ¹	(670)	(1,834)	1,164
Total common equity tier 1 capital	42,583	40,190	2,393

¹ Includes accruals for dividends to shareholders for the current year and other items.

UBS Group AG vs UBS AG consolidated loss-absorbing capacity and leverage ratio information

The going concern capital of UBS AG consolidated was USD 3.8 billion lower than the going concern capital of UBS Group AG consolidated as of 30 June 2021, reflecting lower common equity tier 1 (CET1) capital of USD 2.4 billion and lower going concern loss-absorbing additional tier 1 (AT1) capital of USD 1.4 billion.

The aforementioned difference in CET1 capital was primarily due to higher UBS Group AG consolidated IFRS equity of USD 3.4 billion and lower UBS Group AG accruals for future capital returns to shareholders, partly offset by compensation-related regulatory capital accruals and a capital reserve for potential share repurchases at the UBS Group AG level.

The going concern loss-absorbing AT1 capital of UBS AG consolidated was USD 1.4 billion lower than that of UBS Group AG consolidated as of 30 June 2021, mainly reflecting deferred contingent capital plan awards granted at the Group level to eligible employees for the performance years 2016 to 2020, partly offset by two loss-absorbing AT1 capital instruments lent by UBS Group AG to UBS AG.

Differences in capital between UBS Group AG consolidated and UBS AG consolidated related to employee compensation plans will reverse to the extent underlying services are performed by employees of, and are consequently charged to, UBS AG and its subsidiaries. Such reversal generally occurs over the service period of the employee compensation plans.

The leverage ratio framework for UBS AG consolidated is consistent with that of UBS Group AG consolidated. As of 30 June 2021, the going concern leverage ratio of UBS AG consolidated was 0.4 percentage points lower than that of UBS Group AG consolidated, mainly because the going concern capital of UBS AG consolidated was USD 3.8 billion lower.

- › Refer to the “Capital management” section of the UBS Group second quarter 2021 report, available under “Quarterly reporting” at ubs.com/investors, for information about the developments of loss-absorbing capacity, RWA and LRD for UBS Group AG consolidated
- › Refer to the “Introduction” section of this report for more information about the differences in equity between UBS AG consolidated and UBS Group AG consolidated

Consolidated financial statements

Unaudited

Table of contents

UBS AG interim consolidated financial statements (unaudited)

17	Income statement
18	Statement of comprehensive income
20	Balance sheet
22	Statement of changes in equity
24	Statement of cash flows
26	1 Basis of accounting and other financial reporting effects
28	2 Segment reporting
29	3 Net interest income
29	4 Net fee and commission income
30	5 Other income
30	6 Personnel expenses
30	7 General and administrative expenses
30	8 Income taxes
31	9 Expected credit loss measurement
38	10 Fair value measurement
47	11 Derivative instruments
48	12 Other assets and liabilities
50	13 Debt issued designated at fair value
50	14 Debt issued measured at amortized cost
51	15 Interest rate benchmark reform
54	16 Provisions and contingent liabilities
60	17 Currency translation rates
61	18 Supplemental guarantor information required under SEC regulations

UBS AG interim consolidated financial statements (unaudited)

Income statement

<i>USD million</i>	Note	For the quarter ended			Year-to-date	
		30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Interest income from financial instruments measured at amortized cost and fair value through other comprehensive income	3	2,107	2,098	2,135	4,205	4,591
Interest expense from financial instruments measured at amortized cost	3	(860)	(859)	(1,112)	(1,719)	(2,519)
Net interest income from financial instruments measured at fair value through profit or loss	3	359	351	354	710	616
Net interest income	3	1,607	1,589	1,376	3,196	2,689
Other net income from financial instruments measured at fair value through profit or loss		1,471	1,314	1,944	2,785	3,719
Credit loss (expense) / release	9	80	28	(272)	108	(540)
Fee and commission income	4	6,047	6,197	4,730	12,244	10,211
Fee and commission expense	4	(484)	(478)	(419)	(962)	(875)
Net fee and commission income	4	5,563	5,719	4,311	11,282	9,336
Other income	5	350	185	153	535	317
Total operating income		9,071	8,836	7,512	17,906	15,521
Personnel expenses	6	4,072	4,086	3,682	8,158	7,391
General and administrative expenses	7	2,070	2,141	1,879	4,211	3,960
Depreciation and impairment of property, equipment and software		439	449	409	887	814
Amortization and impairment of goodwill and intangible assets		9	8	17	17	32
Total operating expenses		6,589	6,684	5,987	13,274	12,197
Operating profit / (loss) before tax		2,481	2,151	1,525	4,632	3,324
Tax expense / (benefit)	8	563	439	328	1,001	703
Net profit / (loss)		1,919	1,713	1,197	3,631	2,621
Net profit / (loss) attributable to non-controlling interests		6	3	3	9	6
Net profit / (loss) attributable to shareholders		1,913	1,710	1,194	3,623	2,615

Statement of comprehensive income

	For the quarter ended			Year-to-date	
<i>USD million</i>	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Comprehensive income attributable to shareholders					
Net profit / (loss)	1,913	1,710	1,194	3,623	2,615
Other comprehensive income that may be reclassified to the income statement					
Foreign currency translation					
Foreign currency translation movements related to net assets of foreign operations, before tax	447	(1,407)	447	(960)	172
Effective portion of changes in fair value of hedging instruments designated as net investment hedges, before tax	(203)	705	(196)	502	(61)
Foreign currency translation differences on foreign operations reclassified to the income statement	(9)	1	0	(8)	0
Effective portion of changes in fair value of hedging instruments designated as net investment hedges reclassified to the income statement	8	0	2	8	(7)
Income tax relating to foreign currency translations, including the impact of net investment hedges	(4)	10	(2)	6	(2)
Subtotal foreign currency translation, net of tax	239	(691)	249	(452)	103
Financial assets measured at fair value through other comprehensive income					
Net unrealized gains / (losses), before tax	21	(131)	19	(110)	226
Realized gains reclassified to the income statement from equity	(3)	(8)	(15)	(11)	(24)
Realized losses reclassified to the income statement from equity	0	2	0	2	0
Income tax relating to net unrealized gains / (losses)	(4)	35	(3)	31	(54)
Subtotal financial assets measured at fair value through other comprehensive income, net of tax	14	(102)	1	(88)	149
Cash flow hedges of interest rate risk					
Effective portion of changes in fair value of derivative instruments designated as cash flow hedges, before tax	542	(1,172)	291	(630)	2,244
Net (gains) / losses reclassified to the income statement from equity	(268)	(254)	(171)	(522)	(274)
Income tax relating to cash flow hedges	(51)	266	(25)	215	(370)
Subtotal cash flow hedges, net of tax	222	(1,160)	95	(937)	1,600
Cost of hedging					
Change in fair value of cost of hedging, before tax	(24)	(13)	(18)	(37)	(12)
Amortization of initial cost of hedging to the income statement	7	7	5	14	7
Income tax relating to cost of hedging	0	0	0	0	0
Subtotal cost of hedging, net of tax	(16)	(6)	(13)	(23)	(4)
Total other comprehensive income that may be reclassified to the income statement, net of tax	459	(1,958)	333	(1,500)	1,847
Other comprehensive income that will not be reclassified to the income statement					
Defined benefit plans					
Gains / (losses) on defined benefit plans, before tax	0	(35)	(417)	(35)	(314)
Income tax relating to defined benefit plans	0	3	(81)	4	43
Subtotal defined benefit plans, net of tax	0	(32)	(498)	(31)	(270)
Own credit on financial liabilities designated at fair value¹					
Gains / (losses) from own credit on financial liabilities designated at fair value, before tax	118	(29)	(1,095)	89	62
Income tax relating to own credit on financial liabilities designated at fair value	0	0	223	0	0
Subtotal own credit on financial liabilities designated at fair value, net of tax	118	(29)	(872)	89	62
Total other comprehensive income that will not be reclassified to the income statement, net of tax	119	(61)	(1,370)	58	(208)
Total other comprehensive income	578	(2,019)	(1,037)	(1,442)	1,639
Total comprehensive income attributable to shareholders	2,491	(309)	157	2,181	4,254

Statement of comprehensive income (continued)

USD million	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Comprehensive income attributable to non-controlling interests					
Net profit / (loss)	6	3	3	9	6
Other comprehensive income that will not be reclassified to the income statement					
Foreign currency translation movements, before tax	14	(12)	1	2	(4)
Income tax relating to foreign currency translation movements	0	0	0	0	0
Subtotal foreign currency translation, net of tax	14	(12)	1	2	(4)
Total other comprehensive income that will not be reclassified to the income statement, net of tax	14	(12)	1	2	(4)
Total comprehensive income attributable to non-controlling interests	20	(9)	4	10	3
Total comprehensive income					
Net profit / (loss)	1,919	1,713	1,197	3,631	2,621
Other comprehensive income	592	(2,032)	(1,035)	(1,440)	1,635
<i>of which: other comprehensive income that may be reclassified to the income statement</i>	<i>459</i>	<i>(1,958)</i>	<i>333</i>	<i>(1,500)</i>	<i>1,847</i>
<i>of which: other comprehensive income that will not be reclassified to the income statement</i>	<i>133</i>	<i>(73)</i>	<i>(1,369)</i>	<i>60</i>	<i>(212)</i>
Total comprehensive income	2,510	(319)	161	2,192	4,256

¹ Refer to Note 10 for more information.

Balance sheet

<i>USD million</i>	Note	30.6.21	31.3.21	31.12.20
Assets				
Cash and balances at central banks		160,672	158,914	158,231
Loans and advances to banks		16,376	18,348	15,344
Receivables from securities financing transactions		83,494	82,384	74,210
Cash collateral receivables on derivative instruments	11	29,787	35,050	32,737
Loans and advances to customers	9	391,406	380,141	380,977
Other financial assets measured at amortized cost	12	27,201	26,837	27,219
Total financial assets measured at amortized cost		708,937	701,674	688,717
Financial assets at fair value held for trading	10	122,628	120,717	125,492
<i>of which: assets pledged as collateral that may be sold or repledged by counterparties</i>		<i>44,333</i>	<i>48,385</i>	<i>47,098</i>
Derivative financial instruments	10, 11	121,622	148,284	159,618
Brokerage receivables	10	23,010	24,201	24,659
Financial assets at fair value not held for trading	10	64,952	68,763	80,038
Total financial assets measured at fair value through profit or loss		332,211	361,964	389,808
Financial assets measured at fair value through other comprehensive income	10	7,775	8,100	8,258
Investments in associates		1,198	1,542	1,557
Property, equipment and software		11,732	11,610	11,958
Goodwill and intangible assets		6,452	6,427	6,480
Deferred tax assets		8,951	9,161	9,174
Other non-financial assets	12	8,603	8,755	9,374
Total assets		1,085,861	1,109,234	1,125,327

Balance sheet (continued)

<i>USD million</i>	Note	30.6.21	31.3.21	31.12.20
Liabilities				
Amounts due to banks		14,615	12,564	11,050
Payables from securities financing transactions		5,972	6,651	6,321
Cash collateral payables on derivative instruments	11	32,193	36,571	37,313
Customer deposits		517,462	508,903	527,929
Funding from UBS Group AG		55,907	57,699	53,979
Debt issued measured at amortized cost	14	84,491	87,495	85,351
Other financial liabilities measured at amortized cost	12	10,671	9,624	10,421
Total financial liabilities measured at amortized cost		721,311	719,508	732,364
Financial liabilities at fair value held for trading	10	33,348	37,062	33,595
Derivative financial instruments	10, 11	121,688	146,041	161,102
Brokerage payables designated at fair value	10	39,129	45,600	38,742
Debt issued designated at fair value	10, 13	72,799	64,635	59,868
Other financial liabilities designated at fair value	10, 12	32,908	30,769	31,773
Total financial liabilities measured at fair value through profit or loss		299,871	324,108	325,080
Provisions	16	2,792	2,693	2,791
Other non-financial liabilities	12	6,241	5,171	7,018
Total liabilities		1,030,216	1,051,481	1,067,254
Equity				
Share capital		338	338	338
Share premium		24,542	24,579	24,580
Retained earnings		24,414	26,926	25,251
Other comprehensive income recognized directly in equity, net of tax		6,067	5,603	7,585
Equity attributable to shareholders		55,361	57,446	57,754
Equity attributable to non-controlling interests		284	307	319
Total equity		55,645	57,753	58,073
Total liabilities and equity		1,085,861	1,109,234	1,125,327

Statement of changes in equity

<i>USD million</i>	Share capital	Share premium	Retained earnings
Balance as of 1 January 2020	338	24,659	23,419
Tax (expense) / benefit		(2)	
Dividends			(2,550)
Translation effects recognized directly in retained earnings			(11)
Share of changes in retained earnings of associates and joint ventures			(40)
New consolidations / (deconsolidations) and other increases / (decreases)		0	
Total comprehensive income for the period			2,406
<i>of which: net profit / (loss)</i>			2,615
<i>of which: OCI that may be reclassified to the income statement, net of tax</i>			
<i>of which: OCI that will not be reclassified to the income statement, net of tax – defined benefit plans</i>			(270)
<i>of which: OCI that will not be reclassified to the income statement, net of tax – own credit</i>			62
<i>of which: OCI that will not be reclassified to the income statement, net of tax – foreign currency translation</i>			
Balance as of 30 June 2020	338	24,657	23,225
Balance as of 1 January 2021	338	24,580	25,251
Tax (expense) / benefit		2	
Dividends			(4,539)
Translation effects recognized directly in retained earnings			19
Share of changes in retained earnings of associates and joint ventures			2
New consolidations / (deconsolidations) and other increases / (decreases)		(39)	
Total comprehensive income for the period			3,681
<i>of which: net profit / (loss)</i>			3,623
<i>of which: OCI that may be reclassified to the income statement, net of tax</i>			
<i>of which: OCI that will not be reclassified to the income statement, net of tax – defined benefit plans</i>			(31)
<i>of which: OCI that will not be reclassified to the income statement, net of tax – own credit</i>			89
<i>of which: OCI that will not be reclassified to the income statement, net of tax – foreign currency translation</i>			
Balance as of 30 June 2021	338	24,542	24,414

¹ Excludes other comprehensive income related to defined benefit plans and own credit that is recorded directly in Retained earnings.

<i>Other comprehensive income recognized directly in equity, net of tax¹</i>	<i>of which: foreign currency translation</i>	<i>of which: financial assets measured at fair value through OCI</i>	<i>of which: cash flow hedges</i>	<i>of which: cost of hedging</i>	Total equity attributable to shareholders	Non-controlling interests	Total equity
5,306	4,032	14	1,260		53,722	174	53,896
					(2)		(2)
					(2,550)	(4)	(2,554)
11		0	11		0		0
					(40)		(40)
					0	0	0
1,847	103	149	1,600	(4)	4,254	3	4,256
					2,615	6	2,621
1,847	103	149	1,600	(4)	1,847		1,847
					(270)		(270)
					62		62
					0	(4)	(4)
7,164	4,134	163	2,871	(4)	55,384	173	55,557
7,585	5,126	151	2,321	(13)	57,754	319	58,073
					2		2
					(4,539)	(4)	(4,542)
(19)		0	(19)	0	0		0
					2		2
					(39)	(42)	(81)
(1,500)	(452)	(88)	(937)	(23)	2,181	10	2,192
					3,623	9	3,631
(1,500)	(452)	(88)	(937)	(23)	(1,500)		(1,500)
					(31)		(31)
					89		89
					0	2	2
6,067	4,675	63	1,365	(36)	55,361	284	55,645

Statement of cash flows

	Year-to-date	
<i>USD million</i>	30.6.21	30.6.20
Cash flow from / (used in) operating activities		
Net profit / (loss)	3,631	2,621
Non-cash items included in net profit and other adjustments:		
Depreciation and impairment of property, equipment and software	887	814
Amortization and impairment of goodwill and intangible assets	17	32
Credit loss expense / (release)	(108)	540
Share of net profits of associates / joint ventures and impairment of associates	(74)	(29)
Deferred tax expense / (benefit)	278	191
Net loss / (gain) from investing activities	(239)	240
Net loss / (gain) from financing activities	2,070	(7,047)
Other net adjustments	4,742	(595)
Net change in operating assets and liabilities:		
Loans and advances to banks / amounts due to banks	3,872	5,585
Securities financing transactions	(10,249)	3,167
Cash collateral on derivative instruments	(2,183)	(2,046)
Loans and advances to customers	(19,714)	(14,143)
Customer deposits	573	21,004
Financial assets and liabilities at fair value held for trading and derivative financial instruments	(1,278)	38,756
Brokerage receivables and payables	2,047	1,140
Financial assets at fair value not held for trading, other financial assets and liabilities	14,416	(7,484)
Provisions, other non-financial assets and liabilities	261	(1,323)
Income taxes paid, net of refunds	(363)	(364)
Net cash flow from / (used in) operating activities	(1,413)	41,060
Cash flow from / (used in) investing activities		
Purchase of subsidiaries, associates and intangible assets	(1)	(1)
Disposal of subsidiaries, associates and intangible assets ¹	437	14
Purchase of property, equipment and software	(757)	(725)
Disposal of property, equipment and software	264	4
Purchase of financial assets measured at fair value through other comprehensive income	(1,950)	(4,132)
Disposal and redemption of financial assets measured at fair value through other comprehensive income	2,324	1,944
Net (purchase) / redemption of debt securities measured at amortized cost	116	(4,817)
Net cash flow from / (used in) investing activities	434	(7,713)

Statement of cash flows (continued)

	Year-to-date	
<i>USD million</i>	30.6.21	30.6.20
Cash flow from / (used in) financing activities		
Net short-term debt issued / (repaid)	(3,877)	14,912
Distributions paid on UBS shares	(4,539)	(2,550)
Repayment of lease liabilities	(274)	(262)
Issuance of debt designated at fair value and long-term debt measured at amortized cost ²	63,845	46,001
Repayment of debt designated at fair value and long-term debt measured at amortized cost ²	(45,244)	(46,137)
Net changes in non-controlling interests	(4)	(4)
Net cash flow from / (used in) financing activities	9,908	11,960
Total cash flow		
Cash and cash equivalents at the beginning of the period	173,430	119,804
Net cash flow from / (used in) operating, investing and financing activities	8,929	45,308
Effects of exchange rate differences on cash and cash equivalents	(5,389)	1,567
Cash and cash equivalents at the end of the period³	176,971	166,679
<i>of which: cash and balances at central banks⁴</i>	<i>160,541</i>	<i>149,430</i>
<i>of which: loans and advances to banks</i>	<i>15,001</i>	<i>14,339</i>
<i>of which: money market paper</i>	<i>1,428</i>	<i>2,911</i>
Additional information		
Net cash flow from / (used in) operating activities includes:		
Interest received in cash	5,475	6,375
Interest paid in cash	2,703	4,249
Dividends on equity investments, investment funds and associates received in cash	1,263	1,104

¹ Includes cash proceeds from the sale of UBS's minority investment in Clearstream Fund Centre for the period ended 30 June 2021, and dividends received from associates in both periods. ² Includes funding from UBS Group AG measured at amortized cost (recognized in Funding from UBS Group AG in the balance sheet) and measured at fair value (recognized in Other financial liabilities designated at fair value in the balance sheet). ³ USD 3,432 million and USD 5,393 million of cash and cash equivalents (mainly reflected in Loans and advances to banks) were restricted as of 30 June 2021 and 30 June 2020, respectively. Refer to "Note 23 Restricted and transferred financial assets" in the "Consolidated financial statements" section of the Annual Report 2020 for more information. ⁴ Includes only balances with an original maturity of three months or less.

Notes to the UBS AG interim consolidated financial statements (unaudited)

Note 1 Basis of accounting and other financial reporting effects

Basis of preparation

The consolidated financial statements (the financial statements) of UBS AG and its subsidiaries (together, UBS AG) are prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (the IASB), and are presented in US dollars (USD). These interim financial statements are prepared in accordance with IAS 34, *Interim Financial Reporting*.

In preparing these interim financial statements, the same accounting policies and methods of computation have been applied as in the UBS AG consolidated annual financial statements for the period ended 31 December 2020, except for the changes described in this Note. These interim financial statements are unaudited and should be read in conjunction with UBS AG's audited consolidated financial statements included in the Annual Report 2020. In the opinion of management, all necessary adjustments were made for a fair presentation of UBS AG's financial position, results of operations and cash flows.

Preparation of these interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, expenses and disclosures of contingent assets and liabilities. These estimates and assumptions are based on the best available information. Actual results in the future could differ from such estimates and differences may be material to the financial statements. Revisions to estimates, based on regular reviews, are recognized in the period in which they occur. For more information about areas of estimation uncertainty that are considered to require critical judgment, refer to "Note 1a Significant accounting policies" in the "Consolidated financial statements" section of the Annual Report 2020.

Amendments to IFRS 9, IAS 39 and IFRS 7 (*Interest Rate Benchmark Reform – Phase 2*)

On 1 January 2021, UBS AG adopted *Interest Rate Benchmark Reform – Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16*, addressing a number of issues in financial reporting areas that arise when interbank offered rates (IBORs) are reformed or replaced.

The amendments provide a practical expedient which permits certain changes in the contractual cash flows of debt instruments attributable to the replacement of IBORs with alternative reference rates (ARRs) to be accounted for prospectively by updating the instrument's effective interest rate (EIR), provided (i) the change is necessary as a direct consequence of IBOR reform and (ii) the new basis for determining the contractual cash flows is economically equivalent to the previous basis.

UBS AG adopted the amendments, which provide a practical expedient with no material effect on the its financial statements.

Note 1 Basis of accounting and other financial reporting effects (continued)

Furthermore, the amendments provide various hedge accounting reliefs, with the following expected to benefit UBS AG.

– *Risk components*

The amendments permit UBS AG to designate an alternative benchmark rate as a non-contractually specified risk component, even if it is not separately identifiable at the date when it is designated, provided UBS AG can reasonably expect that it will meet the requirements within 24 months of the first designation and the risk component is reliably measurable. As of 30 June 2021, the alternative benchmark rates that UBS AG has designated as the hedged risk in fair value hedges of interest rate risk related to debt instruments and cash flow hedges of forecast transactions were the Secured Overnight Financing Rate (SOFR), the Swiss Average Rate Overnight (SARON) and the Sterling Overnight Index Average (SONIA). The designated notionals were USD 11 billion, USD 1.1 billion and USD 0.7 billion, respectively.

– *Hedge designation*

Following amendments to the hedge documentation to reflect the change in designation relating to IBOR reform, UBS AG will continue its hedge relationships provided the other hedge accounting criteria and requirements of the phase 2 amendment are met. As of 30 June 2021, no such changes have been made.

– *Amounts accumulated in the cash flow hedge reserve*

Upon changing the hedge designation as set out above, the accumulated amounts in the cash flow hedge reserve are

assumed to be based on the alternative benchmark rate. For discontinued hedging relationships, when the interest rate benchmark on which the hedged future cash flows were based is changed as required by IBOR reform, the amount accumulated in the cash flow hedge reserve is also assumed to be based on the alternative benchmark rate for the purpose of assessing whether the hedged future cash flows are still expected to occur. As of 30 June 2021, no such changes have been made.

– *Retrospective effectiveness assessment as applied to hedges designated under IAS 39*

Upon the end of the phase 1 relief for effectiveness assessment UBS AG may elect to reset to zero the cumulative fair value changes of the hedged item and hedging instrument for the purpose of assessing the retrospective effectiveness of a hedging relationship. As of 30 June 2021, no such election has been made.

› **Refer to “Note 25 Hedge accounting” in the “Consolidated financial statements” section of the Annual Report 2020 for details about phase 1 accounting reliefs**

The amendments also introduced additional disclosure requirements regarding UBS AG’s management of the transition to alternative benchmark rates, its progress at the reporting date and the risks to which it is exposed arising from financial instruments because of the transition.

› **Refer to Note 15 for more information**

Note 2 Segment reporting

UBS AG's businesses are organized globally into four business divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management and the Investment Bank. All four business divisions are supported by Group Functions and qualify as reportable segments for the purpose of segment reporting. Together with Group Functions they reflect the management structure of UBS AG.

- › Refer to "Note 2 Segment reporting" in the "Consolidated financial statements" section of the Annual Report 2020 for more information about UBS AG's reporting segments

USD million	Global Wealth Management	Personal & Corporate Banking	Asset Management	Investment Bank	Group Functions	UBS AG
For the six months ended 30 June 2021						
Net interest income	2,023	1,039	(7)	244	(103)	3,196
Non-interest income	7,582	1,063	1,310	4,479	167	14,603
Income	9,606	2,103	1,303	4,724	64	17,798
Credit loss (expense) / release	16	69	0	23	(1)	108
Total operating income	9,622	2,172	1,303	4,747	63	17,906
Total operating expenses	6,958	1,286	822	3,698	511	13,274
Operating profit / (loss) before tax	2,664	886	481	1,049	(448)	4,632
Tax expense / (benefit)						1,001
Net profit / (loss)						3,631
As of 30 June 2021						
Total assets	375,076	222,013	29,027	344,069	115,675	1,085,861
For the six months ended 30 June 2020						
Net interest income	2,054	1,029	(9)	3	(387)	2,689
Non-interest income	6,553	886	1,048	4,906	(20)	13,372
Income	8,607	1,914	1,038	4,909	(407)	16,061
Credit loss (expense) / release	(117)	(187)	0	(200)	(35)	(540)
Total operating income	8,489	1,727	1,038	4,709	(443)	15,521
Total operating expenses	6,421	1,155	724	3,419	478	12,197
Operating profit / (loss) before tax	2,068	573	314	1,290	(921)	3,324
Tax expense / (benefit)						703
Net profit / (loss)						2,621
As of 31 December 2020						
Total assets	367,714	231,710	28,266	369,778	127,858	1,125,327

Note 3 Net interest income

USD million	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Net interest income from financial instruments measured at amortized cost and fair value through other comprehensive income					
Interest income from loans and deposits ¹	1,613	1,586	1,633	3,198	3,504
Interest income from securities financing transactions ²	126	135	202	261	569
Interest income from other financial instruments measured at amortized cost	68	73	87	141	176
Interest income from debt instruments measured at fair value through other comprehensive income	16	35	35	51	52
Interest income from derivative instruments designated as cash flow hedges	284	268	178	553	290
Total interest income from financial instruments measured at amortized cost and fair value through other comprehensive income	2,107	2,098	2,135	4,205	4,591
Interest expense on loans and deposits ³	415	439	606	854	1,499
Interest expense on securities financing transactions ⁴	293	258	224	551	443
Interest expense on debt issued	126	137	256	263	523
Interest expense on lease liabilities	25	26	26	51	53
Total interest expense from financial instruments measured at amortized cost	860	859	1,112	1,719	2,519
Total net interest income from financial instruments measured at amortized cost and fair value through other comprehensive income	1,247	1,239	1,022	2,486	2,073
Net interest income from financial instruments measured at fair value through profit or loss					
Net interest income from financial instruments at fair value held for trading	195	201	244	397	446
Net interest income from brokerage balances	216	197	182	412	318
Net interest income from securities financing transactions at fair value not held for trading ⁵	12	12	18	24	51
Interest income from other financial instruments at fair value not held for trading	75	96	153	170	355
Interest expense on other financial instruments designated at fair value	(138)	(155)	(244)	(294)	(555)
Total net interest income from financial instruments measured at fair value through profit or loss	359	351	354	710	616
Total net interest income	1,607	1,589	1,376	3,196	2,689

¹ Consists of interest income from cash and balances at central banks, loans and advances to banks and customers, and cash collateral receivables on derivative instruments, as well as negative interest on amounts due to banks, customer deposits, and cash collateral payables on derivative instruments. ² Includes interest income on receivables from securities financing transactions and negative interest, including fees, on payables from securities financing transactions. ³ Consists of interest expense on amounts due to banks, cash collateral payables on derivative instruments, customer deposits, and funding from UBS Group AG, as well as negative interest on cash and balances at central banks, loans and advances to banks, and cash collateral receivables on derivative instruments. ⁴ Includes interest expense on payables from securities financing transactions and negative interest, including fees, on receivables from securities financing transactions. ⁵ Includes interest expense on securities financing transactions designated at fair value.

Note 4 Net fee and commission income

USD million	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Fee and commission income					
Underwriting fees	393	420	257	813	460
<i>of which: equity underwriting fees</i>	262	275	123	537	230
<i>of which: debt underwriting fees</i>	131	145	133	276	230
M&A and corporate finance fees	330	238	117	568	335
Brokerage fees	1,037	1,358	959	2,395	2,204
Investment fund fees	1,405	1,437	1,197	2,842	2,492
Portfolio management and related services	2,426	2,284	1,813	4,710	3,872
Other	456	461	387	917	848
Total fee and commission income¹	6,047	6,197	4,730	12,244	10,211
<i>of which: recurring</i>	3,823	3,621	2,980	7,444	6,321
<i>of which: transaction-based</i>	2,182	2,482	1,675	4,664	3,776
<i>of which: performance-based</i>	42	94	75	136	114
Fee and commission expense					
Brokerage fees paid	74	68	63	142	149
Distribution fees paid	153	132	144	285	300
Other	258	277	212	535	426
Total fee and commission expense	484	478	419	962	875
Net fee and commission income	5,563	5,719	4,311	11,282	9,336
<i>of which: net brokerage fees</i>	963	1,290	896	2,253	2,055

¹ Reflects third-party fee and commission income for the second quarter of 2021 of USD 3,585 million for Global Wealth Management (first quarter of 2021: USD 3,673 million; second quarter of 2020: USD 2,809 million), USD 400 million for Personal & Corporate Banking (first quarter of 2021: USD 389 million; second quarter of 2020: USD 313 million), USD 805 million for Asset Management (first quarter of 2021: USD 815 million; second quarter of 2020: USD 700 million), USD 1,248 million for the Investment Bank (first quarter of 2021: USD 1,305 million; second quarter of 2020: USD 872 million) and USD 9 million for Group Functions (first quarter of 2021: USD 15 million; second quarter of 2020: USD 36 million).

Note 5 Other income

UBS AG recognized USD 350 million of other income in the second quarter of 2021, compared with USD 153 million in the second quarter of 2020. This includes gains of USD 101 million from properties held for sale, largely driven by the sale of a

property in Basel, and other income of USD 45 million related to a legacy bankruptcy claim. In addition, the investment in Clearstream Fund Centre was sold to Deutsche Börse AG during the quarter, resulting in a USD 37 million net gain.

Note 6 Personnel expenses

<i>USD million</i>	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Salaries and variable compensation	2,432	2,370	2,276	4,802	4,408
Financial advisor compensation ¹	1,183	1,170	941	2,353	2,035
Contractors	38	36	35	75	64
Social security	187	211	182	398	347
Post-employment benefit plans	124 ²	194	143	319	321
Other personnel expenses	108	105	104	212	217
Total personnel expenses	4,072	4,086	3,682	8,158	7,391

¹ Financial advisor compensation consists of grid-based compensation based directly on compensable revenues generated by financial advisors and supplemental compensation calculated on the basis of financial advisor productivity, firm tenure, assets and other variables. It also includes expenses related to compensation commitments with financial advisors entered into at the time of recruitment that are subject to vesting requirements. ² Includes curtailment gains of USD 36 million, which represent a reduction in the defined benefit obligation related to the Swiss pension plan resulting from a decrease in headcount following restructuring activities.

Note 7 General and administrative expenses

<i>USD million</i>	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Outsourcing costs	95	89	99	184	211
IT expenses	122	125	106	247	222
Consulting, legal and audit fees	115	84	137	199	269
Real estate and logistics costs	126	127	134	253	271
Market data services	93	89	89	182	175
Marketing & communication	36	32	25	68	56
Travel and entertainment	12	8	10	20	54
Litigation, regulatory & similar matters ¹	63	9	2	72	8
Other ²	1,408	1,578	1,278	2,986	2,695
<i>of which: shared services costs charged by UBS Group AG or its subsidiaries</i>	<i>1,294</i>	<i>1,375</i>	<i>1,127</i>	<i>2,669</i>	<i>2,377</i>
<i>of which: UK and German bank levies</i>	<i>(11)</i>	<i>41</i>	<i>3</i>	<i>30</i>	<i>17</i>
Total general and administrative expenses	2,070	2,141	1,879	4,211	3,960

¹ Reflects the net increase in / (release of) provisions for litigation, regulatory and similar matters recognized in the income statement. Refer to Note 16 for more information. ² Includes charitable donations.

Note 8 Income taxes

Income tax expenses of USD 563 million were recognized for the second quarter of 2021, representing an effective tax rate of 22.7%, compared with USD 328 million for the second quarter of 2020 and an effective tax rate of 21.5%.

Current tax expenses were USD 346 million, compared with USD 329 million, and related to taxable profits of UBS Switzerland AG and other entities.

Deferred tax expenses were USD 217 million, compared with a net deferred tax benefit of USD 1 million, and primarily related to the amortization of deferred tax assets previously recognized in relation to tax losses carried forward and deductible temporary differences of UBS Americas Inc.

Note 9 Expected credit loss measurement

a) Credit loss expense / release

Total net credit loss releases were USD 80 million in the second quarter of 2021, reflecting an USD 88 million net release of credit losses related to stage 1 and 2 positions and USD 8 million of net credit loss expenses related to credit-impaired (stage 3) positions.

The USD 88 million stage 1 and 2 net release included the partial release of a post-model adjustment of USD 91 million (representing one-third of the USD 273 million scenario-driven

model output effects from the third quarter of 2020 to the second quarter of 2021), due to the continued positive trend in macroeconomic scenario input data.

Stage 3 net credit loss expenses were USD 8 million, including USD 3 million net expenses in the Investment Bank and USD 5 million net expenses in Personal & Corporate Banking, across various corporate lending positions.

Credit loss (expense) / release

<i>USD million</i>	Global Wealth Management	Personal & Corporate Banking	Asset Management	Investment Bank	Group Functions	Total
For the quarter ended 30.6.21						
Stages 1 and 2	13	51	0	24	(1)	88
Stage 3	0	(5)	0	(3)	0	(8)
Total credit loss (expense) / release	14	46	0	21	(1)	80

Note 9 Expected credit loss measurement (continued)**b) Changes to ECL models, scenarios, scenario weights and key inputs****Scenarios**

The expected credit loss (ECL) scenarios, along with the related macroeconomic factors, were updated and reviewed in light of the economic and political conditions prevailing for the second quarter of 2021 through a series of governance meetings, with input and feedback from UBS risk and finance experts across the business divisions and regions. Effective from the second quarter of 2021, management has included an upside scenario and a mild downside scenario in the ECL calculation similar to the approach applied before the COVID-19 pandemic, as uncertainty regarding future economic developments and the related effects on models further decline and post-model adjustment levels decrease.

The upside scenario assumes that positive developments regarding COVID-19 enable economic activity to rebound more quickly than expected, supported by significant improvements in business and consumer activity. Structural changes from the lockdown period and accelerated technology uptake increase productivity and help to keep growth buoyant beyond the initial rebound in activity. Underlying macroeconomic conditions improve, and asset values increase substantially.

The mild downside scenario assumes a shift in sentiment caused by higher-than-expected inflation and the Federal Reserve's intention to begin tapering its quantitative easing program. Long-term interest rates rise sharply and equities decline as market volatility ensues. Economic activity slows across the globe causing a mild recession.

The baseline and severe downside scenarios included slightly more optimistic assumptions compared with those applied in the first quarter of 2021, reflecting improvements in economic activity, greater optimism regarding the availability and effective distribution of COVID-19 vaccines, and continued government

support. The baseline scenario assumptions on a calendar-year basis are included in the table below.

Scenario weights and post-model adjustments

Management applied the following scenario weightings effective from the second quarter of 2021: upside at 5%, baseline at 55%, mild downside at 10% and severe downside at 30%. This compared with a baseline scenario weighting of 60% and a severe downside scenario weighting of 40% applied in the first quarter of 2021. The incorporation of the two new scenarios and the applied weightings did not have a material effect on allowances and provisions.

In addition, more than one year after the exceptional circumstances of the COVID-19 pandemic began, management has released one-third (USD 91 million) of the USD 273 million post-model adjustment for scenario-driven model output effects into profit or loss in the second quarter of 2021, following a portfolio level review, which supported partial overlay releases, particularly in real estate and large corporate segments. This decision was made following a continued positive trend in macroeconomic scenario input data (from the third quarter of 2020 to the second quarter of 2021), as well as positive vaccination developments and gradual lifting of lockdowns in many economies. Two-thirds of the post-model adjustment for scenario-driven model output effects (USD 183 million) was retained, given the heightened level of uncertainty that remains with regard to the ultimate effects of the crisis. This recognizes that new challenges are frequently arising in the context of the pandemic, for example, the spread of new variants of COVID-19, inflationary pressure from supply chain disruption and surging demand, and the risk of potential tail effects as government and central bank support winds down.

Key parameters	Baseline		
	2020	2021	2022
Real GDP growth (annual percentage change)			
United States	(3.6)	6.9	5.9
Eurozone	(7.4)	4.3	5.3
Switzerland	(4.5)	3.3	3.0
Unemployment rate (% annual average)			
United States	8.1	5.4	4.4
Eurozone	8.5	8.6	8.1
Switzerland	3.2	3.3	3.1
Real estate (annual percentage change, Q4)			
United States	3.4	6.5	2.9
Eurozone	(0.3)	2.9	1.0
Switzerland	4.0	5.0	1.0

Economic scenarios and weights applied

ECL scenario	Assigned weights in %		
	2020	2021	2022
	30.6.21	31.3.21	31.3.20
Upside	5.0	0.0	0.0
Baseline	55.0	60.0	70.0
Mild downside	10.0	0.0	0.0
Severe downside	30.0	40.0	30.0

Note 9 Expected credit loss measurement (continued)

c) ECL-relevant balance sheet and off-balance sheet positions including ECL allowances and provisions

The tables below and on the following pages provide information about financial instruments and certain non-financial instruments that are subject to ECL requirements. For amortized-cost instruments, the carrying amount represents the maximum exposure to credit risk, taking into account the allowance for credit losses. Financial assets measured at fair value through other comprehensive income (FVOCI) are also subject to ECL; however, unlike amortized-cost instruments, the allowance for credit losses for FVOCI instruments does not

reduce the carrying amount of these financial assets. Instead, the carrying amount of financial assets measured at FVOCI represents the maximum exposure to credit risk.

In addition to on-balance sheet financial assets, certain off-balance sheet and other credit lines are also subject to ECL. The maximum exposure to credit risk for off-balance sheet financial instruments is calculated based on the maximum contractual amounts.

USD million	30.6.21				ECL allowances / provisions			
	Carrying amount ¹ / Total exposure				Total	Stage 1	Stage 2	Stage 3
Financial instruments measured at amortized cost								
Cash and balances at central banks	160,672	160,672	0	0	0	0	0	0
Loans and advances to banks	16,376	16,333	42	0	(8)	(6)	(1)	(1)
Receivables from securities financing transactions	83,494	83,494	0	0	(3)	(3)	0	0
Cash collateral receivables on derivative instruments	29,787	29,787	0	0	0	0	0	0
Loans and advances to customers	391,406	371,090	18,403	1,913	(950)	(124)	(156)	(670)
<i>of which: Private clients with mortgages</i>	147,827	137,851	9,140	836	(139)	(26)	(76)	(37)
<i>of which: Real estate financing</i>	42,627	37,950	4,663	14	(49)	(17)	(32)	0
<i>of which: Large corporate clients</i>	14,294	12,671	1,229	395	(246)	(20)	(19)	(207)
<i>of which: SME clients</i>	14,116	11,753	1,814	549	(291)	(20)	(19)	(253)
<i>of which: Lombard</i>	146,167	146,135	0	32	(35)	(6)	0	(29)
<i>of which: Credit cards</i>	1,611	1,255	327	28	(34)	(9)	(9)	(16)
<i>of which: Commodity trade finance</i>	3,399	3,345	38	16	(103)	(5)	0	(98)
Other financial assets measured at amortized cost	27,201	26,456	436	309	(124)	(30)	(9)	(86)
<i>of which: Loans to financial advisors</i>	2,415	1,924	197	295	(103)	(23)	(6)	(74)
Total financial assets measured at amortized cost	708,937	687,833	18,882	2,222	(1,085)	(163)	(166)	(757)
Financial assets measured at fair value through other comprehensive income	7,775	7,775	0	0	0	0	0	0
Total on-balance sheet financial assets in scope of ECL requirements	716,713	695,609	18,882	2,222	(1,085)	(163)	(166)	(757)
Off-balance sheet (in scope of ECL)								
Guarantees	17,457	15,719	1,580	158	(52)	(15)	(9)	(27)
<i>of which: Large corporate clients</i>	3,142	1,995	1,035	112	(13)	(3)	(3)	(7)
<i>of which: SME clients</i>	1,269	1,002	222	46	(13)	(1)	(1)	(12)
<i>of which: Financial intermediaries and hedge funds</i>	7,465	7,257	208	0	(16)	(10)	(5)	0
<i>of which: Lombard</i>	2,166	2,166	0	0	(1)	0	0	(1)
<i>of which: Commodity trade finance</i>	2,372	2,342	30	0	(2)	(1)	0	(1)
Irrevocable loan commitments	37,751	34,505	3,064	181	(118)	(69)	(49)	0
<i>of which: Large corporate clients</i>	22,464	19,621	2,718	125	(103)	(61)	(42)	0
Forward starting reverse repurchase and securities borrowing agreements	8,253	8,253	0	0	0	0	0	0
Committed unconditionally revocable credit lines	40,667	37,072	3,526	68	(36)	(28)	(8)	0
<i>of which: Real estate financing</i>	6,542	6,135	407	0	(5)	(4)	(1)	0
<i>of which: Large corporate clients</i>	4,383	2,924	1,434	25	(7)	(4)	(3)	0
<i>of which: SME clients</i>	5,173	4,498	643	32	(14)	(12)	(2)	0
<i>of which: Lombard</i>	8,632	8,632	0	0	0	0	0	0
<i>of which: Credit cards</i>	9,298	8,825	464	9	(6)	(5)	(2)	0
<i>of which: Commodity trade finance</i>	251	251	0	0	0	0	0	0
Irrevocable committed prolongation of existing loans	5,281	5,260	20	1	(3)	(2)	(1)	0
Total off-balance sheet financial instruments and other credit lines	109,409	100,810	8,191	408	(209)	(114)	(67)	(27)
Total allowances and provisions					(1,294)	(277)	(233)	(784)

¹ The carrying amount of financial assets measured at amortized cost represents the total gross exposure net of the respective ECL allowances.

Note 9 Expected credit loss measurement (continued)

USD million	31.3.21				ECL allowances / provisions			
	Carrying amount ¹ / Total exposure				Total	Stage 1	Stage 2	Stage 3
Financial instruments measured at amortized cost	Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
Cash and balances at central banks	158,914	158,914	0	0	0	0	0	0
Loans and advances to banks	18,348	18,287	61	0	(12)	(8)	(3)	(1)
Receivables from securities financing transactions	82,384	82,385	0	0	(3)	(3)	0	0
Cash collateral receivables on derivative instruments	35,050	35,050	0	0	0	0	0	0
Loans and advances to customers	380,141	359,130	18,995	2,016	(993)	(138)	(184)	(671)
<i>of which: Private clients with mortgages</i>	142,611	132,636	9,118	857	(158)	(37)	(86)	(35)
<i>of which: Real estate financing</i>	41,092	36,099	4,979	15	(56)	(15)	(41)	0
<i>of which: Large corporate clients</i>	13,305	11,155	1,673	477	(271)	(28)	(28)	(216)
<i>of which: SME clients</i>	14,034	11,620	1,886	527	(283)	(19)	(19)	(246)
<i>of which: Lombard</i>	141,139	141,112	0	27	(34)	(5)	0	(30)
<i>of which: Credit cards</i>	1,392	1,063	301	28	(33)	(9)	(8)	(16)
<i>of which: Commodity trade finance</i>	3,695	3,663	16	15	(101)	(5)	0	(96)
Other financial assets measured at amortized cost	26,837	26,103	314	420	(125)	(32)	(7)	(86)
<i>of which: Loans to financial advisors</i>	2,473	1,961	107	405	(104)	(26)	(4)	(75)
Total financial assets measured at amortized cost	701,674	679,868	19,371	2,436	(1,133)	(180)	(195)	(758)
Financial assets measured at fair value through other comprehensive income	8,100	8,100	0	0	0	0	0	0
Total on-balance sheet financial assets in scope of ECL requirements	709,774	687,967	19,371	2,436	(1,133)	(180)	(195)	(758)
Off-balance sheet (in scope of ECL)								
Guarantees	17,493	15,377	1,952	164	(59)	(15)	(15)	(29)
<i>of which: Large corporate clients</i>	3,425	2,025	1,281	119	(17)	(3)	(5)	(9)
<i>of which: SME clients</i>	1,243	936	262	45	(12)	0	(1)	(11)
<i>of which: Financial intermediaries and hedge funds</i>	7,579	7,304	275	0	(18)	(9)	(9)	0
<i>of which: Lombard</i>	2,136	2,136	0	0	(2)	0	0	(1)
<i>of which: Commodity trade finance</i>	2,057	2,031	26	0	(4)	(1)	0	(3)
Irrevocable loan commitments	38,137	34,312	3,730	95	(138)	(75)	(63)	0
<i>of which: Large corporate clients</i>	22,943	19,600	3,278	65	(121)	(68)	(54)	0
Forward starting reverse repurchase and securities borrowing agreements	5,988	5,988	0	0	0	0	0	0
Committed unconditionally revocable credit lines	39,835	35,722	4,023	89	(45)	(27)	(18)	0
<i>of which: Real estate financing</i>	7,227	6,786	432	9	(11)	(5)	(6)	0
<i>of which: Large corporate clients</i>	4,429	2,713	1,690	25	(9)	(3)	(6)	0
<i>of which: SME clients</i>	5,036	4,120	878	39	(14)	(11)	(3)	0
<i>of which: Lombard</i>	8,566	8,566	0	0	(1)	(1)	0	0
<i>of which: Credit cards</i>	9,175	8,695	469	11	(6)	(5)	(1)	0
<i>of which: Commodity trade finance</i>	322	322	0	0	0	0	0	0
Irrevocable committed prolongation of existing loans	5,824	5,785	34	5	(3)	(3)	0	0
Total off-balance sheet financial instruments and other credit lines	107,276	97,184	9,738	354	(245)	(121)	(95)	(29)
Total allowances and provisions					(1,378)	(301)	(290)	(787)

¹ The carrying amount of financial assets measured at amortized cost represents the total gross exposure net of the respective ECL allowances.

Note 9 Expected credit loss measurement (continued)

USD million	31.12.20							
	Carrying amount ¹ / Total exposure				ECL allowances / provisions			
	Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
Financial instruments measured at amortized cost								
Cash and balances at central banks	158,231	158,231	0	0	0	0	0	0
Loans and advances to banks	15,344	15,160	184	0	(16)	(9)	(5)	(1)
Receivables from securities financing transactions	74,210	74,210	0	0	(2)	(2)	0	0
Cash collateral receivables on derivative instruments	32,737	32,737	0	0	0	0	0	0
Loans and advances to customers	380,977	358,396	20,341	2,240	(1,060)	(142)	(215)	(703)
<i>of which: Private clients with mortgages</i>	148,175	138,769	8,448	959	(166)	(35)	(93)	(39)
<i>of which: Real estate financing</i>	43,429	37,568	5,838	23	(63)	(15)	(44)	(4)
<i>of which: Large corporate clients</i>	15,161	12,658	2,029	474	(279)	(27)	(40)	(212)
<i>of which: SME clients</i>	14,872	11,990	2,254	628	(310)	(19)	(23)	(268)
<i>of which: Lombard</i>	133,850	133,795	0	55	(36)	(5)	0	(31)
<i>of which: Credit cards</i>	1,558	1,198	330	30	(38)	(11)	(11)	(16)
<i>of which: Commodity trade finance</i>	3,269	3,214	43	12	(106)	(5)	0	(101)
Other financial assets measured at amortized cost	27,219	26,401	348	469	(133)	(34)	(9)	(90)
<i>of which: Loans to financial advisors</i>	2,569	1,982	137	450	(108)	(27)	(5)	(76)
Total financial assets measured at amortized cost	688,717	665,135	20,873	2,709	(1,211)	(187)	(229)	(795)
Financial assets measured at fair value through other comprehensive income	8,258	8,258	0	0	0	0	0	0
Total on-balance sheet financial assets in scope of ECL requirements	696,976	673,394	20,873	2,709	(1,211)	(187)	(229)	(795)
Off-balance sheet (in scope of ECL)								
Guarantees	17,081	14,687	2,225	170	(63)	(14)	(15)	(34)
<i>of which: Large corporate clients</i>	3,710	2,048	1,549	113	(20)	(4)	(5)	(12)
<i>of which: SME clients</i>	1,310	936	326	48	(13)	(1)	(1)	(11)
<i>of which: Financial intermediaries and hedge funds</i>	7,637	7,413	224	0	(17)	(7)	(9)	0
<i>of which: Lombard</i>	641	633	0	8	(2)	0	0	(2)
<i>of which: Commodity trade finance</i>	1,441	1,416	25	0	(2)	(1)	0	0
Irrevocable loan commitments	41,372	36,894	4,374	104	(142)	(74)	(68)	0
<i>of which: Large corporate clients</i>	24,209	20,195	3,950	64	(121)	(63)	(58)	0
Forward starting reverse repurchase and securities borrowing agreements	3,247	3,247	0	0	0	0	0	0
Committed unconditionally revocable credit lines	42,077	37,176	4,792	108	(50)	(29)	(21)	0
<i>of which: Real estate financing</i>	6,328	5,811	517	0	(12)	(5)	(7)	0
<i>of which: Large corporate clients</i>	4,909	2,783	2,099	27	(9)	(2)	(7)	0
<i>of which: SME clients</i>	5,827	4,596	1,169	63	(16)	(12)	(4)	0
<i>of which: Lombard</i>	9,671	9,671	0	0	0	(1)	0	0
<i>of which: Credit cards</i>	8,661	8,220	430	11	(8)	(6)	(2)	0
<i>of which: Commodity trade finance</i>	242	242	0	0	0	0	0	0
Irrevocable committed prolongation of existing loans	3,282	3,277	5	0	(2)	(2)	0	0
Total off-balance sheet financial instruments and other credit lines	107,059	95,281	11,396	382	(257)	(119)	(104)	(34)
Total allowances and provisions					(1,468)	(306)	(333)	(829)

¹ The carrying amount of financial assets measured at amortized cost represents the total gross exposure net of the respective ECL allowances.

Note 9 Expected credit loss measurement (continued)

The table below provides information about the ECL gross exposure and the ECL coverage ratio for our core loan portfolios (i.e., *Loans and advances to customers* and *Loans to financial advisors*) and relevant off-balance sheet exposures. *Cash and balances at central banks, Loans and advances to banks, Receivables from securities financing transactions, Cash collateral receivables on derivative instruments* and *Financial assets*

measured at fair value through other comprehensive income are not included in the table below, due to their lower sensitivity to ECL.

ECL coverage ratios are calculated by taking ECL allowances and provisions divided by the gross carrying amount of the exposures.

Coverage ratios for core loan portfolio

30.6.21

	Gross carrying amount (USD million)				ECL coverage (bps)			
	Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
On-balance sheet								
Private clients with mortgages	147,966	137,877	9,216	874	9	2	82	427
Real estate financing	42,677	37,967	4,696	14	12	4	69	101
Large corporate clients	14,540	12,691	1,247	602	169	16	151	3,446
SME clients	14,407	11,772	1,833	802	202	17	102	3,152
Lombard	146,202	146,141	0	61	2	0	0	4,698
Credit cards	1,644	1,264	336	44	205	72	261	3,608
Commodity trade finance	3,503	3,350	38	114	295	15	2	8,605
Other loans and advances to customers	21,418	20,152	1,193	73	25	11	13	4,051
Loans to financial advisors	2,518	1,946	202	369	408	116	290	2,016
Total¹	394,875	373,161	18,762	2,952	27	4	86	2,521

	Gross exposure (USD million)				ECL coverage (bps)			
	Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
Off-balance sheet								
Private clients with mortgages	8,063	7,809	251	3	4	4	7	349
Real estate financing	8,048	7,596	452	0	9	7	49	0
Large corporate clients	29,990	24,540	5,187	262	41	27	91	278
SME clients	8,273	7,099	1,040	134	43	20	91	878
Lombard	14,736	14,735	0	0	1	0	0	0
Credit cards	9,298	8,825	464	9	7	5	33	0
Commodity trade finance	2,623	2,593	30	0	8	5	50	0
Financial intermediaries and hedge funds	12,447	11,981	466	0	14	10	120	0
Other off-balance sheet commitments	7,678	7,377	301	0	17	8	21	0
Total²	101,155	92,556	8,191	408	21	12	82	671

¹ Includes Loans and advances to customers of USD 392,357 million and Loans to financial advisors of USD 2,518 million, which are presented on the balance sheet line Other assets measured at amortized cost.

² Excludes Forward starting reverse repurchase and securities borrowing agreements.

Note 9 Expected credit loss measurement (continued)

Coverage ratios for core loan portfolio		31.3.21							
On-balance sheet	Gross carrying amount (USD million)				ECL coverage (bps)				
	Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3	
Private clients with mortgages	142,770	132,673	9,204	893	11	3	93	396	
Real estate financing	41,148	36,113	5,020	15	14	4	81	78	
Large corporate clients	13,577	11,184	1,701	692	200	25	162	3,114	
SME clients	14,317	11,639	1,905	773	198	16	98	3,179	
Lombard	141,173	141,117	0	56	2	0	0	5,260	
Credit cards	1,425	1,073	309	44	233	88	266	3,555	
Commodity trade finance	3,796	3,668	16	111	267	14	2	8,620	
Other loans and advances to customers	22,928	21,801	1,024	103	24	9	26	3,211	
Loans to financial advisors	2,578	1,987	111	480	405	131	337	1,558	
Total¹	383,711	361,254	19,290	3,167	29	5	97	2,355	

Off-balance sheet	Gross exposure (USD million)				ECL coverage (bps)			
	Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
Private clients with mortgages	7,455	7,226	217	13	6	5	16	111
Real estate financing	8,513	8,049	455	9	17	7	192	53
Large corporate clients	30,796	24,339	6,249	209	48	31	102	422
SME clients	8,101	6,626	1,367	108	41	20	70	973
Lombard	14,603	14,603	0	0	2	1	0	0
Credit cards	9,175	8,695	469	11	7	6	30	0
Commodity trade finance	2,379	2,352	26	0	18	5	28	0
Financial intermediaries and hedge funds	11,501	10,879	622	0	18	10	169	0
Other off-balance sheet commitments	8,764	8,428	332	4	14	7	23	0
Total²	101,288	91,196	9,738	354	24	13	98	831

¹ Includes Loans and advances to customers of USD 381,133 million and Loans to financial advisors of USD 2,578 million, which are presented on the balance sheet line Other assets measured at amortized cost.

² Excludes Forward starting reverse repurchase and securities borrowing agreements.

Note 9 Expected credit loss measurement (continued)

Coverage ratios for core loan portfolio		31.12.20							
		Gross carrying amount (USD million)				ECL coverage (bps)			
On-balance sheet		Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
Private clients with mortgages		148,341	138,803	8,540	998	11	2	108	390
Real estate financing		43,492	37,583	5,883	27	15	4	75	1,414
Large corporate clients		15,440	12,684	2,069	686	181	21	192	3,089
SME clients		15,183	12,010	2,277	896	204	16	101	2,991
Lombard		133,886	133,800	0	86	3	0	0	3,592
Credit cards		1,596	1,209	342	46	240	91	333	3,488
Commodity trade finance		3,375	3,219	43	113	315	16	2	8,939
Other loans and advances to customers		20,722	19,229	1,402	91	29	13	25	3,563
Loans to financial advisors		2,677	2,009	142	526	404	135	351	1,446
Total¹		384,714	360,547	20,697	3,470	30	5	106	2,247
Off-balance sheet		Total	Stage 1	Stage 2	Stage 3	Total	Stage 1	Stage 2	Stage 3
Private clients with mortgages		6,285	6,083	198	3	7	6	16	197
Real estate financing		7,056	6,576	481	0	21	9	185	0
Large corporate clients		32,828	25,026	7,598	205	46	27	92	565
SME clients		9,121	7,239	1,734	148	40	19	63	779
Lombard		14,178	14,170	0	8	2	1	0	1,941
Credit cards		8,661	8,220	430	11	9	8	44	0
Commodity trade finance		1,683	1,658	25	0	10	8	15	0
Financial intermediaries and hedge funds		7,690	7,270	448	0	26	13	248	166
Other off-balance sheet commitments		16,309	15,792	482	8	12	6	11	0
Total²		103,812	92,034	11,396	382	25	13	91	894

¹ Includes Loans and advances to customers of USD 382,036 million and Loans to financial advisors of USD 2,677 million which are presented on the balance sheet line Other assets measured at amortized cost.
² Excludes Forward starting reverse repurchase and securities borrowing agreements.

Note 10 Fair value measurement

This Note provides fair value measurement information for both financial and non-financial instruments and should be read in conjunction with "Note 21 Fair value measurement" in the "Consolidated financial statements" section of the Annual Report 2020, which provides more information about valuation principles, valuation governance, fair value hierarchy classification, valuation adjustments, valuation techniques and inputs, sensitivity of fair value measurements, and methods applied to calculate fair values for financial instruments not measured at fair value.

› Refer to the "Balance sheet and off-balance sheet" section of this report for more information about quarter-on-quarter balance sheet movements

All financial and non-financial assets and liabilities measured or disclosed at fair value are categorized into one of three fair value hierarchy levels. In certain cases, the inputs used to measure fair value may fall within different levels of the fair value hierarchy. For disclosure purposes, the level in the hierarchy within which the instrument is classified in its entirety is based on the lowest-level input that is significant to the position's fair value measurement:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities;
- Level 2 – valuation techniques for which all significant inputs are, or are based on, observable market data; or
- Level 3 – valuation techniques for which significant inputs are not based on observable market data.

Note 10 Fair value measurement (continued)

a) Fair value hierarchy

The fair value hierarchy classification of financial and non-financial assets and liabilities measured at fair value is summarized in the table below.

Determination of fair values from quoted market prices or valuation techniques¹

USD million	30.6.21				31.3.21				31.12.20			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value on a recurring basis												
Financial assets at fair value held for trading	103,722	16,782	2,123	122,628	101,907	16,630	2,179	120,717	107,526	15,630	2,337	125,492
of which:												
Equity instruments	86,760	1,336	128	88,224	85,251	736	137	86,124	90,327	1,101	171	91,599
Government bills / bonds	8,123	1,776	10	9,910	8,384	1,890	10	10,284	9,028	2,207	10	11,245
Investment fund units	8,048	1,707	18	9,773	7,400	1,602	31	9,033	7,374	1,794	23	9,192
Corporate and municipal bonds	784	8,524	821	10,129	865	9,926	783	11,575	789	8,432	817	10,038
Loans	0	3,115	1,000	4,114	0	2,234	1,052	3,285	0	1,860	1,134	2,995
Asset-backed securities	7	323	147	478	6	242	166	415	8	236	181	425
Derivative financial instruments	795	119,348	1,479	121,622	1,142	145,508	1,633	148,284	795	157,069	1,754	159,618
of which:												
Foreign exchange contracts	296	49,154	6	49,456	459	70,221	12	70,692	319	68,425	5	68,750
Interest rate contracts	0	38,104	342	38,446	0	39,529	391	39,920	0	50,353	537	50,890
Equity / index contracts	1	28,383	801	29,185	0	31,369	820	32,189	0	33,990	853	34,842
Credit derivative contracts	0	1,739	303	2,043	0	1,914	395	2,309	0	2,008	350	2,358
Commodity contracts	0	1,832	24	1,856	0	2,187	14	2,201	0	2,211	6	2,217
Brokerage receivables	0	23,010	0	23,010	0	24,201	0	24,201	0	24,659	0	24,659
Financial assets at fair value not held for trading	29,125	31,367	4,459	64,952	31,596	32,962	4,206	68,763	40,986	35,110	3,942	80,038
of which:												
Financial assets for unit-linked investment contracts	21,974	9	8	21,991	21,162	0	3	21,166	20,628	101	2	20,731
Corporate and municipal bonds	88	16,009	333	16,430	98	15,114	334	15,547	290	16,957	372	17,619
Government bills / bonds	6,640	3,331	0	9,971	9,985	3,970	0	13,956	19,704	3,593	0	23,297
Loans	0	5,626	1,087	6,712	0	6,900	1,093	7,993	0	7,699	862	8,561
Securities financing transactions	0	6,203	201	6,404	0	6,811	119	6,930	0	6,629	122	6,751
Auction rate securities	0	0	1,563	1,563	0	0	1,587	1,587	0	0	1,527	1,527
Investment fund units	317	172	120	610	263	165	99	528	278	121	105	505
Equity instruments	105	18	594	717	86	0	530	616	86	0	544	631
Other	0	0	554	554	0	0	441	441	0	10	408	418
Financial assets measured at fair value through other comprehensive income on a recurring basis												
Financial assets measured at fair value through other comprehensive income	2,165	5,611	0	7,775	2,154	5,946	0	8,100	1,144	7,114	0	8,258
of which:												
Asset-backed securities	0	5,200	0	5,200	0	5,480	0	5,480	0	6,624	0	6,624
Government bills / bonds	2,121	44	0	2,165	2,115	43	0	2,159	1,103	47	0	1,150
Corporate and municipal bonds	44	367	0	411	38	423	0	461	40	444	0	485
Non-financial assets measured at fair value on a recurring basis												
Precious metals and other physical commodities	5,470	0	0	5,470	5,709	0	0	5,709	6,264	0	0	6,264
Non-financial assets measured at fair value on a non-recurring basis												
Other non-financial assets ²	0	1	67	68	0	1	247	248	0	1	245	246
Total assets measured at fair value	141,277	196,119	8,129	345,525	142,508	225,248	8,266	376,022	156,716	239,583	8,278	404,576

Note 10 Fair value measurement (continued)**Determination of fair values from quoted market prices or valuation techniques (continued)¹**

USD million	30.6.21				31.3.21				31.12.20			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Financial liabilities measured at fair value on a recurring basis												
Financial liabilities at fair value held for trading	27,038	6,216	94	33,348	30,888	6,114	61	37,062	26,889	6,652	55	33,595
<i>of which:</i>												
Equity instruments	20,826	387	75	21,288	26,191	151	50	26,392	22,519	425	40	22,985
Corporate and municipal bonds	37	4,592	13	4,642	32	4,718	7	4,757	31	4,048	9	4,089
Government bills / bonds	5,727	620	0	6,347	4,168	807	0	4,975	3,642	1,036	0	4,678
Investment fund units	442	581	6	1,028	492	397	3	891	696	1,127	5	1,828
Derivative financial instruments	754	117,985	2,950	121,688	1,405	141,522	3,114	146,041	746	156,884	3,471	161,102
<i>of which:</i>												
Foreign exchange contracts	280	47,050	59	47,389	541	67,047	54	67,642	316	70,149	61	70,527
Interest rate contracts	0	32,177	526	32,703	0	33,501	546	34,046	0	43,389	527	43,916
Equity / index contracts	9	34,431	1,902	36,342	0	36,614	2,070	38,684	0	38,870	2,306	41,176
Credit derivative contracts	0	2,000	392	2,392	0	2,139	369	2,508	0	2,403	528	2,931
Commodity contracts	0	2,034	51	2,085	0	1,907	59	1,966	0	2,003	24	2,027
Financial liabilities designated at fair value on a recurring basis												
Brokerage payables designated at fair value	0	39,129	0	39,129	0	45,600	0	45,600	0	38,742	0	38,742
Debt issued designated at fair value	0	60,321	12,478	72,799	0	53,900	10,736	64,635	0	50,273	9,595	59,868
Other financial liabilities designated at fair value	0	30,032	2,876	32,908	0	28,317	2,452	30,769	0	29,682	2,091	31,773
<i>of which:</i>												
Financial liabilities related to unit-linked investment contracts	0	22,217	0	22,217	0	21,357	0	21,357	0	20,975	0	20,975
Securities financing transactions	0	6,181	3	6,184	0	5,651	0	5,651	0	7,317	0	7,317
Over-the-counter debt instruments	0	1,550	592	2,142	0	1,261	526	1,787	0	1,363	697	2,060
Total liabilities measured at fair value	27,792	253,682	18,398	299,871	32,293	275,453	16,362	324,108	27,635	282,233	15,212	325,080

¹ Bifurcated embedded derivatives are presented on the same balance sheet lines as their host contracts and are not included in this table. The fair value of these derivatives was not material for the periods presented. ² Other non-financial assets primarily consist of properties and other non-current assets held for sale, which are measured at the lower of their net carrying amount or fair value less costs to sell.

b) Valuation adjustments and other items

The table below summarizes the valuation adjustment reserves recognized on the balance sheet. Details about each category are provided further below.

Valuation adjustment reserves on the balance sheet

	As of		
Life-to-date gain / (loss), USD million	30.6.21	31.3.21	31.12.20
Deferred day-1 profit or loss reserves	405	387	269
Own credit adjustments on financial liabilities designated at fair value	(278)	(400)	(381)
CVAs, FVAs, DVAs and other valuation adjustments	(956)	(977)	(959)

Deferred day-1 profit or loss reserves

The table below summarizes the changes in deferred day-1 profit or loss reserves during the relevant period.

Deferred day-1 profit or loss is generally released into *Other net income from financial instruments measured at fair value through profit or loss* when pricing of equivalent products or the underlying parameters become observable or when the transaction is closed out.

Deferred day-1 profit or loss reserves

USD million	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Reserve balance at the beginning of the period	387	269	194	269	146
Profit / (loss) deferred on new transactions	97	181	121	278	239
(Profit) / loss recognized in the income statement	(79)	(63)	(72)	(142)	(141)
Foreign currency translation	0	(1)	0	(1)	(1)
Reserve balance at the end of the period	405	387	243	405	243

Note 10 Fair value measurement (continued)

Own credit

The valuation of financial liabilities designated at fair value requires consideration of the own credit component of fair value. Own credit risk is reflected in the valuation of UBS's fair value option liabilities where this component is considered relevant for valuation purposes by UBS's counterparties and other market participants. However, own credit risk is not reflected in the valuation of UBS's liabilities that are fully collateralized or for other obligations for which it is established market practice to not include an own credit component.

A description of UBS's methodology to estimate own credit and the related accounting principles is included in "Note 21 Fair value measurement" in the "Consolidated financial statements" section of the Annual Report 2020.

In the second quarter of 2021, other comprehensive income related to own credit on financial liabilities designated at fair value was positive USD 118 million, primarily due to a widening of UBS's credit spreads.

Own credit adjustments on financial liabilities designated at fair value

USD million	Included in Other comprehensive income				
	For the quarter ended			Year-to-date	
	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
Recognized during the period:					
Realized gain / (loss)	(5)	(6)	8	(11)	9
Unrealized gain / (loss)	123	(23)	(1,103)	100	53
Total gain / (loss), before tax	118	(29)	(1,095)	89	62
	As of				
USD million	30.6.21	31.3.21	30.6.20		
Recognized on the balance sheet as of the end of the period:					
Unrealized life-to-date gain / (loss)	(278)	(400)	(31)		

Credit, funding, debit and other valuation adjustments

A description of UBS's methodology for estimating credit valuation adjustments (CVAs), funding valuation adjustments (FVAs), debit valuation adjustments (DVAs) and other valuation adjustments is included in "Note 21 Fair value measurement" in the "Consolidated financial statements" section of the Annual Report 2020.

In the second quarter of 2021, other valuation adjustments for liquidity decreased, primarily due to lower observed levels of risk across portfolios during the quarter.

Valuation adjustments on financial instruments

Life-to-date gain / (loss), USD million	As of		
	30.6.21	31.3.21	31.12.20
Credit valuation adjustments¹	(51)	(53)	(66)
Funding valuation adjustments	(58)	(58)	(73)
Debit valuation adjustments	1	1	0
Other valuation adjustments	(848)	(867)	(820)
<i>of which: liquidity</i>	<i>(327)</i>	<i>(356)</i>	<i>(340)</i>
<i>of which: model uncertainty</i>	<i>(521)</i>	<i>(511)</i>	<i>(479)</i>

¹ Amounts do not include reserves against defaulted counterparties.

c) Transfers between Level 1 and Level 2

During the first six months of 2021, assets and liabilities transferred from Level 2 to Level 1, or from Level 1 to Level 2, that were held for the entire reporting period, were not material.

Note 10 Fair value measurement (continued)**d) Level 3 instruments: valuation techniques and inputs**

The table below presents material Level 3 assets and liabilities, together with the valuation techniques used to measure fair value, the inputs used in a given valuation technique that are considered significant as of 30 June 2021 and unobservable, and a range of values for those unobservable inputs.

The range of values represents the highest- and lowest-level inputs used in the valuation techniques. Therefore the range does not reflect the level of uncertainty regarding a particular input or an assessment of the reasonableness of UBS's estimates and assumptions, but rather the different underlying characteristics of the relevant assets and liabilities held by UBS. The ranges will therefore vary from period to period and parameter to parameter based on characteristics of the instruments held at each balance

sheet date. Furthermore, the ranges of unobservable inputs may differ across other financial institutions, reflecting the diversity of the products in each firm's inventory.

The significant unobservable inputs disclosed in the table below are consistent with those included in "Note 21 Fair value measurement" in the "Consolidated financial statements" section of the Annual Report 2020. A description of the potential effect that a change in each unobservable input in isolation may have on a fair value measurement, including information to facilitate an understanding of factors that give rise to the input ranges shown, is also provided in "Note 21 Fair value measurement" in the "Consolidated financial statements" section of the Annual Report 2020.

Valuation techniques and inputs used in the fair value measurement of Level 3 assets and liabilities

	Fair value				Valuation technique(s)	Significant unobservable input(s) ¹	Range of inputs						
	Assets		Liabilities				30.6.21			31.12.20			unit ¹
USD billion	30.6.21	31.12.20	30.6.21	31.12.20		low	high	weighted average ²	low	high	weighted average ²		
Financial assets and liabilities at fair value held for trading and Financial assets at fair value not held for trading													
<i>Corporate and municipal bonds</i>	1.2	1.2	0.0	0.0	Relative value to market comparable	Bond price equivalent	15	143	100	1	143	100	points
					Discounted expected cash flows	Discount margin	358	358		268	268		basis points
<i>Traded loans, loans measured at fair value, loan commitments and guarantees</i>	2.6	2.4	0.0	0.0	Relative value to market comparable	Loan price equivalent	1	101	99	0	101	99	points
					Discounted expected cash flows	Credit spread	180	800		190	800		basis points
					Market comparable and securitization model	Credit spread	28	1,558	228	40	1,858	333	basis points
<i>Auction rate securities</i>	1.6	1.5			Discounted expected cash flows	Credit spread	115	222	162	100	188	140	basis points
<i>Investment fund units³</i>	0.1	0.1	0.0	0.0	Relative value to market comparable	Net asset value							
<i>Equity instruments³</i>	0.7	0.7	0.1	0.0	Relative value to market comparable	Price							
Debt issued designated at fair value⁴			12.5	9.6									
Other financial liabilities designated at fair value			2.9	2.1	Discounted expected cash flows	Funding spread	35	175		42	175		basis points
Derivative financial instruments													
<i>Interest rate contracts</i>	0.3	0.5	0.5	0.5	Option model	Volatility of interest rates	49	73		29	69		basis points
					Discounted expected cash flows	Credit spreads	2	496		1	489		basis points
<i>Credit derivative contracts</i>	0.3	0.3	0.4	0.5		Bond price equivalent	3	102		0	100		points
<i>Equity / index contracts</i>	0.8	0.9	1.9	2.3	Option model	Equity dividend yields	0	11		0	13		%
						Volatility of equity stocks, equity and other indices	4	99		4	100		%
						Equity-to-FX correlation	(30)	70		(34)	65		%
						Equity-to-equity correlation	(25)	99		(16)	100		%

¹ The ranges of significant unobservable inputs are represented in points, percentages and basis points. Points are a percentage of par (e.g., 100 points would be 100% of par). ² Weighted averages are provided for non-derivative financial instruments and were calculated by weighting inputs based on the fair values of the respective instruments. Weighted averages are not provided for inputs related to derivative contracts, as this would not be meaningful. ³ The range of inputs is not disclosed, as there is a dispersion of values given the diverse nature of the investments. ⁴ Debt issued designated at fair value is composed primarily of UBS structured notes, which include variable maturity notes with various equity and foreign exchange underlying risks, rates-linked and credit-linked notes, all of which have embedded derivative parameters that are considered to be unobservable. The equivalent derivative instrument parameters are presented in the respective derivative financial instruments lines in this table.

Note 10 Fair value measurement (continued)

e) Level 3 instruments: sensitivity to changes in unobservable input assumptions

The table below summarizes those financial assets and liabilities classified as Level 3 for which a change in one or more of the unobservable inputs to reflect reasonably possible alternative assumptions would change fair value significantly, and the estimated effect thereof. The table presents the favorable and unfavorable effects for each class of financial assets and liabilities for which the potential change in fair value is considered significant. The sensitivity of fair value measurements for debt issued designated at fair value and over-the-counter debt instruments designated at fair value is reported together with the equivalent derivative or securities financing instrument.

The sensitivity data shown below presents an estimation of valuation uncertainty based on reasonably possible alternative values for Level 3 inputs at the balance sheet date and does not represent the estimated effect of stress scenarios. Typically, these financial assets and liabilities are sensitive to a combination of inputs from Levels 1–3. Although well-defined interdependencies may exist between Levels 1–2 and Level 3 parameters (e.g., between interest rates, which are generally Level 1 or Level 2, and prepayments, which are generally Level 3), these have not been incorporated in the table. Furthermore, direct interrelationships between the Level 3 parameters are not a significant element of the valuation uncertainty.

Sensitivity of fair value measurements to changes in unobservable input assumptions

USD million	30.6.21		31.3.21		31.12.20	
	Favorable changes	Unfavorable changes	Favorable changes	Unfavorable changes	Favorable changes	Unfavorable changes
Traded loans, loans designated at fair value, loan commitments and guarantees	22	(13)	26	(21)	29	(28)
Securities financing transactions	69	(68)	71	(51)	40	(52)
Auction rate securities	114	(114)	88	(88)	105	(105)
Asset-backed securities	48	(34)	50	(40)	41	(41)
Equity instruments	150	(120)	127	(99)	129	(96)
Interest rate derivative contracts, net	25	(14)	38	(23)	11	(16)
Credit derivative contracts, net	8	(10)	10	(10)	10	(14)
Foreign exchange derivative contracts, net	15	(9)	17	(11)	20	(15)
Equity / index derivative contracts, net	344	(324)	358	(344)	318	(294)
Other	58	(77)	77	(92)	91	(107)
Total	852	(782)	861	(779)	794	(768)

f) Level 3 instruments: movements during the period

Significant changes in Level 3 instruments

The table on the following pages presents additional information about material Level 3 assets and liabilities measured at fair value on a recurring basis. Level 3 assets and liabilities may be hedged with instruments classified as Level 1 or Level 2 in the fair value hierarchy and, as a result, realized and unrealized gains and losses included in the table may not include the effect of related hedging activity. Furthermore, the realized and

unrealized gains and losses presented in the table are not limited solely to those arising from Level 3 inputs, as valuations are generally derived from both observable and unobservable parameters.

Assets and liabilities transferred into or out of Level 3 are presented as if those assets or liabilities had been transferred at the beginning of the year.

Note 10 Fair value measurement (continued)**Movements of Level 3 instruments**

<i>USD billion</i>	Balance as of 31 December 2019	Total gains / losses included in comprehensive income		Purchases	Sales	Issuances	Settlements	Transfers into Level 3	Transfers out of Level 3	Foreign currency translation	Balance as of 30 June 2020
		Net gains / losses included in income ¹	of which: related to Level 3 instruments held at the end of the reporting period								
Financial assets at fair value held for trading	1.8	(0.1)	0.0	0.3	(1.0)	1.4	0.0	0.3	0.0	0.0	2.7
<i>of which:</i>											
Investment fund units	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Corporate and municipal bonds	0.5	0.0	0.0	0.2	(0.2)	0.0	0.0	0.2	0.0	0.0	0.8
Loans	0.8	0.0	0.0	0.0	(0.6)	1.4	0.0	0.0	0.0	0.0	1.6
Other	0.4	0.0	0.0	0.0	(0.2)	0.0	0.0	0.1	0.0	0.0	0.3
Derivative financial instruments – assets	1.3	0.3	0.4	0.0	0.0	0.5	(0.5)	0.0	(0.1)	0.0	1.5
<i>of which:</i>											
Interest rate contracts	0.3	0.2	0.2	0.0	0.0	0.0	(0.2)	0.0	0.0	0.0	0.3
Equity / index contracts	0.6	0.0	0.1	0.0	0.0	0.5	(0.2)	0.0	(0.1)	0.0	0.8
Credit derivative contracts	0.4	0.1	0.1	0.0	0.0	0.0	(0.2)	0.0	0.0	0.0	0.4
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial assets at fair value not held for trading	4.0	(0.1)	(0.1)	0.5	(0.6)	0.0	0.0	0.1	0.0	0.0	3.7
<i>of which:</i>											
Loans	1.2	0.0	0.0	0.4	(0.5)	0.0	0.0	0.0	0.0	0.0	1.0
Auction rate securities	1.5	(0.1)	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4
Equity instruments	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.5
Other	0.7	0.0	0.0	0.1	(0.1)	0.0	0.0	0.0	0.0	0.0	0.8
Derivative financial instruments – liabilities	2.0	1.2	1.1	0.0	0.0	0.5	(0.8)	0.6	(0.3)	0.0	3.3
<i>of which:</i>											
Interest rate contracts	0.1	0.7	0.7	0.0	0.0	0.0	(0.3)	0.3	0.0	0.0	0.8
Equity / index contracts	1.3	0.2	0.2	0.0	0.0	0.5	(0.4)	0.0	(0.2)	0.0	1.4
Credit derivative contracts	0.5	0.3	0.3	0.0	0.0	0.1	(0.1)	0.3	(0.1)	0.0	0.9
Other	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Debt issued designated at fair value	9.6	0.1	0.2	0.0	0.0	2.9	(3.5)	0.4	(1.0)	0.0	8.5
Other financial liabilities designated at fair value	1.0	0.1	0.1	0.0	0.0	1.5	(0.3)	0.0	0.0	0.0	2.4

¹ Net gains / losses included in comprehensive income are composed of Net interest income, Other net income from financial instruments measured at fair value through profit or loss and Other income. ² Total Level 3 assets as of 30 June 2021 were USD 8.1 billion (31 December 2020: USD 8.3 billion). Total Level 3 liabilities as of 30 June 2021 were USD 18.4 billion (31 December 2020: USD 15.2 billion).

Note 10 Fair value measurement (continued)

Balance as of 31 December 2020 ²	Net gains / losses included in income ¹	Total gains / losses included in comprehensive income		Purchases	Sales	Issuances	Settlements	Transfers into Level 3	Transfers out of Level 3	Foreign currency translation	Balance as of 30 June 2021 ²
		<i>of which: related to Level 3 instruments held at the end of the reporting period</i>									
2.3	0.0	0.0	0.0	0.3	(0.8)	0.4	0.0	0.2	(0.2)	0.0	2.1
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
0.8	0.0	0.0	0.1	(0.1)	0.0	0.0	0.0	0.0	(0.1)	0.0	0.8
1.1	0.0	0.0	0.1	(0.5)	0.4	0.0	0.0	0.0	(0.2)	0.0	1.0
0.4	(0.1)	(0.1)	0.0	(0.2)	0.0	0.0	0.0	0.1	0.0	0.0	0.3
1.8	(0.2)	(0.1)	0.0	0.0	0.0	0.5	(0.4)	0.0	(0.1)	0.0	1.5
0.5	(0.1)	(0.1)	0.0	0.0	0.0	0.0	(0.1)	0.0	0.0	0.0	0.3
0.9	0.1	0.1	0.0	0.0	0.0	0.3	(0.4)	0.0	(0.1)	0.0	0.8
0.3	(0.1)	(0.1)	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3.9	0.1	0.1	0.7	(0.3)	0.0	0.0	0.0	0.1	0.0	0.0	4.5
0.9	0.0	0.0	0.4	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	1.1
1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6
0.5	0.1	0.1	0.1	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.6
1.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2
3.5	0.2	0.0	0.0	0.0	0.0	0.7	(1.2)	0.0	(0.2)	0.0	2.9
0.5	(0.1)	(0.1)	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5
2.3	0.4	0.2	0.0	0.0	0.0	0.5	(1.1)	0.0	(0.2)	0.0	1.9
0.5	(0.2)	(0.2)	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4
0.1	0.1	0.0	0.0	0.0	0.0	0.0	(0.1)	0.0	0.0	0.0	0.1
9.6	0.3	0.2	0.0	0.0	0.0	6.3	(2.9)	0.1	(0.8)	(0.2)	12.5
2.1	0.0	0.0	0.0	0.0	0.0	1.0	(0.2)	0.0	0.0	0.0	2.9

Note 10 Fair value measurement (continued)**g) Financial instruments not measured at fair value**

The table below reflects the estimated fair values of financial instruments not measured at fair value.

Financial instruments not measured at fair value

<i>USD billion</i>	30.6.21		31.3.21		31.12.20	
	Carrying amount	Fair value	Carrying amount	Fair value	Carrying amount	Fair value
Assets						
Cash and balances at central banks	160.7	160.7	158.9	158.9	158.2	158.2
Loans and advances to banks	16.4	16.4	18.3	18.3	15.3	15.3
Receivables from securities financing transactions	83.5	83.5	82.4	82.4	74.2	74.2
Cash collateral receivables on derivative instruments	29.8	29.8	35.0	35.0	32.7	32.7
Loans and advances to customers	391.4	391.0	380.1	380.1	381.0	382.3
Other financial assets measured at amortized cost	27.2	27.7	26.8	27.3	27.2	28.0
Liabilities						
Amounts due to banks	14.6	14.6	12.6	12.6	11.0	11.1
Payables from securities financing transactions	6.0	6.0	6.7	6.7	6.3	6.3
Cash collateral payables on derivative instruments	32.2	32.2	36.6	36.6	37.3	37.3
Customer deposits	517.5	517.5	508.9	509.0	527.9	528.0
Funding from UBS Group AG	55.9	57.5	57.7	59.2	54.0	55.6
Debt issued measured at amortized cost	84.5	85.4	87.5	88.3	85.4	86.3
Other financial liabilities measured at amortized cost ¹	7.0	7.0	6.0	6.0	6.6	6.7

¹ Excludes lease liabilities.

The fair values included in the table above have been calculated for disclosure purposes only. The valuation techniques and assumptions relate only to UBS's financial instruments not otherwise measured at fair value. Other institutions may use

different methods and assumptions for their fair value estimation, and therefore such fair value disclosures cannot necessarily be compared from one financial institution to another.

Note 11 Derivative instruments

a) Derivative instruments

	Derivative financial assets	Notional values related to derivative financial assets ¹	Derivative financial liabilities	Notional values related to derivative financial liabilities ¹	Other notional values ²
<i>As of 30.6.21, USD billion</i>					
Derivative financial instruments					
Interest rate contracts	38.4	995	32.7	912	9,918
Credit derivative contracts	2.0	54	2.4	54	0
Foreign exchange contracts	49.5	3,074	47.4	2,869	2
Equity / index contracts	29.2	458	36.3	615	90
Commodity contracts	1.9	59	2.1	58	15
Loan commitments measured at FVTPL	0.0	1	0.0	11	
Unsettled purchases of non-derivative financial instruments ³	0.3	29	0.3	26	
Unsettled sales of non-derivative financial instruments ³	0.3	39	0.4	23	
Total derivative financial instruments, based on IFRS netting⁴	121.6	4,708	121.7	4,569	10,024
Further netting potential not recognized on the balance sheet ⁵	(107.5)		(106.8)		
<i>of which: netting of recognized financial liabilities / assets</i>	<i>(86.8)</i>		<i>(86.8)</i>		
<i>of which: netting with collateral received / pledged</i>	<i>(20.6)</i>		<i>(20.0)</i>		
Total derivative financial instruments, after consideration of further netting potential	14.2		14.9		

As of 31.3.21, USD billion

Derivative financial instruments					
Interest rate contracts	39.9	991	34.0	901	11,707
Credit derivative contracts	2.3	65	2.5	62	0
Foreign exchange contracts	70.7	3,283	67.6	3,067	2
Equity / index contracts	32.2	468	38.7	599	97
Commodity contracts	2.2	62	2.0	54	12
Loan commitments measured at FVTPL	0.0	1	0.0	9	
Unsettled purchases of non-derivative financial instruments ³	0.6	26	0.3	32	
Unsettled sales of non-derivative financial instruments ³	0.4	42	0.8	21	
Total derivative financial instruments, based on IFRS netting⁴	148.3	4,938	146.0	4,745	11,817
Further netting potential not recognized on the balance sheet ⁵	(130.1)		(127.5)		
<i>of which: netting of recognized financial liabilities / assets</i>	<i>(105.1)</i>		<i>(105.1)</i>		
<i>of which: netting with collateral received / pledged</i>	<i>(25.0)</i>		<i>(22.5)</i>		
Total derivative financial instruments, after consideration of further netting potential	18.2		18.5		

As of 31.12.20, USD billion

Derivative financial instruments					
Interest rate contracts	50.9	928	43.9	880	11,292
Credit derivative contracts	2.4	58	2.9	65	0
Foreign exchange contracts	68.7	2,951	70.5	2,820	1
Equity / index contracts	34.8	450	41.2	581	91
Commodity contracts	2.2	58	2.0	50	10
Loan commitments measured at FVTPL			0.0	10	
Unsettled purchases of non-derivative financial instruments ³	0.3	18	0.2	10	
Unsettled sales of non-derivative financial instruments ³	0.2	17	0.3	13	
Total derivative financial instruments, based on IFRS netting⁴	159.6	4,480	161.1	4,430	11,394
Further netting potential not recognized on the balance sheet ⁵	(144.4)		(141.2)		
<i>of which: netting of recognized financial liabilities / assets</i>	<i>(117.2)</i>		<i>(117.2)</i>		
<i>of which: netting with collateral received / pledged</i>	<i>(27.2)</i>		<i>(23.9)</i>		
Total derivative financial instruments, after consideration of further netting potential	15.2		19.9		

¹ In cases where derivative financial instruments are presented on a net basis on the balance sheet, the respective notional values of the netted derivative financial instruments are still presented on a gross basis. Notional amounts of exchange-traded agency transactions and OTC-cleared transactions entered into on behalf of clients are not disclosed, as they have a significantly different risk profile. ² Other notional values relate to derivatives that are cleared through either a central counterparty or an exchange. The fair value of these derivatives is presented on the balance sheet net of the corresponding cash margin under Cash collateral receivables on derivative instruments and Cash collateral payables on derivative instruments and was not material for all periods presented. ³ Changes in the fair value of purchased and sold non-derivative financial instruments between trade date and settlement date are recognized as derivative financial instruments. ⁴ Financial assets and liabilities are presented net on the balance sheet if UBS AG has the unconditional and legally enforceable right to offset the recognized amounts, both in the normal course of business and in the event of default, bankruptcy or insolvency of UBS AG or its counterparties, and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. ⁵ Reflects the netting potential in accordance with enforceable master netting and similar arrangements where not all criteria for a net presentation on the balance sheet have been met. Refer to "Note 22 Offsetting financial assets and financial liabilities" in the "Consolidated financial statements" section of the Annual Report 2020 for more information.

Note 11 Derivative instruments (continued)**b) Cash collateral on derivative instruments**

<i>USD billion</i>	Receivables 30.6.21	Payables 30.6.21	Receivables 31.3.21	Payables 31.3.21	Receivables 31.12.20	Payables 31.12.20
Cash collateral on derivative instruments, based on IFRS netting ¹	29.8	32.2	35.0	36.6	32.7	37.3
Further netting potential not recognized on the balance sheet ²	(18.3)	(16.9)	(21.1)	(20.7)	(21.1)	(21.6)
<i>of which: netting of recognized financial liabilities / assets</i>	(15.9)	(14.4)	(18.2)	(18.3)	(19.6)	(19.6)
<i>of which: netting with collateral received / pledged</i>	(2.4)	(2.5)	(2.9)	(2.3)	(1.5)	(2.1)
Cash collateral on derivative instruments, after consideration of further netting potential	11.5	15.3	14.0	15.9	11.6	15.7

¹ Financial assets and liabilities are presented net on the balance sheet if UBS AG has the unconditional and legally enforceable right to offset the recognized amounts, both in the normal course of business and in the event of default, bankruptcy or insolvency of UBS AG or its counterparties, and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. ² Reflects the netting potential in accordance with enforceable master netting and similar arrangements where not all criteria for a net presentation on the balance sheet have been met. Refer to "Note 22 Offsetting financial assets and financial liabilities" in the "Consolidated financial statements" section of the Annual Report 2020 for more information.

Note 12 Other assets and liabilities**a) Other financial assets measured at amortized cost**

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Debt securities	18,484	18,533	18,801
<i>of which: government bills / bonds</i>	9,531	9,664	9,789
Loans to financial advisors	2,415	2,473	2,569
Fee- and commission-related receivables	1,980	2,069	2,014
Finance lease receivables	1,363	1,344	1,447
Settlement and clearing accounts	1,225	564	614
Accrued interest income	532	522	592
Other	1,202	1,333	1,182
Total other financial assets measured at amortized cost	27,201	26,837	27,219

b) Other non-financial assets

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Precious metals and other physical commodities	5,470	5,709	6,264
Bail deposit ¹	1,382	1,364	1,418
Prepaid expenses	746	743	731
VAT and other tax receivables	395	317	392
Properties and other non-current assets held for sale	68	248	246
Other	542	372	323
Total other non-financial assets	8,603	8,755	9,374

¹ Refer to item 1 in Note 16b for more information.

Note 12 Other assets and liabilities (continued)

c) Other financial liabilities measured at amortized cost

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Other accrued expenses	1,549	1,544	1,508
Accrued interest expenses	1,050	946	1,382
Settlement and clearing accounts	2,151	1,268	1,181
Lease liabilities	3,634	3,667	3,821
Other	2,288	2,200	2,530
Total other financial liabilities measured at amortized cost	10,671	9,624	10,421

d) Other financial liabilities designated at fair value

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Financial liabilities related to unit-linked investment contracts	22,217	21,357	20,975
Securities financing transactions	6,184	5,651	7,317
Over-the-counter debt instruments	2,142	1,787	2,060
Funding from UBS Group AG	2,266	1,907	1,375
Other	99	68	46
Total other financial liabilities designated at fair value	32,908	30,769	31,773
<i>of which: life-to-date own credit (gain) / loss</i>	<i>115</i>	<i>208</i>	<i>148</i>

e) Other non-financial liabilities

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Compensation-related liabilities	3,771	2,969	4,776
<i>of which: financial advisor compensation plans</i>	<i>1,313</i>	<i>1,200</i>	<i>1,497</i>
<i>of which: other compensation plans</i>	<i>1,287</i>	<i>704</i>	<i>2,034</i>
<i>of which: net defined benefit liability</i>	<i>652</i>	<i>642</i>	<i>711</i>
<i>of which: other compensation-related liabilities¹</i>	<i>518</i>	<i>422</i>	<i>534</i>
Deferred tax liabilities	382	321	558
Current tax liabilities	1,186	1,058	943
VAT and other tax payables	540	504	470
Deferred income	246	209	212
Other	116	111	61
Total other non-financial liabilities	6,241	5,171	7,018

¹ Includes liabilities for payroll taxes and untaken vacation.

Note 13 Debt issued designated at fair value

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Issued debt instruments			
Equity-linked ¹	49,157	44,615	41,069
Rates-linked	16,397	12,668	11,038
Credit-linked	1,826	1,804	1,933
Fixed-rate	2,883	3,343	3,604
Commodity-linked	1,961	1,564	1,497
Other	575	640	726
Total debt issued designated at fair value	72,799	64,635	59,868
<i>of which: issued by UBS AG with original maturity greater than one year²</i>	51,830	47,348	46,427
<i>of which: life-to-date own credit (gain) / loss</i>	164	193	233

¹ Includes investment fund unit-linked instruments issued. ² Issued by the legal entity UBS AG. Based on original contractual maturity without considering any early redemption features. As of 30 June 2021, more than 99% of the balance was unsecured (31 March 2021: 100%; 31 December 2020: 100%).

Note 14 Debt issued measured at amortized cost

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Certificates of deposit	12,193	14,723	15,680
Commercial paper	25,304	26,591	25,472
Other short-term debt	5,219	6,080	5,515
Short-term debt¹	42,716	47,394	46,666
Senior unsecured debt	26,130	23,330	18,483
<i>of which: issued by UBS AG with original maturity greater than one year²</i>	26,109	23,309	18,464
Covered bonds	1,449	2,606	2,796
Subordinated debt	5,232	5,253	7,744
<i>of which: low-trigger loss-absorbing tier 2 capital instruments</i>	4,686	4,709	7,201
<i>of which: non-Basel III-compliant tier 2 capital instruments</i>	547	544	543
Debt issued through the Swiss central mortgage institutions	8,963	8,911	9,660
Other long-term debt	0	2	3
Long-term debt³	41,775	40,101	38,685
Total debt issued measured at amortized cost⁴	84,491	87,495	85,351

¹ Debt with an original contractual maturity of less than one year. ² Issued by the legal entity UBS AG. Based on original contractual maturity without considering any early redemption features. As of 30 June 2021, 100% of the balance was unsecured (31 March 2021: 100%; 31 December 2020: 100%). ³ Debt with an original contractual maturity greater than or equal to one year. The classification of debt issued into short-term and long-term does not consider any early redemption features. ⁴ Net of bifurcated embedded derivatives, the fair value of which was not material for the periods presented.

Note 15 Interest rate benchmark reform

Background

A market-wide reform of major interest rate benchmarks is being undertaken globally, with the Financial Conduct Authority (the FCA) announcing in March 2021 that the publication of London Interbank Offered Rates (LIBORs) will cease for all non-US dollar LIBORs, as well as for one-week and two-month USD LIBOR, after 31 December 2021. Publication of the remaining USD LIBOR tenors will cease immediately after 30 June 2023.

The majority of UBS AG's Interbank Offered Rate (IBOR) exposure is to CHF LIBOR and USD LIBOR. The alternative reference rate (ARR) for CHF LIBOR is the Swiss Average Rate Overnight (SARON). The ARR for USD LIBOR is the Secured Overnight Financing Rate (SOFR); in addition, there are recommended ARRs for GBP LIBOR, JPY LIBOR and EUR LIBOR. For certain products in the US, UBS AG is considering the use of credit-sensitive rates as an alternative to SOFR.

As of 30 June 2021, transition uncertainty with respect to significant interest rate benchmarks remains, with the exception of the Euro Interbank Offered Rate (Euribor). The reform of Euribor is now complete and consisted of a change in the underlying calculation method.

The transition to ARRs includes a number of active steps that will also benefit from the support of associated regulatory activities. There may be some contracts, known as "tough legacy contracts," that cannot be practically transitioned or amended from IBORs to ARRs. The FCA continues to consult market participants about requiring the ICE Benchmark Administration to continue publishing certain LIBOR settings (i.e., one-, three- and six-month settings for the GBP, JPY and USD LIBORs) on a "synthetic" basis, which are not representative of the underlying financial markets, for a certain duration after 31 December 2021. However, these synthetic LIBORs will not be available for use in new contracts, given that they are non-representative, and are instead intended to help reduce disruption where resolution has not been agreed for certain tough legacy contracts. Furthermore, in February 2021, the EU Benchmarks Regulation was amended to enable the European Commission to designate a statutory replacement rate for tough legacy LIBOR contracts that are governed by the laws of EU Member States and remain outstanding after LIBOR cessation. On 6 April 2021, New York State LIBOR legislation was enacted with the intention of minimizing legal uncertainty and adverse economic effects associated with USD LIBOR transition for tough legacy contracts governed by New York law. For USD LIBOR contracts not governed by New York law, a bill has been introduced in Congress with similar objectives.

In October 2020, the International Swaps and Derivatives Association (ISDA) released the IBOR Fallbacks Supplement and IBOR Fallbacks Protocol, amending ISDA standard definitions for interest-rate derivatives to incorporate fallbacks for derivatives linked to certain IBORs. The changes came into effect on 25 January 2021 and, from that date, all newly cleared and non-cleared derivatives between adhering parties that reference ISDA standard definitions now include these fallbacks. UBS AG adhered to the protocol in November 2020.

UBS AG is focused on transitioning existing contracts via bilateral and multi-lateral agreements, leveraging industry solutions (e.g., the use of fallback provisions) and through third-party actions (clearing houses, agents, etc.). Furthermore, in line with regulatory guidance UBS AG has implemented a framework to limit entry into new contracts referencing IBORs.

Governance over the transition to alternative benchmark rates

UBS AG has established a global cross-divisional, cross-functional governance structure and change program to address the scale and complexity of the transition. This global program is sponsored by the Group CFO and led by senior representatives from the business divisions and UBS AG's control and support functions. The program includes governance and execution structures within each business division, together with cross-divisional teams from each control and support function. Progress is overseen centrally via a monthly operating committee and a monthly steering committee, as well as quarterly updates to the joint Audit and Risk committees.

Risks

A core part of UBS AG's change program is the identification, management and monitoring of the risks associated with IBOR reform and transition. These risks include, but are not limited to, the following:

- economic risks to UBS AG and its clients, through the repricing of existing contracts, reduced transparency and / or liquidity of pricing information, market uncertainty or disruption;
- accounting risks, where the transition affects the accounting treatment, including hedge accounting and consequential income statement volatility;
- valuation risks arising from the variation between benchmarks that will cease and ARRs, affecting the risk profile of financial instruments;
- operational risks arising from changes to UBS AG's front-to-back processes and systems to accommodate the transition, as well as the revision of operational controls related to the reform; and
- legal and conduct risks relating to UBS AG's engagement with clients and market counterparties around new benchmark products and amendments required for existing contracts referencing benchmarks that will cease.

Note 15 Interest rate benchmark reform (continued)

In some cases, contracts may contain provisions intended to provide a fallback interest rate in the event of a brief unavailability of the relevant IBOR. These provisions may not be effective or may produce arbitrary results in the event of a permanent cessation of the relevant IBOR. While efforts to transition outstanding transactions from IBORs to ARR's have made substantial progress, including through industry-wide protocols, such as the ISDA IBOR Fallbacks Supplement and IBOR Fallbacks Protocol, there are still substantial volumes of transactions that require modification to effectively transition to ARR's.

UBS AG remains confident that it has the transparency, oversight and operational preparedness to progress with the IBOR transition consistent with market timelines. UBS AG does not expect changes to its risk management approach and strategy as a result of interest rate benchmark reform.

Progress made during 2020 and the first half of 2021

Approaches to transition vary by product type. During 2020, UBS AG transitioned most of its CHF LIBOR-linked deposits to SARON and launched SARON-based mortgages and corporate loans based on all major ARR's in the Swiss market, as well as SOFR-based mortgages in the US market. By the end of the second quarter of 2021, UBS AG had successfully transitioned its GBP LIBOR- and EUR LIBOR-based private and commercial real estate mortgages in the UK and Monaco to the Sterling Overnight Index Average (SONIA) and Euribor, respectively. UBS AG has detailed plans in place to deliver the required changes for all other IBOR exposures, predominantly during 2021.

Financial instruments yet to transition to alternative benchmarks

The amounts included in the table below relate to financial instrument contracts across UBS AG's business divisions where

UBS AG has material exposures subject to IBOR reform that have not yet transitioned to ARR's, and that:

- contractually reference an interest rate benchmark that will transition to an alternative benchmark; and
- have a contractual maturity date (including open-ended contracts) after the agreed cessation dates.

Contracts where penalty terms reference IBORs, or where exposure to an IBOR is not the primary purpose of the contract, have not been included, as these contracts do not have a material impact on the transition process. In addition, contracts that have been changed to incorporate ARR-based interest rates before the relevant cessation date have been excluded from the table below, because UBS AG expects no further transition work to implement the reform.

In line with information provided to management and external parties monitoring UBS AG's transition progress, the table below includes the following financial metrics for instruments subject to interest rate benchmark reform:

- gross carrying value / exposure for non-derivative financial instruments; and
- total trade count for derivative financial instruments.

The exposures included in the table below represent the maximum IBOR exposure, with the actual IBOR exposure being dependent upon client preferences and investment decisions. Overall, the effort required to transition is affected by multiple factors, including whether negotiations need to take place with multiple stakeholders (as is the case for syndicated loans or certain listed securities), market readiness – such as liquidity in ARR equivalent products – and a client's technical readiness to handle ARR market conventions.

As significant IBOR exposures transition to ARR's during 2021, the values and trade count disclosed are expected to decrease.

		30.6.21					
		LIBOR benchmark rates ¹					
Measure		CHF	USD	GBP	EUR ²	JPY	XCCY
Carrying value of non-derivative financial instruments							
Total non-derivative financial assets	USD million	31,423	77,502	1,829	6,587	3,070	3,796 ³
Total non-derivative financial liabilities	USD million	2,029	9,834	566	1,919	1,060	0
Trade count of derivative financial instruments							
Total derivative financial instruments	Trade count	9,519	42,566	12,513	9,626	4,247	5,948 ⁴
Off-balance sheet exposures							
Total irrevocable loan commitments	USD million	1	4,433	0	0	0	15,767 ⁵

		31.3.21					
		LIBOR benchmark rates ¹					
Measure		CHF	USD	GBP	EUR ²	JPY	XCCY
Carrying value of non-derivative financial instruments							
Total non-derivative financial assets	USD million	36,046	72,185	5,399	8,253	3,060	4,469 ³
Total non-derivative financial liabilities	USD million	2,612	13,142	1,429	2,252	1,460	0
Trade count of derivative financial instruments							
Total derivative financial instruments	Trade count	9,749	40,080	13,006	9,613	3,961	5,206 ⁴
Off-balance sheet exposures							
Total irrevocable loan commitments	USD million	106	4,656	167	0	0	15,188 ⁵

¹ Contracts have been disclosed without regard to early termination rights. Instead, it is assumed that such contracts will transition away from IBORs without such rights being exercised. ² Includes primarily EUR LIBOR positions. ³ Includes loans related to revolving multi-currency credit lines. ⁴ Includes cross-currency swaps where either leg or both legs are indexed to an IBOR. ⁵ Includes loan commitments that can be drawn in different currencies at the client's discretion.

Note 15 Interest rate benchmark reform (continued)

Non-derivative instruments

UBS AG's significant non-derivative IBOR exposures primarily relate to brokerage receivable and payable balances, corporate and private loans, and mortgages, linked to CHF and USD LIBORs.

In March 2021, following the FCA announcement regarding the cessation timelines for IBORs, UBS AG started a centralized communication initiative for private mortgages linked to CHF LIBOR, with the objective of transitioning these exposures either through the activation of existing fallbacks or the amendment of contractual terms, where such fallbacks do not exist. During the second quarter of 2021, mortgages that were linked to CHF LIBOR have been reduced by approximately USD 2 billion and the remaining USD 3 billion of mortgages linked to GBP LIBOR as of 31 March 2021 have successfully transitioned. US mortgages linked to USD LIBOR are planned to transition to SOFR from 2022–2023. US securities-based lending increased by approximately USD 4 billion in the second quarter of 2021, with agreements expected to switch to an alternative benchmark from the fourth quarter of 2021.

UBS AG is also proactively discussing transition mechanisms with many of its brokerage and corporate clients in order to transition their exposures throughout 2021 from CHF LIBOR, EUR LIBOR and GBP LIBOR. During the second quarter of 2021, the gross carrying amount of IBOR-indexed non-derivative financial assets and liabilities related to brokerage accounts, predominantly linked to GBP and USD LIBOR, was reduced by approximately USD 8 billion in aggregate as a result of successful transitions.

For certain non-derivative financial assets and financial liabilities, in particular bonds issued by third parties, UBS AG is dependent on the participation and engagement of others in effecting the transition from IBORs. UBS AG is actively monitoring such exposures and is in discussions with clients.

As presented in the table on the previous page, UBS AG had approximately USD 16 billion (31 March 2021, USD 15 billion) of irrevocable commitments as of 30 June 2021 that can be drawn down in different currencies with IBOR-based interest rates, primarily USD LIBOR and Euribor, and that expire after the relevant benchmark cessation dates. Related drawn-down amounts under these commitments were USD 4 billion (31 March 2021, USD 4 billion).

In addition, UBS AG had approximately USD 10 billion (31 March 2021, USD 16 billion) of committed revocable credit lines outstanding that allow clients to draw down a number of IBOR-linked products. UBS AG is in discussions with impacted clients, with plans in place to have all contracts amended by the relevant cessation dates.

Derivative instruments

UBS AG holds derivatives for trading and hedging purposes, including those designated in hedge accounting relationships. A significant number of interest rate and cross-currency swaps have floating legs that reference various benchmarks that will cease.

The majority of derivatives are transacted with clearing houses where UBS AG is dependent upon industry-wide compression activities to reduce exposure and clearing house actions to convert any remaining derivatives nearer the cessation dates. London Clearing House (LCH), which is the clearing house for a significant number of UBS AG's IRS derivatives, has confirmed that a standardized transition will be undertaken in December 2021 to transition IBOR-based derivatives to respective ARRs. UBS AG expects derivative volumes to fluctuate in line with business activity until such clearing house actions are taken.

For derivatives not transacted with clearing houses, as previously noted, UBS AG adhered to the ISDA IBOR Fallback Protocol in November 2020, although its preferred approach, in line with regulatory expectations, is to actively switch to ARRs before the relevant cessation dates or to bilaterally compress where feasible. UBS AG has begun a series of outreach activities to understand counterparties' intentions regarding whether they seek to adhere to the protocol or will actively switch.

In order to minimize the operational risk of converting high volumes of transactions at the time of cessation, UBS AG is making progress with its preparations to convert derivative instruments in bulk to ARR equivalents.

Note 16 Provisions and contingent liabilities**a) Provisions**

The table below presents an overview of total provisions.

<i>USD million</i>	30.6.21	31.3.21	31.12.20
Provisions other than provisions for expected credit losses	2,583	2,448	2,534
Provisions for expected credit losses	209	245	257
Total provisions	2,792	2,693	2,791

The following table presents additional information for provisions other than provisions for expected credit losses.

<i>USD million</i>	Litigation, regulatory and similar matters ¹	Restructuring ²	Other ³	Total
Balance as of 31 December 2020	2,135	67	332	2,534
Balance as of 31 March 2021	2,072	58	318	2,448
Increase in provisions recognized in the income statement	87	114	31	233
Release of provisions recognized in the income statement	(24)	(5)	(4)	(33)
Provisions used in conformity with designated purpose	(27)	(20)	(31)	(78)
Capitalized reinstatement costs	0	0	(1)	(1)
Reclassifications	0	1	(1)	0
Foreign currency translation / unwind of discount	11	(1)	4	13
Balance as of 30 June 2021	2,119	148	317	2,583

¹ Comprises provisions for losses resulting from legal, liability and compliance risks. ² Includes personnel-related restructuring provisions of USD 104 million as of 30 June 2021 (31 March 2021: USD 9 million; 31 December 2020: USD 13 million) and provisions for onerous contracts of USD 40 million as of 30 June 2021 (31 March 2021: USD 44 million; 31 December 2020: USD 49 million). ³ Mainly includes provisions related to real estate, employee benefits and operational risks.

Restructuring provisions primarily relate to personnel-related provisions and onerous contracts. Personnel-related restructuring provisions are used within a short time period but potential changes in amount may be triggered when natural staff attrition reduces the number of people affected by a restructuring event and therefore the estimated costs. Onerous contracts for property are recognized when UBS AG is committed to pay for

non-lease components, such as utilities, service charges, taxes and maintenance, when a property is vacated or not fully recovered from sub-tenants.

Information about provisions and contingent liabilities in respect of litigation, regulatory and similar matters, as a class, is included in Note 16b. There are no material contingent liabilities associated with the other classes of provisions.

b) Litigation, regulatory and similar matters

UBS operates in a legal and regulatory environment that exposes it to significant litigation and similar risks arising from disputes and regulatory proceedings. As a result, UBS (which for purposes of this Note may refer to UBS AG and/or one or more of its subsidiaries, as applicable) is involved in various disputes and legal proceedings, including litigation, arbitration, and regulatory and criminal investigations.

Such matters are subject to many uncertainties, and the outcome and the timing of resolution are often difficult to predict, particularly in the earlier stages of a case. There are also situations where UBS may enter into a settlement agreement. This may occur in order to avoid the expense, management distraction or reputational implications of continuing to contest liability, even for those matters for which UBS believes it should be exonerated. The uncertainties inherent in all such matters affect the amount and timing of any potential outflows for both matters with respect to which provisions have been established and other contingent liabilities. UBS makes provisions for such matters brought against it when, in the opinion of management after seeking legal advice, it is more likely than not that UBS has a present legal or constructive obligation as a result of past

events, it is probable that an outflow of resources will be required, and the amount can be reliably estimated. Where these factors are otherwise satisfied, a provision may be established for claims that have not yet been asserted against UBS, but are nevertheless expected to be, based on UBS's experience with similar asserted claims. If any of those conditions is not met, such matters result in contingent liabilities. If the amount of an obligation cannot be reliably estimated, a liability exists that is not recognized even if an outflow of resources is probable. Accordingly, no provision is established even if the potential outflow of resources with respect to such matters could be significant. Developments relating to a matter that occur after the relevant reporting period, but prior to the issuance of financial statements, which affect management's assessment of the provision for such matter (because, for example, the developments provide evidence of conditions that existed at the end of the reporting period), are adjusting events after the reporting period under IAS 10 and must be recognized in the financial statements for the reporting period.

Note 16 Provisions and contingent liabilities (continued)

Specific litigation, regulatory and other matters are described below, including all such matters that management considers to be material and others that management believes to be of significance due to potential financial, reputational and other effects. The amount of damages claimed, the size of a transaction or other information is provided where available and appropriate in order to assist users in considering the magnitude of potential exposures.

In the case of certain matters below, we state that we have established a provision, and for the other matters, we make no such statement. When we make this statement and we expect disclosure of the amount of a provision to prejudice seriously our position with other parties in the matter because it would reveal what UBS believes to be the probable and reliably estimable outflow, we do not disclose that amount. In some cases we are subject to confidentiality obligations that preclude such disclosure. With respect to the matters for which we do not state whether we have established a provision, either: (a) we have not established a provision, in which case the matter is treated as a contingent liability under the applicable accounting standard; or (b) we have established a provision but expect disclosure of that fact to prejudice seriously our position with other parties in the matter because it would reveal the fact that UBS believes an outflow of resources to be probable and reliably estimable.

With respect to certain litigation, regulatory and similar matters for which we have established provisions, we are able to estimate the expected timing of outflows. However, the aggregate amount of the expected outflows for those matters for which we are able to estimate expected timing is immaterial relative to our current and expected levels of liquidity over the relevant time periods.

The aggregate amount provisioned for litigation, regulatory and similar matters as a class is disclosed in the "Provisions" table in Note 16a above. It is not practicable to provide an aggregate estimate of liability for our litigation, regulatory and similar matters as a class of contingent liabilities. Doing so would require UBS to provide speculative legal assessments as to claims and proceedings that involve unique fact patterns or novel legal theories, that have not yet been initiated or are at early stages of adjudication, or as to which alleged damages have not been quantified by the claimants. Although UBS therefore cannot provide a numerical estimate of the future losses that could arise from litigation, regulatory and similar matters, UBS believes that the aggregate amount of possible future losses from this class that are more than remote substantially exceeds the level of current provisions.

Litigation, regulatory and similar matters may also result in non-monetary penalties and consequences. For example, the non-prosecution agreement UBS entered into with the US Department of Justice (DOJ), Criminal Division, Fraud Section in connection with submissions of benchmark interest rates, including, among others, the British Bankers' Association London Interbank Offered Rate (LIBOR), was terminated by the DOJ based on its determination that UBS had committed a US crime in relation to foreign exchange matters. As a consequence, UBS AG pleaded guilty to one count of wire fraud for conduct in the LIBOR matter, paid a fine and was subject to probation, which ended in January 2020.

A guilty plea to, or conviction of, a crime could have material consequences for UBS. Resolution of regulatory proceedings may require UBS to obtain waivers of regulatory disqualifications to maintain certain operations, may entitle regulatory authorities to limit, suspend or terminate licenses and regulatory authorizations, and may permit financial market utilities to limit, suspend or terminate UBS's participation in such utilities. Failure to obtain such waivers, or any limitation, suspension or termination of licenses, authorizations or participations, could have material consequences for UBS.

The risk of loss associated with litigation, regulatory and similar matters is a component of operational risk for purposes of determining capital requirements. Information concerning our capital requirements and the calculation of operational risk for this purpose is included in the "Capital management" section of the UBS Group second quarter 2021 report.

Provisions for litigation, regulatory and similar matters by business division and in Group Functions¹

<i>USD million</i>	Global Wealth Management	Personal & Corporate Banking	Asset Management	Investment Bank	Group Functions	Total
Balance as of 31 December 2020	861	115	0	227	932	2,135
Balance as of 31 March 2021	810	109	1	217	935	2,072
Increase in provisions recognized in the income statement	20	0	0	66	1	87
Release of provisions recognized in the income statement	(11)	(11)	0	(2)	0	(24)
Provisions used in conformity with designated purpose	(27)	0	0	0	0	(27)
Foreign currency translation / unwind of discount	8	2	0	1	0	11
Balance as of 30 June 2021	800	100	1	282	936	2,119

¹ Provisions, if any, for matters described in this Note are recorded in Global Wealth Management (item 3 and item 4) and Group Functions (item 2). Provisions, if any, for the matters described in items 1 and 6 of this Note are allocated between Global Wealth Management and Personal & Corporate Banking, and provisions, if any, for the matters described in this Note in item 5 are allocated between the Investment Bank and Group Functions.

Note 16 Provisions and contingent liabilities (continued)

1. Inquiries regarding cross-border wealth management businesses

Tax and regulatory authorities in a number of countries have made inquiries, served requests for information or examined employees located in their respective jurisdictions relating to the cross-border wealth management services provided by UBS and other financial institutions. It is possible that the implementation of automatic tax information exchange and other measures relating to cross-border provision of financial services could give rise to further inquiries in the future. UBS has received disclosure orders from the Swiss Federal Tax Administration (FTA) to transfer information based on requests for international administrative assistance in tax matters. The requests concern a number of UBS account numbers pertaining to current and former clients and are based on data from 2006 and 2008. UBS has taken steps to inform affected clients about the administrative assistance proceedings and their procedural rights, including the right to appeal. The requests are based on data received from the German authorities, who seized certain data related to UBS clients booked in Switzerland during their investigations and have apparently shared this data with other European countries. UBS expects additional countries to file similar requests.

Since 2013, UBS (France) S.A., UBS AG and certain former employees have been under investigation in France for alleged complicity in unlawful solicitation of clients on French territory, regarding the laundering of proceeds of tax fraud, and banking and financial solicitation by unauthorized persons. In connection with this investigation, the investigating judges ordered UBS AG to provide bail ("*caution*") of EUR 1.1 billion and UBS (France) S.A. to post bail of EUR 40 million, which was reduced on appeal to EUR 10 million.

A trial in the court of first instance took place from 8 October 2018 until 15 November 2018. On 20 February 2019, the court announced a verdict finding UBS AG guilty of unlawful solicitation of clients on French territory and aggravated laundering of the proceeds of tax fraud, and UBS (France) S.A. guilty of aiding and abetting unlawful solicitation and laundering the proceeds of tax fraud. The court imposed fines aggregating EUR 3.7 billion on UBS AG and UBS (France) S.A. and awarded EUR 800 million of civil damages to the French state. UBS has appealed the decision. Under French law, the judgment is suspended while the appeal is pending. The trial in the Court of

Appeal took place between 8-24 March 2021. At the conclusion of the trial, the prosecutor asserted that the maximum penalty was EUR 2.2 billion and requested the court to award a penalty of at least EUR 2 billion. The French state asked for civil damages of EUR 1 billion. The judgment on the merits of the case is currently set for 27 September 2021. A subsequent appeal to the Cour de Cassation, France's highest court, is possible with respect to questions of law.

UBS believes that based on both the law and the facts the judgment of the court of first instance should be reversed. UBS believes it followed its obligations under Swiss and French law as well as the European Savings Tax Directive. Even assuming liability, which it contests, UBS believes the penalties and damage amounts awarded greatly exceed the amounts that could be supported by the law and the facts. In particular, UBS believes the court incorrectly based the penalty on the total regularized assets rather than on any unpaid taxes on those assets for which a fraud has been characterized and further incorrectly awarded damages based on costs that were not proven by the civil party. Notwithstanding that UBS believes it should be acquitted, our balance sheet at 30 June 2021 reflected provisions with respect to this matter in an amount of EUR 450 million (USD 534 million at 30 June 2021). The wide range of possible outcomes in this case contributes to a high degree of estimation uncertainty. The provision reflected on our balance sheet at 30 June 2021 reflects our best estimate of possible financial implications, although it is reasonably possible that actual penalties and civil damages could exceed the provision amount.

In 2016, UBS was notified by the Belgian investigating judge that it is under formal investigation ("*inculpé*") regarding the laundering of proceeds of tax fraud, of banking and financial solicitation by unauthorized persons, and of serious tax fraud.

Our balance sheet at 30 June 2021 reflected provisions with respect to matters described in this item 1 in an amount that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.

Note 16 Provisions and contingent liabilities (continued)

2. Claims related to sales of residential mortgage-backed securities and mortgages

From 2002 through 2007, prior to the crisis in the US residential loan market, UBS was a substantial issuer and underwriter of US residential mortgage-backed securities (RMBS) and was a purchaser and seller of US residential mortgages.

In November 2018, the DOJ filed a civil complaint in the District Court for the Eastern District of New York. The complaint seeks unspecified civil monetary penalties under the Financial Institutions Reform, Recovery and Enforcement Act of 1989 related to UBS's issuance, underwriting and sale of 40 RMBS transactions in 2006 and 2007. UBS moved to dismiss the civil complaint on 6 February 2019. On 10 December 2019, the district court denied UBS's motion to dismiss.

Our balance sheet at 30 June 2021 reflected a provision with respect to matters described in this item 2 in an amount that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of this matter cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.

3. Madoff

In relation to the Bernard L. Madoff Investment Securities LLC (BMIS) investment fraud, UBS AG, UBS (Luxembourg) S.A. (now UBS Europe SE, Luxembourg branch) and certain other UBS subsidiaries have been subject to inquiries by a number of regulators, including the Swiss Financial Market Supervisory Authority (FINMA) and the Luxembourg Commission de Surveillance du Secteur Financier. Those inquiries concerned two third-party funds established under Luxembourg law, substantially all assets of which were with BMIS, as well as certain funds established in offshore jurisdictions with either direct or indirect exposure to BMIS. These funds faced severe losses, and the Luxembourg funds are in liquidation. The documentation establishing both funds identifies UBS entities in various roles, including custodian, administrator, manager, distributor and promoter, and indicates that UBS employees serve as board members.

In 2009 and 2010, the liquidators of the two Luxembourg funds filed claims against UBS entities, non-UBS entities and certain individuals, including current and former UBS employees, seeking amounts totaling approximately EUR 2.1 billion, which includes amounts that the funds may be held liable to pay the trustee for the liquidation of BMIS (BMIS Trustee).

A large number of alleged beneficiaries have filed claims against UBS entities (and non-UBS entities) for purported losses relating to the Madoff fraud. The majority of these cases have been filed in Luxembourg, where decisions that the claims in eight test cases were inadmissible have been affirmed by the Luxembourg Court of Appeal, and the Luxembourg Supreme Court has dismissed a further appeal in one of the test cases.

In the US, the BMIS Trustee filed claims against UBS entities, among others, in relation to the two Luxembourg funds and one of the offshore funds. The total amount claimed against all defendants in these actions was not less than USD 2 billion. In 2014, the US Supreme Court rejected the BMIS Trustee's motion for leave to appeal decisions dismissing all claims except those for the recovery of approximately USD 125 million of payments alleged to be fraudulent conveyances and preference payments. In 2016, the bankruptcy court dismissed these claims against the UBS entities. In February 2019, the Court of Appeals reversed the dismissal of the BMIS Trustee's remaining claims, and the US Supreme Court subsequently denied a petition seeking review of the Court of Appeals' decision. The case has been remanded to the Bankruptcy Court for further proceedings.

4. Puerto Rico

Declines since 2013 in the market prices of Puerto Rico municipal bonds and of closed-end funds (funds) that are sole-managed and co-managed by UBS Trust Company of Puerto Rico and distributed by UBS Financial Services Incorporated of Puerto Rico (UBS PR) led to multiple regulatory inquiries, which in 2014 and 2015, led to settlements with the Office of the Commissioner of Financial Institutions for the Commonwealth of Puerto Rico, the US Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority.

Since then UBS clients in Puerto Rico who own the funds or Puerto Rico municipal bonds and/or who used their UBS account assets as collateral for UBS non-purpose loans filed customer complaints and arbitration demands. Allegations include fraud, misrepresentation and unsuitability of the funds and of the loans seeking aggregate damages of USD 3.4 billion, of which USD 2.9 billion have been resolved through settlements, arbitration or withdrawal of claims.

A shareholder derivative action was filed in 2014 against various UBS entities and current and certain former directors of the funds, alleging hundreds of millions of US dollars in losses in the funds. In 2015, defendants' motion to dismiss was denied.

In 2011, a purported derivative action was filed on behalf of the Employee Retirement System of the Commonwealth of Puerto Rico (System) against over 40 defendants, including UBS PR, which was named in connection with its underwriting and consulting services. Plaintiffs alleged that defendants violated their purported fiduciary duties and contractual obligations in connection with the issuance and underwriting of USD 3 billion of bonds by the System in 2008 and sought damages of over USD 800 million. In 2016, the court granted the System's request to join the action as a plaintiff. In 2017, the court denied defendants' motion to dismiss the complaint. In 2020, the court denied plaintiffs' motion for summary judgment.

Note 16 Provisions and contingent liabilities (continued)

Beginning in 2015, certain agencies and public corporations of the Commonwealth of Puerto Rico (Commonwealth) defaulted on certain interest payments on Puerto Rico bonds. In 2016, US federal legislation created an oversight board with power to oversee Puerto Rico's finances and to restructure its debt. The oversight board has imposed a stay on the exercise of certain creditors' rights. In 2017, the oversight board placed certain of the bonds into a bankruptcy-like proceeding under the supervision of a Federal District Judge.

In May 2019, the oversight board filed complaints in Puerto Rico federal district court bringing claims against financial, legal and accounting firms that had participated in Puerto Rico municipal bond offerings, including UBS, seeking a return of underwriting and swap fees paid in connection with those offerings. UBS estimates that it received approximately USD 125 million in fees in the relevant offerings.

In August 2019, and February and November 2020, four US insurance companies that insured issues of Puerto Rico municipal bonds sued UBS and several other underwriters of Puerto Rico municipal bonds in three separate cases. The actions collectively seek recovery of an aggregate of USD 955 million in damages from the defendants. The plaintiffs in these cases claim that defendants failed to reasonably investigate financial statements in the offering materials for the insured Puerto Rico bonds issued between 2002 and 2007, which plaintiffs argue they relied upon in agreeing to insure the bonds notwithstanding that they had no contractual relationship with the underwriters. In June 2021 the court in the first of the three cases denied defendants' motion to dismiss; defendants are seeking leave to appeal that decision. In July 2021, the court in another of these cases granted defendants' motion to dismiss. A motion to dismiss is pending in the remaining case.

Our balance sheet at 30 June 2021 reflected provisions with respect to matters described in this item 4 in amounts that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provisions that we have recognized.

5. Foreign exchange, LIBOR and benchmark rates, and other trading practices

Foreign exchange-related regulatory matters: Beginning in 2013, numerous authorities commenced investigations concerning possible manipulation of foreign exchange markets and precious metals prices. As a result of these investigations, UBS entered into resolutions with the UK Financial Conduct Authority (FCA), the US Commodity Futures Trading Commission (CFTC), FINMA, the Board of Governors of the Federal Reserve System (Federal Reserve Board) and the Connecticut Department of Banking, the DOJ's Criminal Division and the European Commission. UBS has ongoing obligations under the Cease and Desist Order of the Federal Reserve Board and the Office of the Comptroller of the

Currency (as successor to the Connecticut Department of Banking), and to cooperate with relevant authorities and to undertake certain remediation measures. UBS has also been granted conditional immunity by the Antitrust Division of the DOJ and by authorities in other jurisdictions in connection with potential competition law violations relating to foreign exchange and precious metals businesses. Investigations relating to foreign exchange matters by certain authorities remain ongoing notwithstanding these resolutions.

Foreign exchange-related civil litigation: Putative class actions have been filed since 2013 in US federal courts and in other jurisdictions against UBS and other banks on behalf of putative classes of persons who engaged in foreign currency transactions with any of the defendant banks. UBS has resolved US federal court class actions relating to foreign currency transactions with the defendant banks and persons who transacted in foreign exchange futures contracts and options on such futures under a settlement agreement that provides for UBS to pay an aggregate of USD 141 million and provide cooperation to the settlement classes. Certain class members have excluded themselves from that settlement and have filed individual actions in US and English courts against UBS and other banks, alleging violations of US and European competition laws and unjust enrichment.

In 2015, a putative class action was filed in federal court against UBS and numerous other banks on behalf of persons and businesses in the US who directly purchased foreign currency from the defendants and alleged co-conspirators for their own end use. In March 2017, the court granted UBS's (and the other banks') motions to dismiss the complaint. The plaintiffs filed an amended complaint in August 2017. In March 2018, the court denied the defendants' motions to dismiss the amended complaint.

LIBOR and other benchmark-related regulatory matters: Numerous government agencies, including the SEC, the CFTC, the DOJ, the FCA, the UK Serious Fraud Office, the Monetary Authority of Singapore, the Hong Kong Monetary Authority, FINMA, various state attorneys general in the US and competition authorities in various jurisdictions, have conducted investigations regarding potential improper attempts by UBS, among others, to manipulate LIBOR and other benchmark rates at certain times. UBS reached settlements or otherwise concluded investigations relating to benchmark interest rates with the investigating authorities. UBS has ongoing obligations to cooperate with the authorities with whom we have reached resolutions and to undertake certain remediation measures with respect to benchmark interest rate submissions. UBS has been granted conditional leniency or conditional immunity from authorities in certain jurisdictions, including the Antitrust Division of the DOJ and the Swiss Competition Commission (WEKO), in connection with potential antitrust or competition law violations related to certain rates. However, UBS has not reached a final settlement with WEKO, as the Secretariat of WEKO has asserted that UBS does not qualify for full immunity.

Note 16 Provisions and contingent liabilities (continued)

LIBOR and other benchmark-related civil litigation: A number of putative class actions and other actions are pending in the federal courts in New York against UBS and numerous other banks on behalf of parties who transacted in certain interest rate benchmark-based derivatives. Also pending in the US and in other jurisdictions are a number of other actions asserting losses related to various products whose interest rates were linked to LIBOR and other benchmarks, including adjustable rate mortgages, preferred and debt securities, bonds pledged as collateral, loans, depository accounts, investments and other interest-bearing instruments. The complaints allege manipulation, through various means, of certain benchmark interest rates, including USD LIBOR, Euroyen TIBOR, Yen LIBOR, EURIBOR, CHF LIBOR, GBP LIBOR, SGD SIBOR and SOR and Australian BBSW, and seek unspecified compensatory and other damages under varying legal theories.

USD LIBOR class and individual actions in the US: In 2013 and 2015, the district court in the USD LIBOR actions dismissed, in whole or in part, certain plaintiffs' antitrust claims, federal racketeering claims, CEA claims, and state common law claims. Although the Second Circuit vacated the district court's judgment dismissing antitrust claims, the district court again dismissed antitrust claims against UBS in 2016. Certain plaintiffs have appealed that decision to the Second Circuit. Separately, in 2018, the Second Circuit reversed in part the district court's 2015 decision dismissing certain individual plaintiffs' claims and certain of these actions are now proceeding. UBS entered into an agreement in 2016 with representatives of a class of bondholders to settle their USD LIBOR class action. The agreement has received final court approval. In 2018, the district court denied plaintiffs' motions for class certification in the USD class actions for claims pending against UBS, and plaintiffs sought permission to appeal that ruling to the Second Circuit. In July 2018, the Second Circuit denied the petition to appeal of the class of USD lenders and in November 2018 denied the petition of the USD exchange class. In December 2019, UBS entered into an agreement with representatives of the class of USD lenders to settle their USD LIBOR class action. The agreement has received final court approval. In January 2019, a putative class action was filed in the District Court for the Southern District of New York against UBS and numerous other banks on behalf of US residents who, since 1 February 2014, directly transacted with a defendant bank in USD LIBOR instruments. The complaint asserts antitrust claims. The defendants moved to dismiss the complaint in August 2019. On 26 March 2020 the court granted defendants' motion to dismiss the complaint in its entirety. Plaintiffs have appealed the dismissal. In August 2020, an individual action was filed in the Northern District of California against UBS and numerous other banks alleging that the defendants conspired to fix the interest rate used as the basis for loans to consumers by jointly setting the USD LIBOR rate and monopolized the market for LIBOR-based consumer loans and credit cards.

Other benchmark class actions in the US: In 2014, 2015 and 2017, the court in one of the Euroyen TIBOR lawsuits dismissed certain of the plaintiffs' claims, including plaintiffs' federal antitrust and racketeering claims. In August 2020, the court granted defendants' motion for judgment on the pleadings and dismissed the lone remaining claim in the action as impermissibly

extraterritorial. Plaintiffs have appealed. In 2017, the court dismissed the other Yen LIBOR / Euroyen TIBOR action in its entirety on standing grounds. In April 2020, the appeals court reversed the dismissal and in August 2020 plaintiffs in that action filed an amended complaint. Defendants moved to dismiss the amended complaint in October 2020. In 2017, the court dismissed the CHF LIBOR action on standing grounds and failure to state a claim. Plaintiffs filed an amended complaint following the dismissal, and the court granted a renewed motion to dismiss in September 2019. Plaintiffs have appealed. Also in 2017, the court in the EURIBOR lawsuit dismissed the case as to UBS and certain other foreign defendants for lack of personal jurisdiction. Plaintiffs have appealed. In October 2018, the court in the SIBOR / SOR action dismissed all but one of plaintiffs' claims against UBS. Plaintiffs filed an amended complaint following the dismissal, and the court granted a renewed motion to dismiss in July 2019. Plaintiffs appealed. In March 2021, the Second Circuit reversed the dismissal. In November 2018, the court in the BBSW lawsuit dismissed the case as to UBS and certain other foreign defendants for lack of personal jurisdiction. Following that dismissal, plaintiffs filed an amended complaint in April 2019, which UBS and other defendants named in the amended complaint moved to dismiss. In February 2020, the court in the BBSW action granted in part and denied in part defendants' motions to dismiss the amended complaint. In August 2020, UBS and other BBSW defendants joined a motion for judgment on the pleadings. The court dismissed the GBP LIBOR action in August 2019. Plaintiffs have appealed.

Government bonds: Putative class actions have been filed since 2015 in US federal courts against UBS and other banks on behalf of persons who participated in markets for US Treasury securities since 2007. A consolidated complaint was filed in 2017 in the US District Court for the Southern District of New York alleging that the banks colluded with respect to, and manipulated prices of, US Treasury securities sold at auction and in the secondary market and asserting claims under the antitrust laws and for unjust enrichment. Defendants' motions to dismiss the consolidated complaint was granted on 31 March 2021. Plaintiffs filed an amended complaint, which defendants moved to dismiss in June 2021. Similar class actions have been filed concerning European government bonds and other government bonds.

In May 2021, the European Commission issued a decision finding that UBS and six other banks breached European Union antitrust rules in 2007-2011 relating to European government bonds. The European Commission fined UBS EUR 172 million. UBS is appealing the amount of the fine.

With respect to additional matters and jurisdictions not encompassed by the settlements and orders referred to above, our balance sheet at 30 June 2021 reflected a provision in an amount that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.

Note 16 Provisions and contingent liabilities (continued)**6. Swiss retrocessions**

The Federal Supreme Court of Switzerland ruled in 2012, in a test case against UBS, that distribution fees paid to a firm for distributing third-party and intra-group investment funds and structured products must be disclosed and surrendered to clients who have entered into a discretionary mandate agreement with the firm, absent a valid waiver. FINMA issued a supervisory note to all Swiss banks in response to the Supreme Court decision. UBS has met the FINMA requirements and has notified all potentially affected clients.

The Supreme Court decision has resulted, and may continue to result, in a number of client requests for UBS to disclose and potentially surrender retrocessions. Client requests are assessed on a case-by-case basis. Considerations taken into account when assessing these cases include, among other things, the existence

of a discretionary mandate and whether or not the client documentation contained a valid waiver with respect to distribution fees.

Our balance sheet at 30 June 2021 reflected a provision with respect to matters described in this item 6 in an amount that UBS believes to be appropriate under the applicable accounting standard. The ultimate exposure will depend on client requests and the resolution thereof, factors that are difficult to predict and assess. Hence, as in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.

Note 17 Currency translation rates

The following table shows the rates of the main currencies used to translate the financial information of UBS AG's operations with a functional currency other than the US dollar into US dollars.

	Closing exchange rate				Average rate ¹				
	As of				For the quarter ended			Year-to-date	
	30.6.21	31.3.21	31.12.20	30.6.20	30.6.21	31.3.21	30.6.20	30.6.21	30.6.20
1 CHF	1.08	1.06	1.13	1.06	1.10	1.09	1.04	1.09	1.04
1 EUR	1.19	1.17	1.22	1.12	1.20	1.20	1.11	1.20	1.11
1 GBP	1.38	1.38	1.37	1.24	1.39	1.38	1.24	1.39	1.26
100 JPY	0.90	0.90	0.97	0.93	0.91	0.93	0.93	0.92	0.93

¹ Monthly income statement items of operations with a functional currency other than the US dollar are translated into US dollars using month-end rates. Disclosed average rates for a quarter represent an average of three month-end rates, weighted according to the income and expense volumes of all operations of UBS AG with the same functional currency for each month. Weighted average rates for individual business divisions may deviate from the weighted average rates for UBS AG.

Note 18 Supplemental guarantor information required under SEC regulations

Joint liability of UBS Switzerland AG

In 2015, the Personal & Corporate Banking and Wealth Management businesses booked in Switzerland were transferred from UBS AG to UBS Switzerland AG through an asset transfer in accordance with the Swiss Merger Act. Under the terms of the asset transfer agreement, UBS Switzerland AG assumed joint liability for contractual obligations of UBS AG existing on the asset transfer date, including the full and unconditional

guarantee of certain registered debt securities issued by UBS AG. To reflect this joint liability, UBS Switzerland AG is presented in a separate column as a subsidiary co-guarantor.

The joint liability of UBS Switzerland AG for contractual obligations of UBS AG decreased by USD 2.5 billion in the first half of 2021 to USD 7.6 billion as of 30 June 2021, mainly related to derivative financial instruments.

Supplemental guarantor consolidated income statement

<i>USD million</i>	UBS AG (standalone) ¹	UBS Switzerland AG (standalone) ¹	Other subsidiaries ²	Elimination entries	UBS AG (consolidated)
For the six months ended 30 June 2021					
Operating income					
Interest income from financial instruments measured at amortized cost and fair value through other comprehensive income	1,521	1,812	1,228	(356)	4,205
Interest expense from financial instruments measured at amortized cost	(1,441)	(276)	(517)	515	(1,719)
Net interest income from financial instruments measured at fair value through profit or loss	619	114	110	(133)	710
Net interest income	699	1,650	820	26	3,196
Other net income from financial instruments measured at fair value through profit or loss	1,757	417	720	(109)	2,785
Credit loss (expense) / release	47	80	3	(23)	108
Fee and commission income	2,064	2,571	7,996	(387)	12,244
Fee and commission expense	(412)	(239)	(690)	380	(962)
Net fee and commission income	1,652	2,331	7,306	(7)	11,282
Other income	3,231	118	519	(3,333)	535
Total operating income	7,387	4,596	9,367	(3,445)	17,906
Operating expenses					
Personnel expenses	1,915	1,116	5,125	1	8,158
General and administrative expenses	1,722	1,710	2,152	(1,373)	4,211
Depreciation and impairment of property, equipment and software	453	141	351	(58)	887
Amortization and impairment of goodwill and intangible assets	4	0	13	0	17
Total operating expenses	4,095	2,967	7,641	(1,429)	13,274
Operating profit / (loss) before tax	3,293	1,629	1,726	(2,016)	4,632
Tax expense / (benefit)	222	299	493	(13)	1,001
Net profit / (loss)	3,070	1,331	1,233	(2,003)	3,631
Net profit / (loss) attributable to non-controlling interests	0	0	9	0	9
Net profit / (loss) attributable to shareholders	3,070	1,331	1,224	(2,003)	3,623

¹ Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under "Complementary financial information" at ubs.com/investors, for information prepared in accordance with Swiss GAAP. ² The "Other subsidiaries" column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.

Note 18 Supplemental guarantor information required under SEC regulations (continued)**Supplemental guarantor consolidated statement of comprehensive income**

<i>USD million</i>	UBS AG (standalone) ¹	UBS Switzerland AG (standalone) ¹	Other subsidiaries ²	Elimination entries	UBS AG (consolidated)
For the six months ended 30 June 2021					
Comprehensive income attributable to shareholders					
Net profit / (loss)	3,070	1,331	1,224	(2,003)	3,623
Other comprehensive income					
Other comprehensive income that may be reclassified to the income statement					
Foreign currency translation, net of tax	(38)	(641)	(287)	515	(452)
Financial assets measured at fair value through other comprehensive income, net of tax	0	0	(88)	0	(88)
Cash flow hedges, net of tax	(662)	(159)	(110)	(5)	(937)
Cost of hedging, net of tax	(23)				(23)
Total other comprehensive income that may be reclassified to the income statement, net of tax	(723)	(801)	(485)	509	(1,500)
Other comprehensive income that will not be reclassified to the income statement					
Defined benefit plans, net of tax	41	(123)	50	0	(31)
Own credit on financial liabilities designated at fair value, net of tax	89				89
Total other comprehensive income that will not be reclassified to the income statement, net of tax	131	(123)	50	0	58
Total other comprehensive income	(592)	(924)	(435)	509	(1,442)
Total comprehensive income attributable to shareholders	2,478	407	790	(1,494)	2,181
Total comprehensive income attributable to non-controlling interests			10		10
Total comprehensive income	2,478	407	800	(1,494)	2,192

¹ Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under "Complementary financial information" at ubs.com/investors, for information prepared in accordance with Swiss GAAP. ² The "Other subsidiaries" column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.

Note 18 Supplemental guarantor information required under SEC regulations (continued)

Supplemental guarantor consolidated balance sheet

USD million					
As of 30 June 2021	UBS AG (standalone) ¹	UBS Switzerland AG (standalone) ¹	Other subsidiaries ²	Elimination entries	UBS AG (consolidated)
Assets					
Cash and balances at central banks	42,807	88,250	29,616		160,672
Loans and advances to banks	38,654	6,427	20,083	(48,788)	16,376
Receivables from securities financing transactions	60,265	8,701	50,113	(35,584)	83,494
Cash collateral receivables on derivative instruments	30,817	886	12,064	(13,980)	29,787
Loans and advances to customers	105,202	225,329	85,489	(24,613)	391,406
Other financial assets measured at amortized cost	8,767	7,428	12,979	(1,974)	27,201
Total financial assets measured at amortized cost	286,512	337,020	210,343	(124,938)	708,937
Financial assets at fair value held for trading	107,827	56	17,728	(2,983)	122,628
<i>of which: assets pledged as collateral that may be sold or repledged by counterparties</i>	<i>52,493</i>	<i>0</i>	<i>6,835</i>	<i>(14,995)</i>	<i>44,333</i>
Derivative financial instruments	117,032	5,172	36,950	(37,532)	121,622
Brokerage receivables	14,497		8,516	(3)	23,010
Financial assets at fair value not held for trading	39,698	7,741	35,237	(17,724)	64,952
Total financial assets measured at fair value through profit or loss	279,053	12,970	98,431	(58,242)	332,211
Financial assets measured at fair value through other comprehensive income	135		7,641		7,775
Investments in subsidiaries and associates	53,492	37	54	(52,384)	1,198
Property, equipment and software	6,703	1,378	3,963	(312)	11,732
Goodwill and intangible assets	214		6,211	28	6,452
Deferred tax assets	835		8,116		8,951
Other non-financial assets	5,813	1,935	858	(3)	8,603
Total assets	632,757	353,339	335,616	(235,852)	1,085,861
Liabilities					
Amounts due to banks	33,193	32,461	47,086	(98,126)	14,615
Payables from securities financing transactions	17,503	849	23,265	(35,645)	5,972
Cash collateral payables on derivative instruments	31,481	536	14,095	(13,919)	32,193
Customer deposits	99,713	286,370	119,737	11,642	517,462
Funding from UBS Group AG	55,907				55,907
Debt issued measured at amortized cost	75,543	8,976	1	(29)	84,491
Other financial liabilities measured at amortized cost	4,915	3,019	5,012	(2,274)	10,671
Total financial liabilities measured at amortized cost	318,256	332,211	209,195	(138,351)	721,311
Financial liabilities at fair value held for trading	28,822	482	6,850	(2,806)	33,348
Derivative financial instruments	117,636	4,460	37,131	(37,539)	121,688
Brokerage payables designated at fair value	26,521		12,613	(5)	39,129
Debt issued designated at fair value	72,034		860	(95)	72,799
Other financial liabilities designated at fair value	11,054		26,164	(4,311)	32,908
Total financial liabilities measured at fair value through profit or loss	256,068	4,942	83,618	(44,756)	299,871
Provisions	1,337	289	1,170	(3)	2,792
Other non-financial liabilities	1,858	1,076	3,370	(63)	6,241
Total liabilities	577,518	338,517	297,354	(183,174)	1,030,216
Equity attributable to shareholders	55,239	14,822	37,978	(52,678)	55,361
Equity attributable to non-controlling interests			284		284
Total equity	55,239	14,822	38,262	(52,678)	55,645
Total liabilities and equity	632,757	353,339	335,616	(235,852)	1,085,861

¹ Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under "Complementary financial information" at ubs.com/investors, for information prepared in accordance with Swiss GAAP. ² The "Other subsidiaries" column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.

Note 18 Supplemental guarantor information required under SEC regulations (continued)**Supplemental guarantor consolidated statement of cash flows**

USD million

For the six months ended 30 June 2021

	UBS AG ¹	UBS Switzerland AG ¹	Other subsidiaries ¹	UBS AG (consolidated)
Net cash flow from / (used in) operating activities	(3,264)	1,407	445	(1,413)
Cash flow from / (used in) investing activities				
Purchase of subsidiaries, associates and intangible assets	0	(1)	0	(1)
Disposal of subsidiaries, associates and intangible assets ²	16	0	421	437
Purchase of property, equipment and software	(313)	(134)	(310)	(757)
Disposal of property, equipment and software	264	0	1	264
Purchase of financial assets measured at fair value through other comprehensive income	(11)	0	(1,939)	(1,950)
Disposal and redemption of financial assets measured at fair value through other comprehensive income	11	0	2,313	2,324
Net (purchase) / redemption of debt securities measured at amortized cost	273	293	(449)	116
Net cash flow from / (used in) investing activities	239	158	36	434
Cash flow from / (used in) financing activities				
Net short-term debt issued / (repaid)	(3,863)	(14)	0	(3,877)
Distributions paid on UBS shares	(4,539)	0	0	(4,539)
Repayment of lease liabilities	(143)	0	(130)	(274)
Issuance of debt designated at fair value and long-term debt measured at amortized cost ³	63,422	289	134	63,845
Repayment of debt designated at fair value and long-term debt measured at amortized cost ³	(44,428)	(570)	(246)	(45,244)
Net changes in non-controlling interests	0	0	(4)	(4)
Net activity related to group internal capital transactions and dividends	2,224	(537)	(1,687)	0
Net cash flow from / (used in) financing activities	12,673	(833)	(1,932)	9,908
Total cash flow				
Cash and cash equivalents at the beginning of the year	39,400	93,342	40,689	173,430
Net cash flow from / (used in) operating, investing and financing activities	9,648	732	(1,451)	8,929
Effects of exchange rate differences on cash and cash equivalents	(945)	(3,926)	(518)	(5,389)
Cash and cash equivalents at the end of the period⁴	48,103	90,148	38,721	176,971
<i>of which: cash and balances at central banks</i>	<i>42,676</i>	<i>88,250</i>	<i>29,616</i>	<i>160,541</i>
<i>of which: loans and advances to banks</i>	<i>4,655</i>	<i>1,610</i>	<i>8,735</i>	<i>15,001</i>
<i>of which: money market paper</i>	<i>772</i>	<i>288</i>	<i>369</i>	<i>1,428</i>

¹ Cash flows generally represent a third-party view from a UBS AG consolidated perspective, except for Net activity related to group internal capital transactions and dividends. ² Includes cash proceeds from the sale of UBS's minority investment in Clearstream Fund Centre and dividends received from associates. ³ Includes funding from UBS Group AG to UBS AG. ⁴ Comprises balances with an original maturity of three months or less. USD 3,432 million of cash and cash equivalents were restricted.

Note 18 Supplemental guarantor information required under SEC regulations (continued)

Supplemental guarantor consolidated income statement

<i>USD million</i>	UBS AG (standalone) ¹	UBS Switzerland AG (standalone) ¹	Other subsidiaries ²	Elimination entries	UBS AG (consolidated)
For the six months ended 30 June 2020					
Operating income					
Interest income from financial instruments measured at amortized cost and fair value through other comprehensive income	1,813	1,821	1,439	(481)	4,591
Interest expense from financial instruments measured at amortized cost	(2,152)	(258)	(759)	651	(2,519)
Net interest income from financial instruments measured at fair value through profit or loss	507	83	175	(149)	616
Net interest income	169	1,645	854	20	2,689
Other net income from financial instruments measured at fair value through profit or loss	2,570	435	386	329	3,719
Credit loss (expense) / release	(239)	(218)	(83)	0	(540)
Fee and commission income	1,855	2,293	6,581	(518)	10,211
Fee and commission expense	(307)	(454)	(623)	509	(875)
Net fee and commission income	1,548	1,839	5,958	(8)	9,336
Other income	2,207	135	831	(2,857)	317
Total operating income	6,255	3,836	7,947	(2,517)	15,521
Operating expenses					
Personnel expenses	1,713	1,027	4,651	0	7,391
General and administrative expenses	1,619	1,568	1,983	(1,210)	3,960
Depreciation and impairment of property, equipment and software	430	122	320	(57)	814
Amortization and impairment of goodwill and intangible assets	2	0	30	0	32
Total operating expenses	3,764	2,716	6,983	(1,267)	12,197
Operating profit / (loss) before tax	2,490	1,120	964	(1,250)	3,324
Tax expense / (benefit)	138	215	266	83	703
Net profit / (loss)	2,352	904	698	(1,333)	2,621
Net profit / (loss) attributable to non-controlling interests	0	0	6	0	6
Net profit / (loss) attributable to shareholders	2,352	904	691	(1,333)	2,615

¹ Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under "Complementary financial information" at ubs.com/investors, for information prepared in accordance with Swiss GAAP. ² The "Other subsidiaries" column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.

Note 18 Supplemental guarantor information required under SEC regulations (continued)**Supplemental guarantor consolidated statement of comprehensive income**

<i>USD million</i>	UBS AG (standalone) ¹	UBS Switzerland AG (standalone) ¹	Other subsidiaries ²	Elimination entries	UBS AG (consolidated)
For the six months ended 30 June 2020					
Comprehensive income attributable to shareholders					
Net profit / (loss)	2,352	904	691	(1,333)	2,615
Other comprehensive income					
Other comprehensive income that may be reclassified to the income statement					
Foreign currency translation, net of tax	7	278	(111)	(72)	103
Financial assets measured at fair value through other comprehensive income, net of tax	0	0	149	0	149
Cash flow hedges, net of tax	1,348	84	176	(8)	1,600
Cost of hedging, net of tax	9	0	(13)	0	(4)
Total other comprehensive income that may be reclassified to the income statement, net of tax	1,364	362	201	(80)	1,847
Other comprehensive income that will not be reclassified to the income statement					
Defined benefit plans, net of tax	(131)	(97)	(42)	0	(270)
Own credit on financial liabilities designated at fair value, net of tax	62				62
Total other comprehensive income that will not be reclassified to the income statement, net of tax	(69)	(97)	(42)	0	(208)
Total other comprehensive income	1,295	265	160	(80)	1,639
Total comprehensive income attributable to shareholders	3,647	1,169	851	(1,413)	4,254
Total comprehensive income attributable to non-controlling interests			3		3
Total comprehensive income	3,647	1,169	854	(1,413)	4,256

¹ Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under "Complementary financial information" at ubs.com/investors, for information prepared in accordance with Swiss GAAP. ² The "Other subsidiaries" column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.

Note 18 Supplemental guarantor information required under SEC regulations (continued)

Supplemental guarantor consolidated balance sheet

<i>USD million</i>					
As of 31 December 2020	UBS AG (standalone) ¹	UBS Switzerland AG (standalone) ¹	Other subsidiaries ²	Elimination entries	UBS AG (consolidated)
Assets					
Cash and balances at central banks	34,426	91,638	32,167		158,231
Loans and advances to banks	40,171	6,385	19,465	(50,678)	15,344
Receivables from securities financing transactions	56,568	4,026	43,350	(29,735)	74,210
Cash collateral receivables on derivative instruments	32,771	1,543	10,093	(11,671)	32,737
Loans and advances to customers	99,952	228,279	73,513	(20,767)	380,977
Other financial assets measured at amortized cost	8,411	8,084	13,368	(2,644)	27,219
Total financial assets measured at amortized cost	272,299	339,956	191,957	(115,495)	688,717
Financial assets at fair value held for trading	110,812	55	16,260	(1,634)	125,492
<i>of which: assets pledged as collateral that may be sold or repledged by counterparties</i>	<i>54,468</i>	<i>1</i>	<i>6,247</i>	<i>(13,617)</i>	<i>47,098</i>
Derivative financial instruments	154,313	6,342	44,005	(45,041)	159,618
Brokerage receivables	16,898		7,763	(2)	24,659
Financial assets at fair value not held for trading	46,198	13,068	36,444	(15,672)	80,038
Total financial assets measured at fair value through profit or loss	328,221	19,464	104,473	(62,350)	389,808
Financial assets measured at fair value through other comprehensive income	187		8,072		8,258
Investments in subsidiaries and associates	53,606	38	439	(52,526)	1,557
Property, equipment and software	6,999	1,335	3,975	(350)	11,958
Goodwill and intangible assets	217		6,234	28	6,480
Deferred tax assets	840	1	8,334	(1)	9,174
Other non-financial assets	6,641	2,063	854	(183)	9,374
Total assets	669,010	362,857	324,337	(230,878)	1,125,327
Liabilities					
Amounts due to banks	41,414	34,096	43,066	(107,527)	11,050
Payables from securities financing transactions	17,247	566	18,407	(29,899)	6,321
Cash collateral payables on derivative instruments	35,875	561	12,495	(11,618)	37,313
Customer deposits	98,441	293,371	112,372	23,745	527,929
Funding from UBS Group AG	53,979				53,979
Debt issued measured at amortized cost	75,658	9,687	3	3	85,351
Other financial liabilities measured at amortized cost	5,285	2,567	5,745	(3,175)	10,421
Total financial liabilities measured at amortized cost	327,898	340,848	192,088	(128,470)	732,364
Financial liabilities at fair value held for trading	28,800	335	5,989	(1,529)	33,595
Derivative financial instruments	156,192	5,593	44,359	(45,043)	161,102
Brokerage payables designated at fair value	25,045		13,704	(7)	38,742
Debt issued designated at fair value	58,986		935	(54)	59,868
Other financial liabilities designated at fair value	11,255		23,445	(2,927)	31,773
Total financial liabilities measured at fair value through profit or loss	280,279	5,927	88,433	(49,559)	325,080
Provisions	1,293	301	1,197		2,791
Other non-financial liabilities	2,173	987	3,907	(49)	7,018
Total liabilities	611,643	348,063	285,625	(178,078)	1,067,254
Equity attributable to shareholders	57,367	14,794	38,393	(52,800)	57,754
Equity attributable to non-controlling interests			319		319
Total equity	57,367	14,794	38,712	(52,800)	58,073
Total liabilities and equity	669,010	362,857	324,337	(230,878)	1,125,327

¹ Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under "Complementary financial information" at ubs.com/investors, for information prepared in accordance with Swiss GAAP. ² The "Other subsidiaries" column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.

Note 18 Supplemental guarantor information required under SEC regulations (continued)**Supplemental guarantor consolidated statement of cash flows**

<i>USD million</i>				
For the six months ended 30 June 2020	UBS AG ¹	UBS Switzerland AG ¹	Other subsidiaries ¹	UBS AG (consolidated)
Net cash flow from / (used in) operating activities	7,484	16,765	16,811	41,060
Cash flow from / (used in) investing activities				
Purchase of subsidiaries, associates and intangible assets	0	(1)	0	(1)
Disposal of subsidiaries, associates and intangible assets	14	0	0	14
Purchase of property, equipment and software	(277)	(139)	(309)	(725)
Disposal of property, equipment and software	1	0	3	4
Purchase of financial assets measured at fair value through other comprehensive income	(77)	0	(4,055)	(4,132)
Disposal and redemption of financial assets measured at fair value through other comprehensive income	27	0	1,917	1,944
Net (purchase) / redemption of debt securities measured at amortized cost	(3,126)	(373)	(1,318)	(4,817)
Net cash flow from / (used in) investing activities	(3,437)	(513)	(3,762)	(7,713)
Cash flow from / (used in) financing activities				
Net short-term debt issued / (repaid)	14,916	(3)	(1)	14,912
Distributions paid on UBS shares	(2,550)	0	0	(2,550)
Repayment of lease liabilities	(133)	0	(129)	(262)
Issuance of debt designated at fair value and long-term debt measured at amortized cost ²	45,597	336	68	46,001
Repayment of debt designated at fair value and long-term debt measured at amortized cost ²	(45,770)	(306)	(62)	(46,137)
Net changes in non-controlling interests	0	0	(4)	(4)
Net activity related to group internal capital transactions and dividends	1,513	(749)	(763)	0
Net cash flow from / (used in) financing activities	13,573	(723)	(890)	11,960
Total cash flow				
Cash and cash equivalents at the beginning of the year	39,598	62,551	17,655	119,804
Net cash flow from / (used in) operating, investing and financing activities	17,620	15,529	12,160	45,308
Effects of exchange rate differences on cash and cash equivalents	48	1,549	(30)	1,567
Cash and cash equivalents at the end of the period³	57,266	79,629	29,784	166,679
<i>of which: cash and balances at central banks</i>	<i>51,139</i>	<i>77,212</i>	<i>21,078</i>	<i>149,430</i>
<i>of which: loans and advances to banks</i>	<i>4,492</i>	<i>1,979</i>	<i>7,867</i>	<i>14,339</i>
<i>of which: money market paper</i>	<i>1,635</i>	<i>437</i>	<i>839</i>	<i>2,911</i>

¹ Cash flows generally represent a third-party view from a UBS AG consolidated perspective, except for Net activity related to group internal capital transactions and dividends. ² Includes funding from UBS Group AG to UBS AG. ³ Comprises balances with an original maturity of three months or less. USD 5,393 million of cash and cash equivalents were restricted.

UBS AG standalone financial information

Unaudited

Table of contents

UBS AG interim standalone financial information (unaudited)

- 71** Income statement
- 72** Balance sheet
- 73** Basis of accounting and items impacting comparability

UBS AG interim standalone financial information (unaudited)

Income statement

	USD million		CHF million	
	Year-to-date	30.6.20	Year-to-date	30.6.20
	30.6.21	30.6.20	30.6.21	30.6.20
Interest and discount income ¹	2,039	2,619	1,865	2,518
Interest and dividend income from trading portfolio	1,332	1,192	1,221	1,145
Interest and dividend income from financial investments	51	169	46	162
Interest expense ²	(2,582)	(3,478)	(2,361)	(3,344)
Gross interest income	839	501	772	481
Credit loss (expense) / release	60	(121)	55	(116)
Net interest income	898	381	828	365
Fee and commission income from securities and investment business and other fee and commission income	1,985	1,791	1,814	1,720
Credit-related fees and commissions	64	122	59	118
Fee and commission expense	(412)	(307)	(376)	(295)
Net fee and commission income	1,637	1,606	1,497	1,542
Net trading income	1,544	2,439	1,383	2,343
Net income from disposal of financial investments	54	74	50	71
Dividend income from investments in subsidiaries and other participations	2,358	1,602	2,181	1,541
Income from real estate holdings	259	256	237	246
Sundry ordinary income	701	607	642	583
Sundry ordinary expenses	(167)	(193)	(150)	(185)
Other income from ordinary activities	3,205	2,346	2,959	2,256
Total operating income	7,284	6,771	6,667	6,506
Personnel expenses	1,881	1,862	1,713	1,789
General and administrative expenses	1,788	1,726	1,634	1,659
Subtotal operating expenses	3,669	3,588	3,347	3,448
Impairment of investments in subsidiaries and other participations	39	86	37	84
Depreciation, amortization and impairment of property, equipment, software, goodwill and intangible assets	391	350	358	336
Changes in provisions and other allowances and losses	74	15	68	15
Total operating expenses	4,173	4,040	3,811	3,883
Operating profit	3,111	2,731	2,856	2,623
Extraordinary income	136	98	126	94
Extraordinary expenses	1	0	1	0
Tax expense / (benefit)	202	182	183	174
Net profit / (loss) for the period	3,045	2,647	2,797	2,542

¹ Interest and discount income includes negative interest income on financial assets of approximately USD 0.2 billion (CHF 0.2 billion) and approximately USD 0.2 billion (CHF 0.2 billion) for the periods ended 30 June 2021 and 30 June 2020, respectively. ² Includes negative interest expense on financial liabilities of approximately USD 0.2 billion (CHF 0.2 billion) and approximately USD 0.1 billion (CHF 0.1 billion) for the periods ended 30 June 2021 and 30 June 2020, respectively.

Balance sheet

	USD million		CHF million	
	30.6.21	31.12.20	30.6.21	31.12.20
Assets				
Cash and balances at central banks	42,734	34,148	39,529	30,239
Due from banks	36,114	38,357	33,405	33,966
Receivables from securities financing transactions	67,067	63,305	62,038	56,058
Due from customers	126,688	124,596	117,188	110,334
Funding provided to significant regulated subsidiaries eligible as total loss-absorbing capacity ¹	26,995	26,354	24,972	23,337
Mortgage loans	5,389	5,406	4,985	4,787
Trading portfolio assets	111,525	115,164	103,163	101,981
Derivative financial instruments	16,160	17,203	14,949	15,234
Financial investments	17,932	23,852	16,588	21,122
Accrued income and prepaid expenses	1,388	1,414	1,284	1,253
Investments in subsidiaries and other participations	50,801	50,444	46,992	44,670
Property, equipment and software	5,693	6,091	5,266	5,394
Other assets	3,488	2,690	3,225	2,381
Total assets	511,973	509,024	473,583	450,756
<i>of which: subordinated assets</i>	<i>19,308</i>	<i>19,999</i>	<i>17,860</i>	<i>17,710</i>
<i>of which: subject to mandatory conversion and / or debt waiver</i>	<i>17,576</i>	<i>18,067</i>	<i>16,259</i>	<i>15,998</i>
Liabilities				
Due to banks	41,083	49,655	38,003	43,971
Payables from securities financing transactions	23,635	24,407	21,863	21,613
Due to customers	136,036	132,747	125,835	117,553
Funding received from UBS Group AG eligible as total loss-absorbing capacity at UBS AG level measured at amortized cost ¹	55,011	53,585	50,887	47,451
Trading portfolio liabilities	28,822	28,806	26,660	25,509
Derivative financial instruments	17,343	21,918	16,043	19,409
Financial liabilities designated at fair value	74,331	58,737	68,758	52,014
<i>of which: funding received from UBS Group AG eligible as total loss-absorbing capacity at UBS AG level¹</i>	<i>2,112</i>	<i>0</i>	<i>1,954</i>	<i>0</i>
Bonds issued	76,266	76,490	70,547	67,734
<i>of which: total loss-absorbing capacity eligible at UBS AG level¹</i>	<i>5,044</i>	<i>7,480</i>	<i>4,666</i>	<i>6,624</i>
Accrued expenses and deferred income	2,692	3,282	2,490	2,906
Other liabilities	4,391	5,591	4,061	4,951
Provisions	1,461	1,411	1,351	1,250
Total liabilities	461,071	456,628	426,498	404,359
Equity				
Share capital	393	393	386	386
General reserve	36,326	36,326	35,649	35,649
<i>of which: statutory capital reserve</i>	<i>36,326</i>	<i>36,326</i>	<i>35,649</i>	<i>35,649</i>
<i>of which: capital contribution reserve</i>	<i>36,326</i>	<i>36,326</i>	<i>35,649</i>	<i>35,649</i>
Voluntary earnings reserve	11,138	11,138	8,253	6,098
Net profit / (loss) for the period	3,045	4,539	2,797	4,265
Total equity	50,902	52,396	47,085	46,397
Total liabilities and equity	511,973	509,024	473,583	450,756
<i>of which: subordinated liabilities</i>	<i>63,019</i>	<i>62,053</i>	<i>58,294</i>	<i>54,950</i>
<i>of which: subject to mandatory conversion and / or debt waiver</i>	<i>62,448</i>	<i>61,486</i>	<i>57,766</i>	<i>54,448</i>

¹ Represents the Swiss GAAP carrying amount of instruments qualifying as total loss-absorbing capital.

Basis of accounting and items impacting comparability

UBS AG standalone financial statements are prepared in accordance with Swiss GAAP (the FINMA Accounting Ordinance, FINMA Circular 2020/1 "Accounting – banks" and the Banking Ordinance).

The accounting policies are principally the same as the IFRS-based accounting policies for the consolidated financial statements outlined in Note 1 to the consolidated financial statements of UBS AG included in the UBS Group AG and UBS AG Annual Report 2020. Major differences between the Swiss GAAP requirements and International Financial Reporting Standards are described in Note 35 to the consolidated financial statements of UBS AG. Further information on the accounting policies applied for the standalone financial statements of UBS AG is provided in Note 2 to the UBS AG standalone financial statements as of 31 December 2020.

In preparing the interim financial information for UBS AG, the same accounting policies and methods of computation have

been applied as in the annual standalone financial statements as of 31 December 2020.

This interim financial information is unaudited and should be read in conjunction with the audited 2020 standalone financial statements of UBS AG, available under "Holding company and significant regulated subsidiaries and sub-groups" under complementary financial information at ubs.com/investors.

In the fourth quarter of 2020, UBS decided not to proceed with the transfer of a portion of the Global Wealth Management business booked in Switzerland from UBS Switzerland AG to UBS AG. As a result of this decision, the beneficial ownership of that business was re-transferred from UBS AG to UBS Switzerland AG with effective date 31 December 2020. UBS AG's share of the profits for the first six months of 2020 of USD 221 million (CHF 213 million) is reflected in *Fee and commission income from securities and investment business and other fee and commission income*.

Alternative performance measures

Alternative performance measures

An alternative performance measure (an APM) is a financial measure of historical or future financial performance, financial position or cash flows other than a financial measure defined or specified in the applicable recognized accounting standards or in other applicable regulations. We report a number of APMs in our external reports (annual, quarterly and other reports). We use APMs to provide a more complete picture of our operating performance and to reflect management's view of the fundamental drivers of our business results. A definition of each APM, the method used to calculate it and the information content are presented in the table below. Our APMs may qualify as non-GAAP measures as defined by US Securities and Exchange Commission (SEC) regulations.

APM label	Calculation	Information content
Invested assets (USD and CHF) – GWM, P&C, AM	Calculated as the sum of managed fund assets, managed institutional assets, discretionary and advisory wealth management portfolios, fiduciary deposits, time deposits, savings accounts, and wealth management securities or brokerage accounts.	This measure provides information about the volume of client assets managed by or deposited with UBS for investment purposes.
Client assets (USD and CHF) – GWM, P&C	Calculated as the sum of invested assets and other assets held purely for transactional purposes or custody only.	This measure provides information about the volume of client assets managed by or deposited with UBS for investment purposes, including other assets held purely for transactional purposes or custody only.
Recurring net fee income (USD and CHF) – GWM, P&C	Calculated as the total of fees for services provided on an ongoing basis, such as portfolio management fees, asset-based investment fund fees and custody fees, which are generated on client assets, and administrative fees for accounts (as well as credit card fees for GWM).	This measure provides information about the amount of recurring net fee income.
Transaction-based income (USD and CHF) – GWM, P&C	Calculated as the total of the non-recurring portion of net fee and commission income, mainly composed of brokerage and transaction-based investment fund fees, as well as fees for payment and foreign exchange transactions (and credit card fees for P&C), together with other net income from financial instruments measured at fair value through profit or loss.	This measure provides information about the amount of the non-recurring portion of net fee and commission income.
Cost / income ratio (%)	Calculated as operating expenses divided by operating income before credit loss expense or release.	This measure provides information about the efficiency of the business by comparing operating expenses with gross income.
Gross margin on invested assets (bps) – AM	Calculated as operating income before credit loss expense or release (annualized as applicable) divided by average invested assets.	This measure provides information about the operating income before credit loss expense or release of the business in relation to invested assets.
Net interest margin (bps) – P&C	Calculated as net interest income (annualized as applicable) divided by average loans.	This measure provides information about the profitability of the business by calculating the difference between the price charged for lending and the cost of funding, relative to loan value.
Net margin on invested assets (bps) – AM	Calculated as operating profit before tax (annualized as applicable) divided by average invested assets.	This measure provides information about the operating profit before tax of the business in relation to invested assets.
Business volume for Personal Banking (CHF and USD) – P&C	Calculated as the sum of client assets and loans.	This measure provides information about the volume of client assets and loans.
Net new business volume for Personal Banking (CHF and USD) – P&C	Calculated as the sum of net inflows and outflows of client assets and loans during a specific period (annualized as applicable).	This measure provides information about the business volume as a result of net new business volume flows during a specific period.
Net new business volume growth for Personal Banking (%) – P&C	Calculated as the sum of net inflows and outflows of client assets and loans during a specific period (annualized as applicable) divided by total business volume / client assets at the beginning of the period.	This measure provides information about the growth of the business volume as a result of net new business volume flows during a specific period.

APM label	Calculation	Information content
Net profit growth (%)	Calculated as the change in net profit attributable to shareholders from continuing operations between current and comparison periods divided by net profit attributable to shareholders from continuing operations of the comparison period.	This measure provides information about profit growth in comparison with the prior period.
Pre-tax profit growth (%)	Calculated as the change in net profit before tax attributable to shareholders from continuing operations between current and comparison periods divided by net profit before tax attributable to shareholders from continuing operations of the comparison period.	This measure provides information about pre-tax profit growth in comparison with the prior period.
Return on common equity tier 1 capital (%)	Calculated as annualized net profit attributable to shareholders divided by average common equity tier 1 capital.	This measure provides information about the profitability of the business in relation to common equity tier 1 capital.
Return on equity (%)	Calculated as annualized net profit attributable to shareholders divided by average equity attributable to shareholders.	This measure provides information about the profitability of the business in relation to equity.
Return on attributed equity (%)	Calculated as annualized business division operating profit before tax divided by average attributed equity.	This measure provides information about the profitability of the business divisions in relation to attributed equity.
Return on leverage ratio denominator, gross (%)	Calculated as annualized operating income before credit loss expense or release divided by average leverage ratio denominator.	This measure provides information about the revenues of the business in relation to leverage ratio denominator.
Return on risk-weighted assets, gross (%)	Calculated as annualized operating income before credit loss expense or release divided by average risk-weighted assets.	This measure provides information about the revenues of the business in relation to risk-weighted assets.
Return on tangible equity (%)	Calculated as annualized net profit attributable to shareholders divided by average equity attributable to shareholders less average goodwill and intangible assets.	This measure provides information about the profitability of the business in relation to tangible equity.
Total book value per share (USD and CHF)	Calculated as equity attributable to shareholders divided by the number of shares outstanding.	This measure provides information about net assets on a per-share basis.
Tangible book value per share (USD and CHF)	Calculated as equity attributable to shareholders less goodwill and intangible assets divided by the number of shares outstanding.	This measure provides information about tangible net assets on a per-share basis.
Loan penetration (%) – GWM	Calculated as loans divided by invested assets.	This measure provides information about the loan volume in relation to invested assets.
Net new money (USD) – AM	Calculated as the sum of the net amount of inflows and outflows of invested assets (as defined in UBS policy) recorded during a specific period.	This measure provides information about the development of invested assets during a specific period as a result of net new money flows and excludes movements due to market performance, foreign exchange translation, dividends, interest and fees.
Impaired loan portfolio as a percentage of total loan portfolio, gross (%) – GWM, P&C	Calculated as impaired loan portfolio divided by total gross loan portfolio.	This measure provides information about the proportion of impaired loan portfolio in the total gross loan portfolio.
Secured loan portfolio as a percentage of total loan portfolio, gross (%) – P&C	Calculated as secured loan portfolio divided by total gross loan portfolio.	This measure provides information about the proportion of secured loan portfolio in the total gross loan portfolio.
Active Digital Banking clients in Personal Banking (%) – P&C	Calculated as the number of clients (within the meaning of numbers of unique business relationships operated by Personal Banking), excluding persons under the age of 15, clients who do not have a private account, clients domiciled outside Switzerland, and clients who have defaulted on loans or credit facilities, who have logged on at least once within the past month divided by the total number of clients (within the aforementioned meaning).	This measure provides information about the proportion of active Digital Banking clients in the total number of UBS clients (within the aforementioned meaning) who are serviced by Personal Banking.

APM label	Calculation	Information content
Active Digital Banking clients in Corporate & Institutional Clients (%) – P&C	Calculated as the number of clients (within the meaning of numbers of unique business relationships or legal entities operated by Corporate & Institutional Clients), excluding clients that do not have an account, mono-product clients and clients that have defaulted on loans or credit facilities, which have logged on at least once within the past month divided by the total number of clients (within the aforementioned meaning).	This measure provides information about the proportion of active Digital Banking clients in the total number of UBS clients (within the aforementioned meaning) which are serviced by Corporate & Institutional Clients.
Mobile Banking log-in share in Personal Banking (%) – P&C	Calculated as the number of Mobile Banking app log-ins divided by total log-ins via E-Banking and the Mobile Banking app in Personal Banking.	This measure provides information about the proportion of Mobile Banking app log-ins in the total number of log-ins via E-Banking and the Mobile Banking app in Personal Banking.
Fee-generating assets (USD) – GWM	Calculated as the sum of discretionary and non-discretionary wealth management portfolios (mandate volume) and assets where generated revenues are predominantly of a recurring nature, i.e., mainly investment and mutual funds, including hedge funds and private markets, where we have a distribution agreement.	This measure provides information about the volume of invested assets that create a revenue stream, whether as a result of the nature of the contractual relationship with clients or through the fee structure of the asset. An increase in the level of fee-generating assets results in an increase in the associated revenue stream.
Net new fee-generating assets (USD) – GWM	Calculated as the sum of the net amount of fee-generating assets inflows and outflows, including dividend and interest inflows into mandates and outflows from mandate fees paid by clients, during a specific period.	This measure provides information about the development of fee-generating assets during a specific period as a result of net flows and excludes movements due to market performance and foreign exchange translation.
Fee-generating asset margin (bps) – GWM	Calculated as revenues from fee-generating assets (a portion of which is included in recurring fee income and a portion of which is included in transaction-based income, annualized as applicable) divided by average fee-generating assets for the relevant mandate fee billing period.	This measure provides information about the revenues from fee-generating assets in relation to their average volume during the relevant mandate fee billing period.

¹ Total book value per share and tangible book value per share in Swiss francs are calculated based on a translation of equity under our US dollar presentation currency.

Abbreviations frequently used in our financial reports

A		CEM	current exposure method	EPS	earnings per share
ABS	asset-backed securities	CEO	Chief Executive Officer	ESG	environmental, social and governance
AEI	automatic exchange of information	CET1	common equity tier 1	ETD	exchange-traded derivatives
AGM	Annual General Meeting of shareholders	CFO	Chief Financial Officer	ETF	exchange-traded fund
A-IRB	advanced internal ratings-based	CFTC	US Commodity Futures Trading Commission	EU	European Union
AIV	alternative investment vehicle	CHF	Swiss franc	EUR	euro
ALCO	Asset and Liability Committee	CIC	Corporate & Institutional Clients	Euribor	Euro Interbank Offered Rate
AMA	advanced measurement approach	CIO	Chief Investment Office	EVE	economic value of equity
AML	anti-money laundering	CLS	Continuous Linked Settlement	EY	Ernst & Young (Ltd)
AoA	Articles of Association	CMBS	commercial mortgage-backed security	F	
APAC	Asia Pacific	C&ORC	Compliance & Operational Risk Control	FA	financial advisor
APM	alternative performance measure	CRD IV	EU Capital Requirements Directive of 2013	FCA	UK Financial Conduct Authority
ARR	alternative reference rate	CRM	credit risk mitigation (credit risk) or comprehensive risk measure (market risk)	FCT	foreign currency translation
ARS	auction rate securities	CRR	Capital Requirements Regulation	FINMA	Swiss Financial Market Supervisory Authority
ASF	available stable funding	CST	combined stress test	FMIA	Swiss Financial Market Infrastructure Act
AT1	additional tier 1	CVA	credit valuation adjustment	FSB	Financial Stability Board
AuM	assets under management			FTA	Swiss Federal Tax Administration
B				FVA	funding valuation adjustment
BCBS	Basel Committee on Banking Supervision	D		FVOCI	fair value through other comprehensive income
BEAT	base erosion and anti-abuse tax	DBO	defined benefit obligation	FVTPL	fair value through profit or loss
BIS	Bank for International Settlements	DCCP	Deferred Contingent Capital Plan	FX	foreign exchange
BoD	Board of Directors	DJSI	Dow Jones Sustainability Indices	G	
BVG	Swiss occupational pension plan	DM	discount margin	GAAP	generally accepted accounting principles
C		DOJ	US Department of Justice	GBP	pound sterling
CAO	Capital Adequacy Ordinance	D-SIB	domestic systemically important bank	GDP	gross domestic product
CCAR	Comprehensive Capital Analysis and Review	DTA	deferred tax asset	GEB	Group Executive Board
CCF	credit conversion factor	DVA	debit valuation adjustment	GIA	Group Internal Audit
CCP	central counterparty	E		GIIPS	Greece, Italy, Ireland, Portugal and Spain
CCR	counterparty credit risk	EAD	exposure at default	GMD	Group Managing Director
CCRC	Corporate Culture and Responsibility Committee	EB	Executive Board	GRI	Global Reporting Initiative
CCyB	countercyclical buffer	EBA	European Banking Authority	GSE	government sponsored entities
CDO	collateralized debt obligation	EC	European Commission	G-SIB	global systemically important bank
CDS	credit default swap	ECB	European Central Bank	H	
CEA	Commodity Exchange Act	ECL	expected credit loss	HQLA	high-quality liquid assets
		EIR	effective interest rate	HR	human resources
		EL	expected loss		
		EMEA	Europe, Middle East and Africa		
		EOP	Equity Ownership Plan		
		EPE	expected positive exposure		

Abbreviations frequently used in our financial reports (continued)

I					
IAA	internal assessment approach	NII	net interest income	SAR	stock appreciation right or Special Administrative Region
IAS	International Accounting Standards	NRV	negative replacement value		
IASB	International Accounting Standards Board	NSFR	net stable funding ratio	SBC	Swiss Bank Corporation
IBOR	Interbank Offered Rate	NYSE	New York Stock Exchange	SDG	Sustainable Development Goal
IFRIC	International Financial Reporting Interpretations Committee	O		SE	structured entity
IFRS	International Financial Reporting Standards	OCA	own credit adjustment	SEC	US Securities and Exchange Commission
IHC	intermediate holding company	OCI	other comprehensive income	SEEOP	Senior Executive Equity Ownership Plan
IMA	internal models approach	OTC	over-the-counter	SFT	securities financing transaction
IMM	internal model method	P		SI	sustainable investing
IRB	internal ratings-based	PD	probability of default	SICR	significant increase in credit risk
IRC	incremental risk charge	PFE	potential future exposure	SIX	SIX Swiss Exchange
IRRBB	interest rate risk in the banking book	PIT	point in time	SME	small and medium-sized entity
ISDA	International Swaps and Derivatives Association	P&L	profit or loss	SMF	Senior Management Function
		POCI	purchased or originated credit-impaired	SNB	Swiss National Bank
		PRA	UK Prudential Regulation Authority	SPPI	solely payments of principal and interest
		PRV	positive replacement value	SRB	systemically relevant bank
K		Q		SRM	specific risk measure
KRT	Key Risk Taker	QCCP	qualifying central counterparty	SVaR	stressed value-at-risk
		QRRE	qualifying revolving retail exposures		
L		R		T	
LAS	liquidity-adjusted stress	RBA	role-based allowances	TBTF	too big to fail
LCR	liquidity coverage ratio	RBC	risk-based capital	TCJA	US Tax Cuts and Jobs Act
LGD	loss given default	RbM	risk-based monitoring	TLAC	total loss-absorbing capacity
LIBOR	London Interbank Offered Rate	RMBS	residential mortgage-backed securities	TTC	through-the-cycle
LLC	limited liability company	RniV	risks not in VaR	U	
LRD	leverage ratio denominator	RoAE	return on attributed equity	UBS RESI	UBS Real Estate Securities Inc.
LTIP	Long-Term Incentive Plan	RoCET1	return on CET1 capital	UoM	units of measure
LTV	loan-to-value	RoTE	return on tangible equity	USD	US dollar
M		RoU	right-of-use	V	
M&A	mergers and acquisitions	RV	replacement value	VaR	value-at-risk
MiFID II	Markets in Financial Instruments Directive II	RW	risk weight	VAT	value added tax
MRT	Material Risk Taker	RWA	risk-weighted assets		
N		S		W	
NAV	net asset value	SA	standardized approach	WEKO	Swiss Competition Commission
NCL	Non-core and Legacy Portfolio	SA-CCR	standardized approach for counterparty credit risk		

This is a general list of the abbreviations frequently used in our financial reporting. Not all of the listed abbreviations may appear in this particular report.

Information sources

Reporting publications

Annual publications

Annual Report (SAP No. 80531): Published in English, this single-volume report provides descriptions of: our Group strategy and performance; the strategy and performance of the business divisions and Group Functions; risk, treasury and capital management; corporate governance, corporate responsibility and our compensation framework, including information about compensation for the Board of Directors and the Group Executive Board members; and financial information, including the financial statements.

Geschäftsbericht (SAP No. 80531): This publication provides a German translation of selected sections of our Annual Report.

Annual Review (SAP No. 80530): This booklet contains key information about our strategy and performance, with a focus on corporate responsibility at UBS. It is published in English, German, French and Italian.

Compensation Report (SAP No. 82307): This report discusses our compensation framework and provides information about compensation for the Board of Directors and the Group Executive Board members. It is available in English and German.

Quarterly publications

The quarterly financial report provides an update on our strategy and performance for the respective quarter. It is available in English.

How to order publications

The annual and quarterly publications are available in .pdf format at ubs.com/investors, under "Financial information," and printed copies can be requested from UBS free of charge. For annual publications, refer to the "Investor services" section at ubs.com/investors. Alternatively, they can be ordered by quoting the SAP number and the language preference, where applicable, from UBS AG, F4UK-AUL, P.O. Box, CH-8098 Zurich, Switzerland.

Other information

Website

The "Investor Relations" website at ubs.com/investors provides the following information about UBS: news releases; financial information, including results-related filings with the US Securities and Exchange Commission; information for shareholders, including UBS share price charts, as well as data and dividend information, and for bondholders; the UBS corporate calendar; and presentations by management for investors and financial analysts. Information is available online in English, with some information also available in German.

Results presentations

Our quarterly results presentations are webcast live. Recordings of most presentations can be downloaded from ubs.com/presentations.

Messaging service

Email alerts to news about UBS can be subscribed for under "UBS News Alert" at ubs.com/global/en/investor-relations/contact/investor-services.html. Messages are sent in English, German, French or Italian, with an option to select theme preferences for such alerts.

Form 20-F and other submissions to the US Securities and Exchange Commission

We file periodic reports and submit other information about UBS to the US Securities and Exchange Commission (the SEC). Principal among these filings is the annual report on Form 20-F, filed pursuant to the US Securities Exchange Act of 1934. The filing of Form 20-F is structured as a wrap-around document. Most sections of the filing can be satisfied by referring to the combined UBS Group AG and UBS AG annual report. However, there is a small amount of additional information in Form 20-F that is not presented elsewhere and is particularly targeted at readers in the US. Readers are encouraged to refer to this additional disclosure. Any document that we file with the SEC is available on the SEC's website: sec.gov. Refer to ubs.com/investors for more information.

Cautionary Statement Regarding Forward-Looking Statements | This report contains statements that constitute “forward-looking statements,” including but not limited to management’s outlook for UBS’s financial performance, statements relating to the anticipated effect of transactions and strategic initiatives on UBS’s business and future development and goals or intentions to achieve climate, sustainability and other social objectives. While these forward-looking statements represent UBS’s judgments, expectations and objectives concerning the matters described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from UBS’s expectations. The outbreak of COVID-19 and the measures taken in response to the pandemic have had and may continue to have a significant adverse effect on global economic activity, and an adverse effect on the credit profile of some of our clients and other market participants, which has resulted in and may continue to increase credit loss expense and credit impairments. In addition, we face heightened operational risks due to remote working arrangements, including risks to supervisory and surveillance controls, as well as increased fraud and data security risks. The unprecedented scale of the measures taken to respond to the pandemic as well as the uncertainty surrounding vaccine supply, distribution, and efficacy against mutated virus strains create significantly greater uncertainty about forward-looking statements. Factors that may affect our performance and ability to achieve our plans, outlook and other objectives also include, but are not limited to: (i) the degree to which UBS is successful in the ongoing execution of its strategic plans, including its cost reduction and efficiency initiatives and its ability to manage its levels of risk-weighted assets (RWA) and leverage ratio denominator (LRD), liquidity coverage ratio and other financial resources, including changes in RWA assets and liabilities arising from higher market volatility; (ii) the degree to which UBS is successful in implementing changes to its businesses to meet changing market, regulatory and other conditions; (iii) the continuing low or negative interest rate environment in Switzerland and other jurisdictions; (iv) developments (including as a result of the COVID-19 pandemic) in the macroeconomic climate and in the markets in which UBS operates or to which it is exposed, including movements in securities prices or liquidity, credit spreads, and currency exchange rates, and the effects of economic conditions, market developments, and geopolitical tensions, and changes to national trade policies on the financial position or creditworthiness of UBS’s clients and counterparties as well as on client sentiment and levels of activity; (v) changes in the availability of capital and funding, including any changes in UBS’s credit spreads and ratings, as well as availability and cost of funding to meet requirements for debt eligible for total loss-absorbing capacity (TLAC); (vi) changes in or the implementation of financial legislation and regulation in Switzerland, the US, the UK, the European Union and other financial centers that have imposed, or resulted in, or may do so in the future, more stringent or entity-specific capital, TLAC, leverage ratio, net stable funding ratio, liquidity and funding requirements, heightened operational resilience requirements, incremental tax requirements, additional levies, limitations on permitted activities, constraints on remuneration, constraints on transfers of capital and liquidity and sharing of operational costs across the Group or other measures, and the effect these will or would have on UBS’s business activities; (vii) UBS’s ability to successfully implement resolvability and related regulatory requirements and the potential need to make further changes to the legal structure or booking model of UBS Group in response to legal and regulatory requirements, proposals in Switzerland and other jurisdictions for mandatory structural reform of banks or systemically important institutions or to other external developments; (viii) UBS’s ability to maintain and improve its systems and controls for the detection and prevention of money laundering and compliance with sanctions to meet evolving regulatory requirements and expectations, in particular in the US; (ix) the uncertainty arising from the UK’s exit from the EU; (x) changes in UBS’s competitive position, including whether differences in regulatory capital and other requirements among the major financial centers will adversely affect UBS’s ability to compete in certain lines of business; (xi) changes in the standards of conduct applicable to our businesses that may result from new regulations or new enforcement of existing standards, including measures to impose new and enhanced duties when interacting with customers and in the execution and handling of customer transactions; (xii) the liability to which UBS may be exposed, or possible constraints or sanctions that regulatory authorities might impose on UBS, due to litigation, contractual claims and regulatory investigations, including the potential for disqualification from certain businesses, potentially large fines or monetary penalties, or the loss of licenses or privileges as a result of regulatory or other governmental sanctions, as well as the effect that litigation, regulatory and similar matters have on the operational risk component of our RWA as well as the amount of capital available for return to shareholders; (xiii) the effects on UBS’s cross-border banking business of tax or regulatory developments and of possible changes in UBS’s policies and practices relating to this business; (xiv) UBS’s ability to retain and attract the employees necessary to generate revenues and to manage, support and control its businesses, which may be affected by competitive factors; (xv) changes in accounting or tax standards or policies, and determinations or interpretations affecting the recognition of gain or loss, the valuation of goodwill, the recognition of deferred tax assets and other matters; (xvi) UBS’s ability to implement new technologies and business methods, including digital services and technologies, and ability to successfully compete with both existing and new financial service providers, some of which may not be regulated to the same extent; (xvii) limitations on the effectiveness of UBS’s internal processes for risk management, risk control, measurement and modeling, and of financial models generally; (xviii) the occurrence of operational failures, such as fraud, misconduct, unauthorized trading, financial crime, cyberattacks and systems failures, the risk of which is increased while COVID-19 control measures require large portions of the staff of both UBS and its service providers to work remotely; (xix) restrictions on the ability of UBS Group AG to make payments or distributions, including due to restrictions on the ability of its subsidiaries to make loans or distributions, directly or indirectly, or, in the case of financial difficulties, due to the exercise by FINMA or the regulators of UBS’s operations in other countries of their broad statutory powers in relation to protective measures, restructuring and liquidation proceedings; (xx) the degree to which changes in regulation, capital or legal structure, financial results or other factors may affect UBS’s ability to maintain its stated capital return objective; (xxi) uncertainty over the scope of actions that may be required by UBS, governments and others to achieve goals relating to climate, environmental and social matters as well as the evolving nature of underlying science and industry and governmental standards; and (xxii) the effect that these or other factors or unanticipated events may have on our reputation and the additional consequences that this may have on our business and performance. The sequence in which the factors above are presented is not indicative of their likelihood of occurrence or the potential magnitude of their consequences. Our business and financial performance could be affected by other factors identified in our past and future filings and reports, including those filed with the SEC. More detailed information about those factors is set forth in documents furnished by UBS and filings made by UBS with the SEC, including UBS’s Annual Report on Form 20-F for the year ended 31 December 2020 and UBS’s First Quarter 2021 Report on Form 6K. UBS is not under any obligation to (and expressly disclaims any obligation to) update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Rounding | Numbers presented throughout this report may not add up precisely to the totals provided in the tables and text. Percentages and percent changes disclosed in text and tables are calculated on the basis of unrounded figures. Absolute changes between reporting periods disclosed in the text, which can be derived from numbers presented in related tables, are calculated on a rounded basis.

Tables | Within tables, blank fields generally indicate non-applicability or that presentation of any content would not be meaningful, or that information is not available as of the relevant date or for the relevant period. Zero values generally indicate that the respective figure is zero on an actual or rounded basis. Values that are zero on a rounded basis can be either negative or positive on an actual basis.

UBS AG
P.O. Box, CH-8098 Zurich
P.O. Box, CH-4002 Basel

ubs.com



This Form 6-K is hereby incorporated by reference into (1) each of the registration statements of UBS AG on Form F-3 (Registration Number 333-253432), and of UBS Group AG on Form S-8 (Registration Numbers 333-200634; 333-200635; 333-200641; 333-200665; 333-215254; 333-215255; 333-228653; 333-230312; and 333-249143), and into each prospectus outstanding under any of the foregoing registration statements, (2) any outstanding offering circular or similar document issued or authorized by UBS AG that incorporates by reference any Forms 6-K of UBS AG that are incorporated into its registration statements filed with the SEC, and (3) the base prospectus of Corporate Asset Backed Corporation (“CABCO”) dated June 23, 2004 (Registration Number 333-111572), the Form 8-K of CABCO filed and dated June 23, 2004 (SEC File Number 001-13444), and the Prospectus Supplements relating to the CABCO Series 2004-101 Trust dated May 10, 2004 and May 17, 2004 (Registration Number 033-91744 and 033-91744-05).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UBS AG

By: /s/ Ralph Hamers
Name: Ralph Hamers
Title: President of the Executive Board

By: /s/ Kirt Gardner
Name: Kirt Gardner
Title: Chief Financial Officer

By: /s/ Christopher Castello
Name: Christopher Castello
Title: Controller and Chief Accounting Officer

Date: July 23, 2021